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FOREWORD
Bernard J. Perey, M.D., M.Sc., F.R.C.S.[C]
This issue of the Journal represents a de­
parture from the usual format. It is meant to 
reflect changes in the editorial policy which 
has now become the responsibility of the 
Royal College of Physicians and Surgeons 
of Canada. The overall objective of the 
College is to make the Journal responsive 
to the needs of its membership, not only in 
providing potential contributors with a 
suitable forum of expression but, also, in 
supplying a practical tool of continuing 
education. It is within the framework of the 
latter goal that the present issue constitutes 
a modest Canadian experiment in medical 
communication. For this reason, it is hoped 
that the membership will actively respond 
with comments, criticism and suggestions 
which will guide the College in its efforts.
The scientific material presented here has 
been chosen from the edited transcripts of a 
postgraduate course on intestinal and ano­
rectal diseases held in Sherbrooke, Que., on 
May 2, 3 and 4, 1974. This course was 
initiated and sponsored by the Royal Col­
lege of Physicians and Surgeons of Canada 
and was jointly organized by the depart­
ments of General Surgery and Continuing 
Medical Education of the University of
Sherbrooke, under the expert direction of 
Drs. G. Devroede and R. Dufresne. The 
following presentations pertain essentially to 
three selected clinical conditions and repre­
sent about one-quarter of the actual course 
which dealt excellently with many other 
aspects of intestinal and anorectal diseases.
One feature of this issue is a short self- 
assessment program prepared under the di­
rection of Dr. Ls-P. Lejeune. Its aim is to 
provide the reader with a rapid appraisal 
of his depth of knowledge of the subject and 
to allow him to improve his performance by 
reading the rest of the issue. Readers in­
terested in more extensive information may 
use the selected references. Indeed, the avail­
able literature on the physiology and patho­
logy of the intestine has reached staggering 
proportions. During the first six months of 
this year, 2,500 publications appeared on 
the subject and about 100 papers conti­
nue to appear every week. If we consider 
that each author who develops new infor­
mation immediately increases the compa­
rative ignorance of the rest of the world by 
the same amount, we have to agree with the 
President of the Royal College, Doctor K. 
J. R. Wightman, that the current “ignorance 
explosion” is more frightening than the 
“knowledge explosion”. Obviously the 
greatest challenge is not in finding new 
knowledge but in transmitting selected 
practical information to the practitioner at 
the bedside.
The faculty participating in this course is 
to be thanked for the excellence of its con­
tribution and for its ready co-operation.
I also wish to express particular thanks to 
Dr. George Konok who has chaired our 
publication committee and has carried out 
most of the required editing.
Finally, it is my pleasure to report that 
the expertise and dedication offered by 
C.M.A. Publications is a good indication of 
the expected success of the joint venture 
undertaken by the Canadian Medical As­
sociation and the Royal College.
BERNARD J .  F. PEREV, M.D.,
Guest Editor,
Centre Hospitalier Universitaire.
Sherbrooke, Que.
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AVANT-PROPOS
Le format different de ce numero du 
Journal vise a refleter la nouvelle orienta­
tion de sa politique editoriale qui est main- 
tenant entre les mains du College Royal 
des Medecins et Chirurgiens du Canada. 
L’objectif ultime du College est de mettre 
le Journal au service de ses membres, non 
seulement en leur offrant un moyen d’ex- 
pression, mais aussi en leur apportant un 
outil pratique d’enseignement continu. C’est 
dans le cadre de ce dernier but que ce nu­
mero constitue une modeste experience 
canadienne en communication medicale. Le 
College espere done que ses membres ex- 
primeront leurs commentaires et suggestions 
afin de Fassister dans sa tache.
Les presentations scientifiques qui appa- 
raissent ici, ont ete extraites des enregistre- 
ments sur bande magnetique d’un cours de 
perfectionnement sur les maladies intesti- 
nales et ano-rectales qui a eu lieu a Sher­
brooke, Que., les 2, 3 et 4 mai 1974. Ce 
cours avait ete organise sous l’egide du 
College Royal par les departements de chi- 
rurgie generate et d’enseignement medical 
continu de l’Universite de Sherbrooke, sous 
l’experte direction des docteurs G. Devroede 
et R. Dufresne. En vue des restrictions d’es- 
pace, il n’a malheureusement ete possible 
de publier que la partie du cours qui portait 
sur trois maladies intestinales. Ceci cons­
titue a peu pres un quart du cours entier.
On trouvera ci-apres un exercice d’auto- 
evaluation prepare sous la direction du doc- 
teur Ls-P. Lejeune. Le but de ce test est 
de permettre au lecteur d’evaluer rapide- 
ment l’etendue de ses propres connaissances 
du sujet traite. Apres avoir lu le texte, le 
lecteur peut aussi reprendre le test et deter­
miner Fefficacite de son etude. Une biblio­
graphic a ete preparee a l’intention de ceux
qui desirent obtenir de Finformation addi- 
tionnelle. Ces references ont ete choisies au 
sein d’une litterature volumineuse. Lors des 
six premiers mois de cette annee, a peu 
pres 2,500 travaux ont ete publies sur la 
physiologie et la pathologie de l’intestin, et 
une centaine de manuscripts continuent a 
paraitre chaque semaine. Si l’on considere 
que chaque auteur qui apporte une donnee 
nouvelle augmente immediatement d’autant 
Fignorance de tout le monde, il faut accep­
ter la constatation du president du College 
Royal, le docteur K. J. R. Wightman, que 
Fexplosion actuelle de Fignorance est plus 
menagante que Fexplosion des connaissan­
ces. De toute evidence, le plus grand defi 
auquel notre profession doit maintenant 
faire face n’est pas tellement l’avancement 
de la science mais plutot la transmission de 
Finformation utile disponible au consom- 
mateur qu’est le medecin clinicien.
Les professeurs ayant participe a ce 
cours de perfectionnement meritent nos fe­
licitations pour Fexcellence de leur contri­
bution, ainsi que pour leur genereuse col­
laboration.
Je desire remercier tout particulierement 
le docteur George Konok qui a dirige notre 
Comite de redaction et qui a rendu cette 
publication possible par Fardeur et la qua- 
lite de son travail.
Enfin, j’ai eu le plaisir de constater que 
Fexpertise et le devouement du personnel 
de “C.M.A. Publications”, est un indice 
encourageant du succes qu’il faut attendre 
du projet entrepris conjointement par l’As- 
sociation Medicale Canadienne et le Col­
lege Royal.
Bernard J. F. Perey, m .d., 
editeur invite,
Centre Hospitalier Universitaire,
Sherbrooke, Que.
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TEST YOUR KNOWLEDGE OF 
INFLAMMATORY BOWEL DISEASES: 
A SELF-ASSESSMENT TEST
Ls-P. LEJEUNE and B. J. PEREY
To the following multiple-choice questions 
the answer is
A if 1, 2, 3 are correct 
B if 1, 3 are correct 
C if 2, 4 are correct 
D if 4 only is correct 
E if 1, 2, 3, 4 are correct
(1) The theory that Crohn’s disease is due 
to a micro-organism is supported by the 
fact(s) that:
1. bacteria can be cultured from diseased 
tissue
2. salicylazosulfapyridine (Salazopyrin) is ef­
fective against the disease
3. azathioprine (Imuran) is effective against 
the disease
4. the disease can be transmitted to laboratory 
animals by injecting a filtrate of diseased 
tissue.
(2) The incidence of Crohn’s disease is in­
creased :
1. between the ages of 20 and 40, and between 
the ages of 50 and 70
2. in the Southern hemisphere
3. among relatives of patients suffering from 
the disease
4. in the male.
(3) Patients suffering from regional ileitis 
have a tendency to develop:
1. an iron deficiency anemia which responds 
poorly to the ingestion of iron
2. a low total iron-binding capacity
3. vitamin Bi2 insufficiency
4. cholelithiasis.
(4) The endoscopic features of Crohn’s 
disease of the rectum include:
1. linear ulcerations
2. the persistence of a normal vascular pattern 
between the lesions
3. the presence of localized rather than dif­
fuse lesions
4. punched out ulcers.
EVALUEZ VOS CONNAISSANCES 
DES MALADIES INFLAMMATOIRES 
DE LTNTESTIN:
EXERCICE D’AUTO-EVALUATION
Ls-P. LEJEUNE and B. J. PEREY
Dans les questions a choix de reponse sui- 
vantes un ou plusieurs enonces peut (ou 
peuvent) etre correct(s).
A lorsque 
B lorsque 
C lorsque 
D lorsque 
E lorsque
1, 2, 3, sont corrects
1, 3 sont corrects
2, 4 sont corrects
4 seulement est correct 
1, 2, 3, 4 sont corrects
(1) L’hypothese que la maladie de Crohn 
est causee par un microorganisme est ap- 
puyee par le(s) fait(s) que:
1. l’on peut faire croitre des bacteries a partir 
de tissu affecte
2. la salicylazosulfapyridine (Salazopyrin) est 
efficace dans cette maladie
3. l’azathioprine (Imuran) est efficace dans 
cette maladie
4. Ton peut transmettre la maladie a des ani- 
maux de laboratoire en injectant un filtrat 
de tissu affecte.
(2) On retrouve une incidence plus elevee 
de maladie de Crohn:
1. entre l’age de 20 et 40 ans et entre l’age 
de 50 a 70 ans
2. dans l’hemisphere Sud
3. dans la parente des malades souffrant de 
cette maladie
4. chez le male.
(3) Les malades atteints d’enterite regionale 
ont tendance a presenter:
1. une anemie ferriprive resistante a l’inges- 
tion de fer
2. une diminution de la capacite de fixation 
du fer
3. une deficience en vitamine B12
4. une incidence de cholelithiase augmentee.
(4) Parmi les signes endoscopiques de la 
maladie de Crohn du rectum on retrouve:
1. des ulcerations lineaires
2. la preservation d’un reseau vasculaire d’ap- 
parence normale entre les lesions
3. le caractere localise plutot que diffus des 
lesions
4. des ulceres a l’emporte-piece.
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(5) Complications of Crohn’s disease in­
clude :
1. ankylosing spondylitis
2. uveitis
3. pyoderma gangrenosum
4. cancer of the large bowel.
(6) Acceptable operations for Crohn’s
disease include:
1. routine division, during each operation, 
of all adhesions in order to assess fully the 
extent of the disease
2. simple closure of the defect in the duo­
denal wall when secondary involvement 
from adjacent bowel has required limited 
resection of the duodenum
3. appendectomy when the appendix is in­
volved
4. total proctocolectomy.
(7) A bypass operation is usually the opera­
tion of choice for regional ileitis when:
1. the patient is receiving corticosteroids
2. there is a posterior perforation with a re­
troperitoneal inflammatory mass
3. the patient is over 60 years of age
4. there is bowel obstruction but the disease 
is inactive.
(8) Histological features suggestive of re­
gional enteritis include:
1. granulomatous lesions
2. a noticeably thickened and abnormal sub­
mucosa
3. vertical mucosal fissures
4. the presence of healthy mucosa between 
ulcers.
(9) Following intestinal resection for Crohn’s
disease, the risk of recurrence is increased:
1. when the disease originally involved the 
small rather than the large bowel
2. when the disease was of short duration at 
the time of surgery
3. in the young
4. in the male.
(5) Parmi les complications de la maladie 
de Crohn on retrouve:
1. la spondylite ankylosante
2. l’uveite
3. la pyodermite gangreneuse
4. le cancer du colon.
(6) Parmi les operations acceptables utili- 
sees dans la maladie de Crohn, on retrouve:
1. la dissection systematique, pendant chaque 
intervention, de toutes les brides adheren- 
tielles presentes afin de preciser l’etendue 
de la pathologie
2. la simple suture du duodenum lorsqu’une 
atteinte secondaire provenant d’une anse 
intestinale adjacente entraine la resection 
d’une petite portion de la paroi de cet 
organe
3. l’appendicectomie lorsque l’appendice est 
atteint
4. la proctocolectomie totale.
(7) La derivation intestinale est habituelle- 
ment l’operation de choix dans l’ileite ter- 
minale lorsque:
1. le malade regoit des corticosteroi'des
2. il y a perforation posterieure avec une 
masse inflammatoire retroperitoneale
3. le malade a plus de 60 ans
4. il y a occlusion intestinale mais la maladie 
est inactive.
(8) Parmi les caracteristiques histopatholo- 
giques qui suggerent le diagnostic d’enterite 
regionale on retrouve:
1. des granulomes
2. une sous-muqueuse nettement epaissie et 
anormale
3. des fissures verticales de la muqueuse
4. la presence de muqueuse normale entre les 
ulcerations.
(9) Apres une resection intestinale pour 
maladie de Crohn, le risque de recidive est 
augmente :
1. si la maladie interessait l’intestin greie plu- 
tot que le colon
2. si la maladie etait de courte duree au mo­
ment de l’intervention
3. chez un individu jeune
4. chez le male.
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(10) In patients suffering from ulcerative 
colitis, acute toxic dilatation of the colon 
may be precipitated by:
1. anticholinergic drugs
2. opiates
3. hypokalemia
4. a barium enema.
(11) In ulcerative colitis the risk of cancer 
of the large bowel is increased:
1. when the disease has been active for more 
than 10 years
2. when corticosteroids have been used
3. when the entire colon is involved
4. in young adults.
(12) Acute toxic megacolon is known to oc­
cur in:
1. ischemic colitis
2. Crohn’s disease
3. diverticulitis
4. ulcerative colitis.
(13) The typical histological features of 
ulcerative colitis include:
1. the presence of vertical mucosal fissures
2. the involvement of all layers of the bowel 
wall
3. the presence of normal mucosa between 
affected areas
4. destruction of the mucosal crypts.
(14) Complications of ulcerative colitis in­
clude :
1. sclerosing cholangitis
2. cirrhosis of the liver
3. arthritis
4. thyroiditis.
(15) The drugs usually considered ap­
propriate in the treatment of moderately 
severe ulcerative colitis limited to the rec­
tum and rectosigmoid colon include:
1. corticosteroid enemas
2. systemic corticosteroids
3. salicylazosulfapyridine (Salazopyrin)
4. ACTH.
(16) When using corticosteroid enemas for 
ulcerative colitis it is advisable:
1. to introduce the enema cannula as far as 
the upper limit of the disease
2. to watch for the development of leuko­
penia
(10) Chez les malades atteints de rectocolite 
hemorragique, la dilatation aigue toxique 
du colon peut etre precipitee par:
1. les anticholinergiques
2. les opiaces
3. l’hypokaliemie
4. un lavement baryte.
(11) Dans la rectocolite hemorragique, la 
degenerescence maligne est plus frequente:
1. lorsque la maladie evolue depuis plus de 
10 ans
2. lorsque les corticosteroi'des ont ete utilises
3. lorsque tout le colon est atteint
4. chez l’adulte jeune.
(12) La dilatation aigue toxique du colon 
peut survenir dans:
1. la colite ischemique
2. la maladie de Crohn
3. la diverticulite aigue
4. la rectocolite hemorragique.
(13) Parmi les caracteristiques histopatho- 
logiques typiques de la rectocolite hemor­
ragique, on retrouve:
1. la presence de fissures verticales de la 
muqueuse
2. l’atteinte de toutes les couches de la paroi 
du colon
3. la presence de muqueuse normale entre 
les zones atteintes
4. la destruction des cryptes de la muqueuse.
(14) Parmi les complications de la rectoco­
lite hemorragique, on retrouve:
1. la cholangite sclerosante
2. la cirrhose du foie
3. l’arthrite
4. la thyroi'dite.
(15) Parmi les formes de therapeutique me- 
dicale habituellement utilisees dans le trai- 
tement des rectocolites hemorragiques de 
severite moderee et limitees au rectum et 
rectosigmoi'de, on retrouve:
1. les lavements de cortico'ides
2. les cortico'ides par voie buccale
3. la salicylazosulfapyridine (Salazopyrin)
4. l’ACTH.
(16) Lorsque les lavements de corticoides 
sont utilises dans le traitement de la recto­
colite hemorragique, il est recommande:
1. d’introduire la canule de lavement jusqu’a 
la limite de la pathologie
2. de surveiller l’apparition d’une leucopenie
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3. to use always at least 300 ml of enema
4. to verify the level reached by the enema 
by use of contrast material.
(17) Endoscopic signs of ulcerative colitis 
include:
1. disappearance of the normal vascular pat­
tern
2. edema of the mucosa
3. contact bleeding
4. involvement limited to part of the circum­
ference of the bowel.
(18) It has been observed that when women 
suffering from ulcerative colitis or Crohn’s 
disease become pregnant:
1. ulcerative colitis does not endanger the 
fetus
2. ulcerative colitis tends to undergo a flare- 
up during the postpartum period
3. Crohn’s disease tends to cause stillbirths
4. Crohn’s disease may improve or worsen.
(19) Acute ischemic colitis:
1. may be ruled out when arteriography 
shows patency of the mesenteric arteries 
and their major branches
2. must be treated surgically
3. is most common in the ascending colon
4. tends to produce a radiological feature 
known as “thumbprinting”.
In the following multiple choice questions, 
the single best answer is to be identified.
(20) In Crohn’s disease, dramatic remis­
sions are usually observed with the use of:
A. salicylazosulfapyridine (Salazopyrin)
B. corticosteroids
C. azathioprine (Imuran)
D. gamma globulin from patients in remission
E. none of the above.
(21) The upper normal limit of the diame­
ter of the transverse colon, as measured on 
plain films, is:
A. 5.5 cm
B. 6.5 cm
C. 7.5 cm
D. 8.5 cm
E. 9.5 cm.
3. de toujours utiliser plus de 300 ml de la­
vement
4. de verifier le niveau atteint par le lave­
ment en y ajoutant un peu de baryte.
(17) Parmi les signes endoscopiques de la 
rectocolite hemorragique il faut inclure:
1. la disparition du reseau vasculaire normal
2. l’oedeme de la muqueuse
3. le saignement facile au contact
4. l’atteinte limitee a une partie de la circon- 
ference de l’intestin.
(18) Au sujet de la grossesse chez les fem­
mes atteintes de rectocolite hemorragique 
ou de maladie de Crohn l’on peut dire que:
1. la rectocolite hemorragique ne presente pas 
de danger pour le foetus
2. la rectocolite hemorragique a tendance a 
s’exacerber pendant la periode post-partum
3. la maladie de Crohn a tendance a condui- 
re a l’accouchement d’enfants mort-nes
4. la maladie de Crohn peut s’ameliorer ou 
s’exacerber au cours de la grossesse.
(19) La colite ischemique aigue:
1. peut etre exclue lorsque l’arteriographie 
demontre la permeabilite des arteres me- 
senteriques et de leurs branches principales
2. doit etre traitee par intervention chirurgi- 
cale
3. est plus f Aquente dans le colon ascendant
4. a tendance a produire une image radiolo- 
gique d’empreintes de doigts (“thumbprint­
ing”).
Dans les questions a choix de reponses sui- 
vantes il s’agit d’identifier la reponse la plus 
appropriee. Un seul enonce est correct.
(20) Dans la maladie de Crohn, des remis­
sions impressionnantes sont habituellement 
obtenues avec:
A. la salicylazosulfapyridine (Salazopyrin)
B. les corticoi'des
C. l’azathioprine (Imuran)
D. la gamma globuline provenant de malades 
en periode de remission
E. aucun des medicaments nommes ci-dessus.
(21) La limite superieure du diametre du 
colon transverse normal, tel que mesure 
sur une plaque simple de l’abdomen est de:
A. 5.5 cm
B. 6.5 cm
C. 7.5 cm
D. 8.5 cm
E. 9.5 cm.
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(22) In acute toxic megacolon, colonic dis­
tension is usually most prominent in:
A. the cecum
B. the ascending colon
C. the transverse colon
D. the descending colon
E. the sigmoid colon.
(23) When acute mesenteric artery occlu­
sion produces severe intestinal ischemia, 
necrosis begins:
A. in the mucosa
B. in the submucosa
C. in the muscularis
D. in the serosa
E. in all layers simultaneously.
(24) When acute occlusion of the superior 
mesenteric artery produces severe intestinal 
ischemia, the patient usually develops im­
mediately:
A. severe abdominal distension
B. severe vomiting
C. massive gastrointestinal bleeding
D. a rigid abdominal wall
E. none of the above.
(22) Dans la dilatation aigue toxique du 
colon, la distention est habituellement plus 
evidente au niveau:
A. du caecum
B. du colon ascendant
C. du colon transverse
D. du colon descendant
E. du colon sigmoi'de.
(23) Lorsque l’occlusion d’une artere me- 
senterique conduit a une ischemie intesti- 
nale severe, la necrose se produit initiale- 
ment:
A. dans la muqueuse
B. dans la sous-muqueuse
C. dans la couche musculaire
D. dans la sereuse
E. dans toutes les couches simultanement.
(24) Lorsque l’occlusion aigue de l’artere 
mesenterique superieure produit une ische­
mie intestinale severe, la malade habituel­
lement demontre immediatement:
A. un meteorisme abdominal severe
B. des vomissements abondants
C. une hemorragie digestive massive
D. une paroi abdominale rigide
E. aucun des signes enonces ci-dessus.
Key TO t h e  C o r r e c t A n sw er s C l e f  des R ep o n s e s E xactes
(1) D (5) E (9) A (13) D (17) A (21) A
(2) B (6) D (10) E (14) A (18) E (22) C
(3) E (7) C (11) B (15) B (19) D (23) A
(4) E (8) E (12) C (16) D (20) E (24) E
Notice to the Reader
If the reader is not satisfied with his per­
formance he is advised to read the rest of 
the Journal and to test his knowledge again.
GOOD LUCK!
Avis au lecteur
Si le lecteur n’est pas satisfait de ses re- 
sultats, il aurait avantage a etudier le reste 
de ce numero et a reprendre le test.
BONNE CHANCE!
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DIFFERENTIAL DIAGNOSIS OF COLITIS
G. J. DEVROEDE
F our hundred years BC, Hippocrates knew 
that diarrhea was not due to a single dis­
ease. During the Middle Ages it became 
known that dysentery affected the less well- 
to-do during the summer months while the 
bloody flux described in 1666 by Syden­
ham was found in all classes of society. In 
1859 Sir Samuel Wilks described “the mor­
bid appearance of the intestine of Miss 
Banks” and coined the phrase “ulcerative 
colitis”. Only very recently has Crohn’s dis­
ease been distinguished from ulcerative co­
litis. Other types of colitis have been de­
scribed and the differential diagnosis of 
colitis has become a complex problem (Ta­
ble I).
The problem is encountered even in the
gathering of data. For instance, there is 
poor observer agreement in the interpreta­
tion of anemia, dehydration, abdominal 
guarding and rigidity. Even pathological 
examination has its limitations. For example, 
in Crohn’s disease of the rectum a single 
biopsy will indicate the diagnosis in only 
about 10% of cases while the accuracy can 
increase to 60% if several biopsies are ex­
amined.
The presence of abdominal pain favours 
the diagnosis of Crohn’s disease rather than 
ulcerative colitis and the presence of an 
abdominal mass suggests diverticular or 
Crohn’s disease. Rectal bleeding is not 
present in all forms of colitis (Table II). 
Patients with Crohn’s disease frequently
TABLE I.—Colitis
Known etiology Unknown etiology
Diverticulitis
Ischemic colitis and arteritis 
Radiation colitis 
Uremic colitis
Crohn’s disease 
Ulcerative colitis 
Pseudomembranous colitis 
Necrotizing colitis
Infections: staphylococcal enteritis
bacillary dysentery (shigellosis) 
gonorrheal proctitis 
tuberculosis of the colon 
lymphogranuloma venereum (Nicolas-Favre) 
histoplasmosis
Parasitic diseases: amebic colitis
schistosomiasis 
balantidiasis
Conditions caused by antibiotics: lincomycin colitis
clindamycin colitis
TABLE II.—D ifferential D iagnosis of Colitis
Bloody diarrhea Bloodless diarrhea
Ulcerative colitis Crohn’s disease
Ischemic colitis Uremic colitis
Radiation proctitis Pseudomembranous colitis
Infections: shigellosis (bacillary dysentery) Infections:
lymphogranuloma venereum staphylococcal enteritis
tuberculosis
histoplasmosis
Parasitic Parasitic diseases (chronic):
diseases (acute).'amebic colitis amebic colitis
schistosomiasis schistosomiasis 
balantidiasis 
Diverticular disease 
Lincomycin colitis 
Clindamycin colitis
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have anal fissures, fistulas and abscesses, 
indolent multiple ulcers of the perineum and 
a marked tendency to develop fistulas.
In colitis, stool cultures and search for 
parasites, endoscopy, mucosal biopsies, ra­
diographic studies of the small and large 
bowel, and skin and serological tests should 
always be done. Occasionally arteriograms 
and, in acute situations, plain films of the 
abdomen will be useful.
Endoscopy is a major diagnostic measure 
that will be the object of detailed discussion 
during this course. It is important to note 
whether the lesions are diffuse or some 
areas of the mucosa remain normal. The 
presence of lesions beyond a normal rectum 
is also an important clue to diagnosis. His­
tological studies of biopsies are specific for 
some parasites, pseudomembranous colitis, 
tuberculosis and histoplasmosis, and they 
are useful in the diagnosis of vascular prob­
lems, uremic colitis and Crohn’s disease.
Recognition of the type of ulcer is useful. 
Discrete, localized ulcers of the rectum and 
sigmoid, in our experience, are usually
caused by Crohn’s disease but may also 
be found in ischemic (Fig. la) and amebic 
(Fig. lb) colitis as well as in other condi­
tions.
The appearance of the mucosa is also 
helpful. A healed granular mucosa is the 
only specific sign of ulcerative colitis. The 
absence of a vascular pattern with increas­
ing mucosal fragility is very common in co­
litis, but in ulcerative colitis the lesions are 
diffuse and extend to the dentate line, spar­
ing no area. In contrast to Crohn’s disease, 
ulcerative colitis is strictly a mucosal dis­
ease. Acute pseudomembranous colitis is 
easy to recognize (Fig. lc). The pseudo­
membranes are yellow and surrounded by a 
fiery red mucosa. They are attached to the 
mucosa and leave a small ulcer when re­
moved. At biopsy (frozen sections are rec­
ommended for rapid diagnosis) a pseudo­
membrane is found attached to the mucosa, 
with dilatation of the glands underneath. 
After treatment the appearance of the bowel 
may become indistinguishable from that of 
ulcerative colitis, but ultimately it will return
Fig. 1.—(a) Ischemic colitis in a patient with severe arteriosclerosis and carbon monoxide poisoning. 
The lesions disappeared as the patient recovered from his intoxication, (b) Amebic colitis, (c) Typical 
pseudomembranous colitis, (d) Actinic proctitis, (e) Telangiectasias in a patient with schistosomiasis, 
(f) Uremic colitis. Note the edema and intramucosal hemorrhage. (Published by courtesy of the Olym­
pus Corporation of Canada, G. D. Searle & Co. of Canada Ltd. and the ACMI Company.)
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to normal. The appearance of the vascular 
pattern can be an important' diagnostic 
feature. Telangiectasias surround the ulcer 
of actinic proctitis (Fig. Id). Dilated capil­
laries were found in another patient who 
was infested by Schistosoma mansoni (Fig. 
le). The egg of this parasite has a hooklet 
on the side which is very well seen in fresh 
specimens (Fig. 2). Edema of the mucosa in 
a fixed, narrowed, sacculated bowel is 
characteristic of diverticulitis. Occasionally 
diverticula— and, very seldom, bleeding 
from one of them— may be seen. Edema 
and capillary extravasation are also- seen in 
patients with uremic colitis (Fig. ’If). These 
lesions regress with improvement of uremia.
Plain radiographs of the abdomen are 
useful to evaluate the size and shape of 
the colon. The upper limit of the diameter 
of the normal transverse colon is 5.5 cm 
and when it exceeds this, in the absence of 
mechanical obstruction, toxic dilatation 
should be the diagnosis. This finding may 
occur in diseases other than ulcerative colitis 
and we have seen it in ischemic colitis, 
Crohn’s disease, and pseudomembranous 
colitis. In the latter disease, thickening of 
the mucosal folds of the transverse colon 
may also be clearly seen on the plain film. 
The diagnostic criteria as detected by the 
barium enema are almost the same as those 
seen at endoscopy. Are the lesions diffuse 
or discrete? Are they distal or proximal? 
Barium enema is greatly superior to en­
doscopy in the estimation of ulcer depth
Fig. 2.—Egg of Schistosoma mansoni showing 
hooklet.
and the identification of fistulas and diver­
ticula. Discrete ulcers, solitary or multiple, 
and skip areas are typical of Crohn’s disease 
and fistulas are frequently seen in this con­
dition. Thumbprinting, which is typical of 
ischemic colitis, may also be seen in pseu­
domembranous colitis and Crohn’s disease. 
Radiology may be misleading in ulcerative 
colitis characterized by diffuse superficial 
microulcerations, as colonoscopy may show 
disease in areas of the colon that are radio- 
logically normal (Fig. 3). For this reason 
we now do routine colonoscopy and take 
multiple biopsies in these cases. The presence 
of an abdominal mass associated with left 
lower quadrant pain and sigmoid spasm as 
found on barium enema is not sufficient 
evidence for the diagnosis of diverticulitis. 
Diverticulitis is in fact peridiverticulitis sec­
ondary to the penetration of colonic bac­
teria through a ruptured diverticulum. 
Rather, such a diagnosis requires clinical 
evidence of peritonitis or fistula or else ra­
diological evidence of extramucosal com­
pression or fistula. Arteriograms may be 
useful in the diagnosis of ischemic colitis. 
Intravenous pyelograms and small bowel
Fig. 3.—Total colitis unrecognized on a stand­
ard barium enema. The radiological diagnosis was 
left-sided colitis, but biopsies obtained during 
colonoscopy were positive all the way to the 
cecum.
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studies are often useful in the differential 
diagnosis of colitis by their demonstration 
of extracolonic lesions. I shall leave the 
detailed discussion of x-ray findings in co­
litis to the radiologists.
The follow-up of patients with colitis is 
important as it may yield diagnostic clues. 
The main difficulties lie in distinguishing 
Crohn’s disease from ulcerative colitis. This 
distinction is not purely academic. For in­
stance, in total ulcerative colitis the risk of 
cancer is 20% after 20 years. By contrast 
it is only 2.8% after 20 years for Crohn’s
disease of the colon, a risk of more modest 
magnitude. Similarly, 20% of patients with 
total ulcerative colitis die within a period 
of 10 years, while this is true of only 10% 
of patients with Crohn’s disease.
In summary, characteristic lesions may 
be recognized by a systematic use of all 
available diagnostic techniques. One or an­
other may provide a definitive clue. In all 
the other cases one should make the diag­
nosis that is most likely on the basis of all 
available data, subject to periodic recon­
sideration.
DISCRIMINANT AND BAYES ANALYSIS IN THE 
DIFFERENTIAL DIAGNOSIS OF COLITIS
JOHN E. LENNARD-JONES
L ewis Carroll, the author of “Alice in 
Wonderland”, was a mathematician. Now 
I, too, will lead you into an Alice-in-Won- 
derland type of world of differential diag­
nosis. It is a mathematical game, and I hope 
you will find it enjoyable. I think, however, 
that it does have important practical mes­
sages for us. What we are concerned with 
is how to define a disease.
A disease can be described as monothetic 
if we can define it by a single characteristic. 
If that characteristic is present, then the 
disease is present; if that characteristic is 
absent, then the disease is absent. One may 
have an enzyme defect like phenylketonuria 
or an infection like tuberculosis. But one 
must not forget that tuberculosis may affect 
different organs in the body, with widely 
varying manifestations, yet one can define 
it because Mycobacterium tuberculosis is 
present in the lesion. One may also define 
a disease anatomically, like polycystic dis­
ease of the kidney, or physiologically, like 
glaucoma.
Many of the diseases we have to deal 
with in gastroenterology do not have such 
a single defining characteristic, and there­
fore they properly belong to the group of 
diseases described as polythetic. As Dr. 
Devroede has pointed out, there are serious 
difficulties in properly classifying chronic
non-specific colonic inflammatory disease. 
Therefore we thought that it would be in­
teresting to apply some mathematical meth­
ods of classification to inflammatory bowel 
disease.
How can we classify diseases? The old 
and well-established method is to take a 
large group of patients and look for com­
mon features. This is what we usually do 
and the medical literature is full of ex­
amples. It is, however, possible to classify 
diseases in an entirely different way. Let us 
suppose that one takes a number of dif­
ferent patients and looks at a number of 
clinical features. If one finds that certain 
patients have similar features, then one can 
group them together. This technique has 
been used quite widely in biology for clas­
sifying animals; it has been used in archeol­
ogy to classify the age of coins. For this 
type of analysis it is essential to collect a 
lot of well-defined data. A computer with­
out any preconceived notions then looks at 
the data to see if they can be divided into 
clusters. Now, supposing that one can div­
ide one’s patients into groups by this method 
or by any other method, then one can anal­
yze the data further to find the smallest 
number of distinguishing features that will 
separate the patients into clusters. In med­
ical taxonomy we try to find the smallest
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number of attributes we can use to dis­
tinguish between diseases.
In order to apply medical taxonomy to 
inflammatory bowel disease we took a total 
of 156 clinical features. Before we started 
we designed definitions for the various 
symptoms and signs and tested them in a 
pilot series of patients. Having defined suit­
able criteria, we put them into a form 
which could be coded and fed into a com­
puter. Forty-seven of the indicants were 
derived from surgical specimens and were 
not available for every patient. The remain­
ing 109 attributes were derived from the 
clinical history and examination, hematol­
ogical and biochemical findings, radiographs 
and histological appearances of rectal biop­
sies.
Information was collected from 109 con­
secutive patients with inflammatory bowel 
disease admitted to St. Mark’s Hospital, 
London, England. The computer divided 
the patients into a series of groups, each 
known as a cluster (Fig. 1). The number 
in the centre of the circle is the number 
of patients in that cluster. You notice a 
cluster that contains 45 patients and, close 
to it, but not actually fitted within the clus­
ter, there are 25 more patients, technically 
known as satellites. There are a number of 
small clusters with six, two, two, two, five
8 unplaced 12
satellites
Fig. 1.—Cluster analysis of 109 patients with 
inflammatory bowel disease. (Reproduced from 
Jones JH, Lennard-Jones JE, Morson BC, et 
al: Numerical taxonomy and discriminant
analysis applied to non-specific colitis. Q Med J 
42: 715. 1973.)
and two patients respectively, and some 
patients who are satellites of these clusters. 
The computer was unable to place eight 
patients in any cluster. Having reached this 
stage we thought it would be interesting to 
correlate these clusters, derived without 
preconceptions about the clinical diagnosis, 
with the diagnostic label that we had at­
tached to these patients. Speaking gener­
ally we found that the 45 patients in the 
large cluster and 22 of its satellites corre­
sponded very closely to the condition we 
call proctocolitis, or ulcerative colitis. The 
patients on the right side, in the multitude 
of small clusters, corresponded to what we 
call Crohn’s disease of the colon. What 
can we learn from all this? First of all, we 
find that the disease we call ulcerative colitis 
is a rather uniform disease. On the other 
hand, we also notice that the patients with 
what we currently call Crohn’s disease form 
a very heterogeneous collection and, of 
course, are much more difficult to define. 
It is interesting to speculate whether or not 
there may be more than one disease here. 
We tend to talk about Crohn’s disease in 
a rather broad way, but we must remember 
that all we have done, in fact, is to put a 
label on a group of patients and there may 
be a number of distinct diseases in the 
group.
But let us look at the data in another 
way. I have said that if you can divide pa­
tients into groups, then you can find out by 
mathematical techniques the smallest num­
ber of attributes that will separate those 
patients into these groups. We took 97 pa­
tients whom we had separated, according 
to the sort of clinical criteria discussed by 
Dr. Devroede, into 61 patients with ulcer­
ative colitis and 36 patients with Crohn’s 
disease (Table I). In this case we studied
TABLE I.- -P attern Analysis of 97 P atients 
with Ulcerative Colitis or Crohn’s D isease
A ttrib u te Grade
Anal canal............ 1. 2 )
Vascular pattern 1. 2. 3 )
) 36 patterns
Inflammation. . . 1. 2. 3 ) e.g. 2.1.3.2 etc.
Granulomas.......... 1. 2 )
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91 attributes on which we had complete 
data. We asked the computer to find the 
smallest number of attributes that would 
divide these patients into the two groups 
and found that this could be done using 
quite a small number of attributes.
Supposing we try to put the various attri­
butes into patterns. For example, you exam­
ine the anal canal with your finger and you 
say that, if it feels smooth, you will grade 
it as “ 1” and if it feels nodular, you will 
grade it as “2”. Of course, if the patient 
has had a fistula or an abscess, and the 
anus is scarred, it will be nodular. This 
then gives a simple definition of a large 
number of anal diseases. Next, you pass a 
sigmoidoscope and you find that there is a 
completely normal vascular pattern through­
out the entire rectum; we classify that as 
“ 1”. If, on the other hand, you see vascular 
patterns only in part of the rectum and 
inflammation in other parts we classify this 
as “2”. If we pass our sigmoidoscope and 
there is a diffuse inflammation involving the 
whole rectum and no vascular pattern is 
visible, we will call it “3”. Then we take 
a single rectal mucosal biopsy and give it 
to the pathologist. If he finds it completely 
normal, we call it “ 1” . If he finds it dif­
fusely abnormal, we call it “3”. If he finds 
a patchy abnormality, we call it “2”. Fi­
nally, if he finds granulomas, we call it “2”; 
if there are no granulomas in the specimen 
we call it “ 1”. Table I shows that we have 
now a series of grades which we can divide 
into various patterns. Let us suppose that 
we take the patients in whom we have diag­
nosed ulcerative edits, and look over our 
patterns. Table II shows that there were 
61 patients with colitis, and 57 of them fell 
into one pattern. They all had a smooth
anal canal on digital examination; they had 
a completely absent vascular pattern on 
sigmoidoscopy; they had diffuse inflamma­
tion on biopsy; they had no granuloma on 
biopsy. There were some other patterns, but 
there was only one pattern that over­
lapped with the patients who had Crohn’s 
disease. This again shows that ulcerative 
colitis is a homogeneous disease. There are 
only five patterns in 61 patients, and one 
pattern is found in 57 of them. In Crohn’s 
colitis, on the other hand, 36 patients 
formed 16 patterns. (If I put these data on 
a figure it would be difficult to comprehend 
at a glance.) Again, we find that in fact 
Crohn’s colitis is quite a heterogeneous 
disease. There is only one pattern shared 
between the two groups of patients with 
ulcerative colitis and Crohn’s disease.
From our discriminant analysis we find 
that in ulcerative colitis a history of bleeding 
and tenesmus is common, and there is an 
absence of a vascular pattern on sigmo­
idoscopy. There is granularity of the mu­
cosal line on x-ray, and here I may say that 
we are strong advocates of the use of dou­
ble-contrast enemas which show the un­
evenness of the mucosal surface. We find 
in biopsies that there is diffuse inflammation 
with depletion of mucus in epithelial cells 
where the mucosa is inflamed. There are no 
chronic anal lesions, and there are no granu­
lomas in the biopsy specimen.
Crohn’s disease is, of course, much more 
difficult to define because it is so hetero­
geneous. I will conclude with the simple 
idea that ulcerative colitis is a disease that 
is relatively easy to define, while Crohn’s 
disease may merely be a label encompassing 
a number of related but not necessarily 
identical diseases.
TABLE II.—Pattern Analysis of 61 Patients with P roctocolitis
N o . o f  p a t ie n ts A n a l  ca n a l V a scu la r  p a tte rn In f la m m a tio n G ran u lom as
1 1 2 2 1
I 1 2 3 1
1* 1 3 2 1
57 1 3 3 1
1 2 3 3 1
61
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CROHN’S DISEASE
INTRODUCTION
OIAGKOETIC JU T T R IA ?  
hUKuXUU. i W i m i i O . . /
ACTUARIAL ANALYSIS Of RfCCf SENCC RATE? :
Fig. L—Recurrent ileitis after ileostomy fot 
Crohn’s disease of the colon.
I shall introduce our first topic by show­
ing a few provocative statistics. Fig. 1 in­
dicates the recurrence rate in various series 
after proctocolectomy for Crohn’s disease of 
the colon. You can see that it is not clear 
whether proctocolectomy in these cases is 
followed by a high or a low recurrence rate 
in the small bowel. One of these reports 
even goes so far as to suggest that involve­
ment of the terminal ileum does not affect 
the recurrence rate. In these studies, 
actuarial analysis of the data was not always 
done and indications for surgery were not 
identical.
What were the criteria used to make a 
diagnosis of Crohn’s disease? Between 1885 
and 1930, many reports of abdominal tuber­
culosis were not supported by the demons­
tration of caseation and acid-fast bacilli. 
Kennedy Dalziel, in 1913, reported eight 
peculiar cases to the British Medical As­
sociation. The patients had chronic inflam­
mation of the small and large bowel, trans­
mural in nature, with giant cells. Dalziel’s
merit was to recognize that this was not 
tuberculosis. Nineteen more years passed 
before Crohn, Ginzburg and Oppenheimer 
called the condition terminal ileitis. Bargen, 
commenting at the time on their paper, sug­
gested changing the name to regional ileitis, 
because the adjective “terminal” could 
sound ominous to the patients. In 1952, 
Wells, in Liverpool, recognized that there 
was a colonic variant of the disease but it 
took the New World 15 more years to ac­
cept this fact.
It was not until the 1968 International 
Congress of Gastroenterology, in Prague, 
that the term Crohn’s disease of the colon 
was universally adopted. The term Crohn’s 
disease seems to be the best choice at this 
time. The alternative term “regional en­
teritis” could indicate a disease occuring 
anywhere from the mouth to the anus but 
could not be applied to skin lesions remote 
from the gastrointestinal tract.
G. J. DEVROEDE
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ETIOLOGY AND EPIDEMIOLOGY OF CROHN’S DISEASE
JOHN E. LENNARD-JONES
D r . D evroede has already brought to our 
attention the difficulty of defining Crohn’s 
disease. It is because of the lack of a simple 
clear-cut definition that we have so much 
difficulty in studying its epidemiology. Hav­
ing defined what we understand by this 
condition, we need to know the population 
from which our patients are drawn in regard 
to its size, age and sex distribution. We also 
need to know how the patients have been 
discovered among this population. Lastly, 
in any epidemiological study we must know 
which patients have been excluded.
The last point is extremely important. 
For example, Evans and Acheson published 
an interesting study from Oxford, England, 
in 1965 but many of the patients they ex­
cluded from their series were described in 
detail and now we would regard these same 
patients as having Crohn’s disease. So it 
is very important that the excluded patients 
should be listed and fully described.
Let us now briefly consider the diagnostic 
criteria of Crohn’s disease. Crohn’s disease 
at present can be diagnosed only on ana­
tomical grounds. I suggested in 1971 that 
the diagnosis can be made on the basis of 
the following characteristics. The disease, 
as it was originally described by Crohn and 
his colleagues, tends to have a predilection 
for the distal ileum. It is characterized by a 
peculiar type of anal lesion and the frequent 
presence of fistulas between the bowel and 
the skin, or between the bowel and another 
viscus. The disease tends to be discontinu­
ous along the length of the gut or around 
its circumference and it can involve any
portion of the intestinal tract from the mouth 
to the anus. Turning to histology, Crohn’s 
disease involves all layers of the bowel wall, 
often showing peculiar, rather characteristic 
fissures. The epithelioid type of granuloma 
is not always present but probably occurs 
in between one-half and three-quarters of all 
patients. There is lymphoid hyperplasia and 
mucin tends to remain in the goblet cells of 
the inflamed colonic mucosa.
As will be described later, not all these 
features are found in every case. There­
fore, if we are going to define Crohn’s dis­
ease, we have to have some sort of a scoring 
system (Table I). I have suggested, and this 
has not been universally accepted, that per­
haps we might define Crohn’s disease by the 
presence of the typical epithelioid cell granu­
loma with one of the other features, or by 
the presence of three of the other features 
without the granulomas. You will notice 
that some of the features can be diagnosed 
clinically and some radiologically but one 
also needs a biopsy or an operative speci­
men to find the histological changes.
What has made epidemiological studies 
difficult is that this disease affects different 
areas of the gut and many of the earlier 
studies were confined to regional ileitis 
only. In an interesting study done in Basle, 
Switzerland, by Fahrlander and Baerlocher 
in 1971, the anatomical distribution of the 
disease was analyzed and it was found that 
in 34% of the patients the disease was con­
fined to the terminal ileum, in 37% it af­
fected the terminal ileum and colon, in 28 % 
it involved the colon only and in 5% the
TABLE I.—D iagnostic F eatures of Crohn’s D isease
Ileal involvement................................
Anal involvement................................
Fistula...................................................
Discontinuity.......................................
Fissure...................................................
Granuloma............................................
Lymphoid hyperplasia.......................
Retention of mucin in goblet cells . . 
Transmural extension.........................
C lin ic a l X - r a y B io p s y O p era tive  sp e c im e n
+ + + ++ + ++ + ++ + + ++ +
* *
+ ++ ++
Crohn’s disease =  +  +  +  or +*.
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anus and rectum. I wish to draw your at­
tention to the fact that the colon and the 
ileum are involved in approximately 70% 
of the patients.
When we consider epidemiology, we must 
think in terms of geography, age and sex 
incidence, and change with time. There 
have been a number of studies done around 
the world (Kyle, 1972 and Evans, 1972) 
and these show that the disease is most 
common in northwest Europe and North 
America. It is much less common in South 
America, probably even less common in 
Australia, almost absent in southeast Asia 
and in Africa. Within the United States it 
is more common among Jews than among 
non-Jewish people and it is also more com­
mon among Caucasians than among black 
people. There is also a very interesting varia­
tion with age in that there tends to be a 
maximum incidence between the ages of 
20 and 40 years, and there is also another 
peak later in life. Sex incidence varies in 
different series but it is approximately equal 
for men and women. There have been only 
three studies in which all the known factors 
were carefully controlled. One was done in 
Sweden, one in northeast Scotland and one 
in Switzerland. The incidence of Crohn’s 
disease in these studies, that is to say the 
number of new cases per 100,000 popula- 
toin per annum, has been approximately
equal, that is 2.5 in Sweden, 2.2 in Scotland 
and 1.6 in Switzerland. Because Crohn’s 
disease is a chronic disease, the prevalence, 
that is the number of patients with this dis­
ease per 100,000 of population on any 
particular day, is of course greater; in 
Sweden it is 27 and in Scotland 32.5. In 
every series, the incidence has approximately 
doubled over the last few years. It could be 
argued that the diagnosis is improving but 
there are valid arguments that this can only 
partially account for the observed increase 
in incidence.
Fig. 1 represents the figures of Dr. Rit­
chie at St. Mark’s Hospital in London, 
showing the age of onset of Crohn’s disease 
and its distribution in the gut. You will 
notice, as Crohn and others found, that the 
peak incidence of primary small intestinal 
disease is early in life, in the 20s and 30s. 
Interestingly enough for disease affecting 
the distal colon and rectum there is a peak 
incidence between the ages of 50 and 70. 
Why there should be this peak in Crohn’s 
disease of the distal colon in the older age 
group is quite unknown but it probably ac­
counts for the fact that in the overall age 
incidence of Crohn’s disease there is a peak 
between the ages of 20 and 30 and a rise 
later in life.
We do not know the cause of Crohn’s 
disease but information can be derived from
Small Intestine t colon (137coses)
Fig. 1.—Age distribution and sites of involvement of Crohn's disease: 350 cases.
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various sources. I have just reviewed the 
epidemiology and there have been one or 
two interesting features worth noting. First, 
it is common in some parts of the world and 
uncommon in others. This suggests that 
perhaps there is an environmental factor 
operating in these countries. There is also 
a suggestion in these series that this disease 
is increasing in incidence in the developed 
countries, again perhaps indicating a mod­
ern environmental factor. Its common oc­
currence late in life and its location 
distally in the colon must be useful clues 
but as yet they are not understood. Second, 
we have some genetic data. In a series of 
patients with Crohn’s disease there is an 
increased prevalence of the disease among 
the relatives. In our own series it is 130 
times the expected prevalence in the general 
population. There is another interesting 
genetic relationship in that Crohn’s disease 
is related to ankylosing spondylitis and the 
latter disease is associated with one parti­
cular tissue antigen, namely HL-A27. It is 
also possible that Crohn’s disease is related 
genetically to ulcerative colitis.
Fig. 2 summarizes some of the gross and
MACROSCOPIC
MICROSCOPIC 
LYMPHOID AGGREGATES 
MUCIN
GRANULOMATA
TRANSMURAL
Fig. 2.—Anatomical features of Crohn’s colitis.
microscopic anatomical features of Crohn’s 
colitis. Perhaps the most interesting feature 
of morbid anatomy is observed in the study 
of the early lesion and this may well be 
ulceration of a small lymphoid follicle in 
the wall of the gut. We know from conven­
tional histology that there are lymphoid ag­
gregates in the wall of the gut, and McGov­
ern, in Australia, suggested that ulceration 
usually begins with the aggregation of lym­
phocytes around the base of a gland.
If we turn to electron microscopy (Alu- 
wihare, 1971) there are again some interest­
ing features. First, the epithelial cells are 
not damaged where the bowel is not ulcer­
ated. Hence it does not appear to be an 
epithelial cell disease. On the contrary, there 
is an increase in the number of lymphocytes 
and plasma cells in the lamina propria and 
the former differ from the ordinary lym­
phocytes in having a rather prominent nu­
cleolus. This is a change often seen when 
lymphocytes are undergoing blast trans­
formation, that is when they are immuno- 
logically stimulated. The epithelioid cells, 
which are so characteristic of Crohn’s dis­
ease, appear under the electron microscope 
like macrophages. They contain many 
lysozymes and a lot of acid phosphatase, 
but they do not appear to be acting as pha­
gocytes. Also of interest is that in areas of 
the bowel remote from the disease bacteria 
are found in the lamina propria. They are 
not found in the wall of the normal colon 
and are not found in ulcerative colitis. All 
these features suggest that there is an im­
munological disorder affecting lymphocytes, 
plasma cells and macrophages, and the 
presence of the bacteria in the lamina pro­
pria perhaps suggests that the defence 
mechanisms of the colon are ineffective.
I will not review the great amount of 
immunological data on Crohn’s disease be­
cause it is so conflicting. There are a number 
of reports suggesting that there is a depres­
sion of cellular immunity in Crohn’s disease. 
For example, a very interesting recent study 
has shown that the lymphocytes in this con­
dition do not undergo the normal blast 
transformation when exposed to the lym­
phocytes of a patient with different tissue 
antigens (Richens et al, 1974).
Lastly, and this is perhaps one of the most 
interesting areas of investigation, we come
an emerging problem.
“Bacteroides species are often over­
looked as a cause of serious infec­
tion both by clinicians and micro­
biologists. They are most commonly 
associated with intra-abdominal 
and pelvic sepsis following gastro­
intestinal surgery.”
“Our experience with this series of seriously 
ill patients provides clinical confirmation to 
complement recent in vitro evidence that M 
clindamycin is the antibiotic of choice for 
use in bacteroides infections. Not only was < 
the response in 17 of the 18 patients favour- u 
able, but in several it was dramatic.”
Tracy, 0 .,e t al. (29 Jan.’72), 
Brit. med. J., p. 280.
Haldane, E. V. and van Rooyen, C.E. (1972). 
C.M.A.J.,p. 1177.
ic Abscess -  surgical removal and drainage
e illustration tfie surgeon is preparing to remove a right 
subphren ic abscess. The patient is in the nephrectomy position, 
and the surge0p»tp<e(?put to make the initia l incision. H e  tr ill 
m anuatly ’ekp iore the figh t extra-peritoneat.spacW.'Whe'rt the > . ,
abscess i^\epcountered, the finper w in be pushed firm ly through < 
th e^ a ll and the pus evacuated with a sucker. Before c los ing , I 1, 
a.sj?8in is p laced and brought out through a separate stab wound '
tow the main incision.
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to microbiology. Many people have looked 
for viruses and other infective agents in 
Crohn’s disease without discovering one. 
Recently, by analogy with leprosy, tissue 
from lesions of Crohn’s disease has been 
injected into the footpad of the thymectom- 
ized, irradiated mouse. This is a mouse 
whose immunological defences have been 
almost completely destroyed. Lesions devel­
op but they develop slowly. It has now 
been found that this granulomatous lesion 
will also develop in an ordinary mouse and 
the reason that this has not been found 
before is probably that people have not 
waited long enough. Now we know that one 
must wait for months before the sarcoid 
lesion appears. This original work has now 
been extended by injecting tissue from the 
lesions of Crohn’s disease into the intestine 
of rabbits (Cave et al, 1973). When this is 
done, a lesion develops which, perhaps, has 
some of the histological characteristics of 
Crohn’s disease but not quite as we see it 
in humans. A more interesting observation 
is that the lesion spreads in the intestine 
and it can be passaged from one rabbit to 
another; it has now been passaged to the 
third generation. Whatever it is that can be 
transmitted will pass through a 0.2 p, filter 
and therefore it is not a bacterium. It could 
be a virus or it could be something like an 
L form of a bacterium.
How can we summarize this information? 
We have noted that there is probably an 
environmental factor. There is also evidence 
that there may be an infective factor. 
Genetic and immunologic data suggest that 
perhaps some patients are particularly liable 
to develop this disease and that this in­
creased risk may be immunologically me­
diated. This is perhaps where our knowledge 
of the etiology of Crohn’s disease rests for 
the present.
Upjohn T H E  U P JO H N  C O M P A N Y  O F  C A N A D A
865 Y O R K  M IL L S  R O A D /D O N  M IL L S , O N T A R IO
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CLINICAL FEATURES AND PROGNOSIS OF CROHN’S DISEASE
J. P. McMANUS
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C ro h n’s disease presents an ever-increas­
ing challenge to clinicians despite great ad­
vances on many biological frontiers. Since 
the inflammatory process respects no ana­
tomical boundaries, retention of the eponym­
ous term may be justified. The clinical 
features and complications are determined 
mainly by the histological nature and the 
anatomical site of the lesion and the func­
tion of the part of the gut affected (Tables 
I and II).
Inflammation is accompanied by the non­
specific features of fever, malaise and 
anorexia which may dominate the clinical 
picture. When inflammation is extensive, 
there is accompanying disturbance of func­
tion. Gastroduodenal lesions are commonly 
associated with dyspepsia or symptoms of 
delayed gastric emptying. Involvement of 
the small intestine is accompanied by dis­
turbances of transit or regional disturbances 
of absorption producing a varying spectrum 
of deficiency syndromes. When colonic 
function is compromised there will be diar­
rhea, and if the vital reservoir role of the 
rectum is also impaired the patient will 
suffer from urgency and even incontinence.
Associated with ulceration, there is a loss 
of blood and protein which, if extensive, 
results in anemia and severe hypoproteine- 
mia. These in turn may have a deleterious 
effect on the function of other organs. Fis­
tulas are characterized by an inappropriate 
flux from skin surfaces or organ orifices; a 
short-circuit connection between small and 
large bowel results in fecal contamination 
with resultant diarrhea and steatorrhea. 
Fibrosis, a very common histological find­
ing in this disease, causes stasis and colic. 
It is now recognized that what used to be
TABLE I.—Relationship of Pathophysiology to the Nature of the Gut Lesion
(1) Inflammation: fever, malaise, anorexia
regional disturbance of function—gastroduodenum
small bowel 
colon
(2) Ulceration: loss of blood, protein
(3) Fistulas: inappropriate flux
bacterial contamination—diarrhea
short circuit—steatorrhea
(4) Fibrosis: stasis, colic
TABLE II.—Relationship of Pathophysiology to the E xtent and Anatomical Site of the Lesion
and the Function of the R egion Affected
(1) Gastroduodenum: transit—pyloroduodenal “hold-up”
digestion — “a typical dyspepsia”
(2) Small intestine: transit—hurry
stasis
obstruction
absorption—-regional differences
(3) Colon and rectum: absorption—water
electrolyte exchange 
transit—hurry 
hold-up
reservoir—urgency
incontinence
Plus: (a) perianal disease—fistulas, abscess, fissures or tags;
(b) skin involvement—perineum, buttocks;
(c) fistulas—gut, skin, genital or urinary tract.
Plus: Systemic complications—uveitis, arthritis, ankylosing spondylitis, 
liver dysfunction, severe oral aphthous ulceration, skin problems.
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regarded as strictures in the colon are in 
fact more often areas of local muscle spasm 
and hypertrophy.
The complications of Crohn’s disease can 
be conveniently classified as psychological, 
visceral, extravisceral, metabolic and iatro­
genic.
In considering psychological disturbances, 
it must be remembered that the disease very 
often affects the young, individuals in their 
prime, whose social, intellectual and sexual 
life, indeed whose whole future, may be 
severely interrupted and is to be disrupted 
repeatedly because of the incurable, chronic, 
progressive nature of the condition. One 
must realize the catastrophic effects the 
condition may have on the patient’s morale. 
Diarrhea, urgency and incontinence may 
make the victim bad tempered and this re­
flects not his basic personality but the effect 
of the disease on his psyche. Then again, 
the situation may be aggravated by disturb­
ing side effects, e.g. hirsutism, acne, or 
obesity in patients receiving large doses of 
corticosteroids for prolonged periods of 
time.
Of the visceral complications, the perianal 
fistulas, fissures, abscesses and redundant 
edematous skin tags are the most readily 
recognized. The visceral manifestations, fis­
tulas and strictures have already been men­
tioned. In my own experience severe colonic 
bleeding is more a feature, albeit very rare, 
of granulomatous colitis than of ulcerative 
colitis. Toxic dilatation reflecting severe 
disease advancing on a broad front is a less 
demanding but a rare manifestation of 
colonic involvement. Perforation is also a 
much less common sequel than in ulcerative 
colitis.
Five or six years ago it would have been 
agreed that there was no increased risk of 
malignant disease associated with Crohn’s 
disease. Then, in the beginning of 1973, a 
report from London and later in the same 
year a study from the Mayo Clinic leave 
no doubt that there is an increased incidence 
of malignant disease of the large bowel, of 
the order of 20- to 30-fold, and a strong 
suggestion of an increased incidence of 
carcinoma of the small intestine associated 
with chronic Crohn’s disease. What, then, 
are the implications for the patients and 
clinicians? Should we be screening these pa­
tients for carcinoma antigens? Should we 
use colonoscopy and, when the instruments 
become available, should we be passing en­
teroscopes routinely? Should a constant 
watch for pre-malignant changes in rectal 
biopsies be maintained? Personal experience 
suggests these changes are not necessarily 
always present in patients who develop car­
cinoma of the colon complicating ulcerative 
colitis.
It is evident that the same spectrum of 
extravisceral manifestations may occur with 
Crohn’s disease as with ulcerative colitis, 
although in general less frequently than in 
the latter condition. Oral aphthous ulcera­
tion can be a severe problem and on occa­
sion has tilted the balance in favour of 
surgery in patients with chronic intractable 
disease. The skin manifestations may not 
always correlate well with the state of activ­
ity of the disease. As regards the hepatic 
lesions, fatty infiltration, pericholangitis, 
chronic active hepatitis, cirrhosis, granulo- 
mata, amyloid deposits and hepatic abscesses 
have all been described. Only cholangitic 
carcinoma, which rarely occurs as a com­
plication of ulcerative colitis, has not yet 
been documented in patients with Crohn’s 
disease.
In all fairness it must be kept in mind 
that the incidence of these extravisceral 
manifestations in Crohn’s disease as well 
as in ulcerative colitis, reflects the skill and 
the enthusiasm of the centre reporting. Thus 
an ophthalmic group and a rheumatology 
unit will report a high incidence of eye com­
plications and of arthropathy respectively 
compared with other series. There is an 
association of ankylosing spondylitis with 
Crohn’s disease and an increased family in­
cidence of both of these conditions with 
ulcerative colitis. McConnell has suggested 
that this is the result of overlapping geno­
types. Time does not permit discussion of 
the renal manifestations such as fistula 
giving rise to infection, hydroureter, the 
increased incidence of renal calculi and the 
possibility of amyloidosis.
The nutritional and metabolic complica­
tions are common, but happily they respond 
quite rapidly to successful treatment of the 
underlying disease. They are of considerable 
practical interest and often may be im­
portant manifestations of the disease. The
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mechanisms involved are often multiple. 
There may be malnutrition because the pa­
tient does not want to eat against a back­
ground of a catabolic process, the result of 
the inflammatory disease. The situation may 
be aggravated by a degree of malabsorption 
caused in turn by various factors, com­
pounded by increased loss from the bowel. 
There may be a subocclusion producing 
bacterial proliferation with its accompanying 
disturbances of absorption or, paradoxically, 
there may be an increased rate of transit 
interfering with proper digestion and absorp­
tion of nutrients. Often there is anemia, 
again multifactorial, caused by nutritional 
factors, increased loss of blood, malabsorp­
tion and marrow depression, now recognized 
as the so-called anemia of chronic disease. 
The whole situation can be aggravated by
Fig. 1.—Results of a Mayo Clinic study show­ing survival rates of 449 patients with Crohn’s disease.
hemolysis or, more rarely, marrow depres­
sion related to Salazopyrin therapy. Aza- 
thioprine can now also be added to the list 
of potentially toxic drugs used in the treat­
ment of this disease. The hypoalbuminemia 
may be a reflection of the diminished in­
take, increased loss, increased catabolism 
and, perhaps, impairment of liver function.
Iatrogenic complications must always be 
considered in view of the barrage of non­
specific therapy that may be administered 
over a long period of time. The three main 
lines of therapy, namely corticosteroids, 
Salazopyrin and azathioprine, all have well- 
recognized side effects. An increased un­
derstanding of the metabolism of these drugs 
can markedly diminish the incidence of side 
effects and increase the therapeutic benefits. 
Complications of surgical techniques have 
become less frequent through the abandon­
ment of side-to-side intestinal anastomosis, 
increased understanding of the metabolic 
sequelae and implications of intestinal re­
section, and the avoidance of ileostomy 
in patients who have Crohn’s disease of the 
small bowel.
Finally, in regard to the difficult, frustrat­
ing area of prognosis, the recent study at 
the Mayo Clinic confirms the reduced surv­
ival in patients with Crohn’s disease (Fig. 1). 
It is perhaps noteworthy that the survival 
has improved since 1953, i.e. about the 
time that corticosteroids became available. 
The value of surgery and its role in de­
termining the long-term prognosis will be 
discussed by other contributors.
392 THE CANADIAN JOURNAL OF SURGERY Vol. 1
ENDOSCOPY IN CROHN’S DISEASE
G. J. DEVROEDE
T he presence of extensive indolent anal and 
perineal ulcerations, with numerous deep 
fistulas, is a classical feature of Crohn’s 
disease. The miliary tubercles that sur­
round the ulcerations contain granulomas 
(Fig. 1; other lesions are seen in Fig. 2). 
The fistulous abscesses are not always as 
extensive. One can see (a) the opening of a 
fistula in the anterior midline of the anal 
canal just at the level of the dentate line. 
This patient had an ischiorectal abscess with 
characteristic histological lesions of Crohn’s 
disease and no lesions anywhere else in 
the gastrointestinal tract. This is a case of 
Crohn’s disease of the anus. Occasionally 
patients with Crohn’s disease elsewhere in 
the gastrointestinal tract have anal fissures 
(b) such as these which do not have particu-
Fig. 1.—Anal and perineal ulceration in Crohn’s 
disease.
Fig. 2.—(a) Crohn’s disease of the anus. A fis tula opens in the anterior midline of the anal canal 
at the level of the dentate line, (b) Anal fissures, (c) A granuloma was found under the reddish spot 
in the centre of this picture. The mucosa was intact. This represents one of the earliest visible lesions 
of Crohn’s disease in the colon, (d) Punched-out ulcerations, (e) Linear ulceration, (f) Scar of a 
previous granuloma representing resolution of a lesion. (Published by courtesy of the Olympus Cor­
poration of Canada, G. D. Searle & Co. of Canada Ltd. and the ACMI Company.)
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lar characteristics and are not indolent but 
are painful. Present and Janowitz found 
epithelioid granulomas in 8% of the pa­
tients who had Crohn’s disease and a nor­
mal sigmoidoscopic appearance with a pin­
kish mucosa and a normal vascular pattern. 
The use of commercial hypertonic enemas 
such as Fleet or Travad may be responsible 
for minor changes observed at endoscopy. 
One can still recognize the vascular pattern 
but there is a reddish appearance of the 
mucosa which might be mistaken for an in­
flammatory reaction. Petechiae may appear. 
The earliest lesion of Crohn’s disease that 
can be recognized at endoscopy is very simi­
lar in appearance. The reddish spot in the 
middle of the photograph (c) was biopsied 
and a classical granuloma was found. This 
picture illustrates the difficulty in recogniz­
ing early lesions at proctoscopy. With more 
extensive disease (d) punched-out ulcera­
tions may be found. In our experience 
Crohn’s disease of the colon is the most 
common cause of localized ulcerations in 
the rectum and sigmoid. The mucosa be­
tween the ulcers may be completely normal, 
or in acute bouts of the disease it may be 
edematous and inflamed. Figure (e) shows 
one of the most characteristic lesions of 
Crohn’s disease. The linear, longitudinal 
ulceration was biopsied and granulomas 
were found underneath. This should not be 
confused with that caused by a proctoscope 
which has a slightly curvilinear appearance.
Another type of trauma can result from the 
too forcible introduction of an enema can­
nula by a nurse. It may also be seen after 
insertion of a proctoscope or a thermometer. 
Classically this traumatic ulcer is found at 
the anorectal angle.
In some cases fistulas occur and may be 
seen. Finally, lesions of Crohn’s disease may 
disappear. At (f) the whitish area in the cen­
tre is the scar of a previous granuloma. The 
patient had a stenosing lesion in the small 
bowel. In the rectum there was a tuft of 
granulation tissue containing giant cells and 
typical granulomas. The small bowel was 
resected because of obstruction and the pa­
tient was subsequently treated with Salazo- 
pyrin. Three years after surgery she is com­
pletely asymptomatic and has no evidence of 
recurrent disease. At proctoscopy the area 
where giant cells and granulomas had been 
found is completely epithelialized and only 
this scar is to be seen.
In summary, the main feature of Crohn’s 
disease of the rectum is the localized rather 
than diffuse pattern of the lesions. As a con­
sequence the vascular pattern can be fre­
quently identified. Characteristic lesions 
may be small erythematous areas, linear 
ulcerations or more extensive undermining 
ulcers. Crohn’s disease, in contrast to ulcer­
ative colitis, may spare the distal part of the 
bowel. Follow-up of patients with colitis 
without rectal involvement demonstrates 
that they usually have Crohn’s disease.
HISTOPATHOLOGY OF CROHN’S DISEASE
M. LERICHE
The pathological diagnosis of Crohn’s dis­
ease is based on the detection, after a 
careful search, of a pattern, rather than of 
isolated diagnostic features. The histological 
signs of this disease are numerous and, 
when grouped together, form a character­
istic pattern. Taken individually, none of 
the signs are specific and they can be found 
in widely varying afflictions of the gastro­
intestinal tract such as tuberculosis and 
ulcerative colitis.
The sarcoid reaction, when present, is a 
most helpful histological sign. As shown in 
Fig. 1, the typical lesion is composed of a 
few giant cells of the Langhans type sur­
rounded by some epithelioid cells and a thin 
rim of lymphocytes. There is also a sur­
rounding inflammatory sclerosis. Caseation 
and Koch’s bacilli are absent from the 
granuloma but there may be a patch of 
fibrinoid necrosis in its centre, making the 
interpretation of the lesion difficult. More
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often than not the pathologist is confronted 
with a more rudimentary form of the 
sarcoid reaction, a lesion without giant cells 
and consisting mainly of a few reticular 
cells surrounded by lymphocytes. The sar­
coid lesion is seldom abundant and, accord­
ing to Lockhart-Mummery and Morson, it 
is completely absent in about 40% of the 
patients with Crohn’s disease. When present 
it can be seen in any portion of the in­
testinal tract and in all layers of the bowel 
wall. It is most common in the submucosa 
and the serosa. When it is confined to the 
serosa only, a foreign-body granuloma must 
be excluded. Besides the bowel wall, lymph 
nodes, the liver and the skin may also con­
tain granulomas.
The absence of sarcoid lesion, while not 
excluding the diagnosis of Crohn’s disease, 
demands a search for fissures which form 
the next important histological feature of 
this disease. These fissures, as shown in Fig. 
2, start from the mucosal surface and run 
deeply into the bowel wall forming vertical 
clefts with both sides lined with poly­
morphonuclear cells enmeshed in a fibrin 
net. This feature distinguishes a true fissure 
from an artefact. Like sarcoid lesions, fis­
sures are also relatively rare and careful 
scrutiny of many sections is required to
Fig. 1.—Sarcoid reaction in Crohn’s disease. A 
typical lesion showing giant cells surrounded by 
epithelioid cells and a rim of lymphocytes. There 
is no caseation.
discover them. Again, fissures are not 
specific for Crohn’s disease and may be 
seen in lymphomas and ulcerative colitis. 
The fissures found in ulcerative colitis do 
have some distinguishing features, however. 
They are usually horizontal, symmetrical 
and have a hook-like appearance. The fis­
sures are usually regarded as the earliest 
form of intramural abscesses and fistulas.
More often than not, the mucosa is 
healthy except in the small areas where ulcers 
and fissures are present. The glands of the 
mucosa are normal but there may be areas 
of Brunnerian metaplasia or atrophy. Crypt 
abscesses may be present in the mucosa and 
these must not be regarded at pathogno­
monic of ulcerative colitis. The tunica 
muscularis mucosae is normal except when 
it is involved by the ulcers.
The submucosa is always noticeably 
thickened and abnormal. In the early stage 
there is edema; in the more advanced cases 
a chronic fibrous inflammatory process con­
sisting of two major components is present. 
The first of these is the granulomatous reac­
tion already described. The second compo­
nent, always present, is an inflammatory 
reaction showing lymphocytes and plasma 
cells. Frequently there are lymph follicles, 
somes showing germinal centres and dilated 
lymphatic channels. In this layer, parti­
cularly, endarteritis and thrombosis can be
Fig. 2.—A fissure forming a vertical cleft with 
its origin at the mucosal surface.
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found. The myenteric nerve plexus is often 
prominent, probably owing to edema of the 
bowel wall rather than to any intrinsic 
changes in the plexus.
The submucosa is widened and altered by 
inflammatory sclerosis. At times it con­
tains lymph follicles attached to the my­
enteric layer. In the mesenteric lymph nodes 
we have observed lymphatic stasis with 
widened sinusoids and the occasional 
sarcoid reaction. To sum up the foregoing 
description, one can say that the only mi­
croscopic feature present in all patients is a 
thickened bowel wall with transmural in­
flammation.
Crohn’s disease may affect every portion 
of the gastrointestinal tract and the various 
topographic forms may have certain peculiar 
histological features of their own. In the 
colon the mucosal ulcers are larger than 
those found in the small bowel. The in­
flammatory polyps classically described in 
ulcerative colitis may also be present in 
Crohn’s disease of the colon. Sometimes 
these inflammatory polyps form peculiar 
bridges. I wish to emphasize that the mu­
cosal bridges of ulcerative colitis are very 
different from the ones observed in Crohn’s 
disease. In the former there are true bridges 
of mucosa creeping over polished mucosa 
giving the appearance of oilcloth. In 
Crohn’s disease the bridges are irregular 
channels through a sclerotic wall, forming a 
lace pattern (Fig. 3). Crypt abscesses are 
not uncommon in Crohn’s disease, as are 
metaplasic cells of the Paneth’s cell type. 
Granulomas are more frequent in the colon 
than when the disease is seen in the small
Fig. 3.—Probes demonstrate the presence of 
mucosal bridges in Crohn’s disease.
bowel. In the colonic form the nodular 
aspect of the inflammatory reaction is often 
absent, the bowel wall showing a rather uni­
form diffuse infiltration by inflammatory 
cells. Diverticular disease of the colon is not 
uncommonly associated with Crohn’s dis­
ease and an erroneous clinical and patho­
logical diagnosis may lead to incomplete 
resection of the diseased bowel with an in­
creased likelihood of postoperative compli­
cations. In the anorectal form the histo­
logical signs are the same as those already 
described. In this form, however, the lesions 
are readily accessible to direct examination 
and biopsy. When taking multiple biopsies, 
one should remember that normal looking 
mucosa may already show characteristic mi­
croscopic changes. With regard to the pro­
gression of the disease, two points deserve 
particular emphasis. In the early phase the 
pathologist is almost never consulted be­
cause the patient receives medical therapy 
or, if he is operated upon, a biopsy of the 
involved area is not taken. However, in a 
few specimens of the early lesion, marked 
edema of the bowel wall, hyperplasia of the 
lymph follicles in the subcucosa and, at 
times, minimal ulceration on the superficial 
aspect of the lymph-node follicle have been 
observed. The second point worth em­
phasizing is that in a phase of remission, 
mucosal ulcers may become scarred and 
covered over by regenerative type of mu­
cosa with rudimentary glands and some 
Paneth’s cells. The tunica muscularis mu­
cosa never regenerates completely and the 
new mucosa usually lies drectly against the 
submucosa.
In summary, the most important histo­
logical signs leading to the diagnosis of 
Crohn’s disease are broad submucosal in­
volvement, vertical fissures, sarcoid reac­
tion either in the intestinal wall, the lymph 
nodes or the anal lesion, small ulcers of the 
mucosa, healthy mucosa between ulcers, 
transmural inflammation with lymphoid 
follicles, sclerosis of the wall, and changes 
in the arteries and nerves. Individually, 
none of these features are pathognonomic 
and the diagnosis of Crohn’s disease conti­
nues to pose problems for the histopatho- 
logist. Perhaps the discovery of an etiologi­
cal agent will put the diagnosis on a firmer 
basis.
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RADIOLOGICAL FEATURES OF CROHN’S DISEASE
B. G. STROM
C haracteristic  changes of granulomatous 
disease of the bowel, also known as Crohn’s 
disease, include mucosal changes, ulcers, 
fistulas and abscesses and thickening of the 
whole bowel wall. All these changes are re­
flected in the various signs seen at the radio­
logical examination. A complete description 
of the radiological features of this disease is 
not the object of this presentation and, 
therefore, only a few typical examples of ra­
diological signs will be presented with com­
ments on the differential diagnosis. The 
discussion will be limited to bowel disease, 
leaving urological complications, bone in­
volvement and other complications aside.
Granulomatous disease of the gastro­
intestinal tract has been described from the 
mouth to the anus but the typical and dia­
gnostic changes are best seen in the small 
and large bowel. The mucosal changes give 
a typical granulomatous appearance to the 
intestinal mucosa, completely different from 
the normal, delicate pattern (Fig. 1). 
Ulcers show as barium-filled clefts or 
crypts outside the lumen (Fig. 2) and 
fistulas may be outlined by the contrast 
material. Sometimes a fistula is shown 
as a short circuit to other bowel loops, 
often between the terminal ileum and the 
sigmoid (Fig. 3). An abscess most often 
is seen as a space-occupying lesion, often 
with compression of adjacent bowel loops, 
sometimes simulating an appendiceal 
abscess (Fig. 4). Most of the enterocutane- 
ous fistulas appear in the postoperative 
period and sometimes fistulography is 
necessary to identify the whole tract. Thick­
ening of the bowel wall and mesentery is 
seen as a separation of bowel loops. Also, 
the presence of non-flexible loops of bowel 
with long curves contrasts with the grace­
ful pliability of normal small bowel (Fig. 5). 
Stenotic lesions cause a pre-stenotic dilata­
tion, often the site of food retention. Forma­
tion of enteroliths has also been reported.
In the usual case the diagnosis is not dif­
ficult, particularly with the help of clinical 
information but sometimes, especially with 
ileocecal involvement, intestinal tuberculosis
has to be considered in the differential 
diagnosis. A useful sign of Crohn’s disease 
is the so-called string sign which does not 
occur in tuberculosis.
Attempts have been made to assess the 
diagnostic value of various radiological 
signs. Apparently contraction, stenosis and 
rigidity are the most conclusive signs, fol­
lowed by mucosal irregularities and ulcers 
and clefts. The interpretation of skip lesions, 
fistulas and mucosal-fold thickness is more 
difficult and subjective.
In the large bowel interpretation is more 
difficult because fewer typical changes are 
seen. Mucosal changes, ulcers and fissures, 
skip lesions and, in long-standing cases, 
shortening and stenosis can be demon­
strated, but thickening and rigidity of the 
wall and edema of the mesentery are not 
clearly shown (Fig. 6). Tuberculosis may 
mimic Crohn’s disease but the main dif-
Fig. 1.—Granulomatous changes in the terminal 
ileum and cecum.
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Fig. 3.—Fistula between the terminal ileum and sigmoid.
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Fig. 4.—Abscess from Crohn’s disease present­
ing as space-occupying lesion.
Fig. 5.—Rigid ileal loops in Crohn’s disease.
Fig. 6.—Granulomatous colitis. Fig. 7.—Skip lesions in the hepatic flexure with 
rectal sparing in granulomatous colitis.
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ficulty is in differentiating ulcerative from 
granulomatous colitis. The location of the 
disease may give a clue. Ulcerative colitis 
is generally seen in the rectum, with ex­
ceptions varying from series to series. In 
the large series from St. Erik’s Hospital in 
Stockholm, of 490 patients with ulcerative 
colitis only 2% did not show changes in 
the rectum. On the other hand, in the same 
institution in 149 cases of Crohn’s disease 
there was rectal involvement of moderate 
degree in 39% while 91% showed in­
volvement of the terminal ileum. In 
ulcerative colitis a change called “back­
wash ileitis” may be seen in the terminal 
ileum but its radiological appearance is 
quite different from that of granulomatous 
ileitis, showing a wider, smoother, hypo­
tonic terminal segment. Other criteria in­
clude the type of ulcer encountered. In ul­
cerative colitis these are mostly of uniform 
size and shape, whereas in granulomatous 
colitis many different forms and sizes 
coexist. A retrospective British study 
reports that the following features are com-
Fig. 8.—Marked thumbprinting in a case of 
ischemic colitis.
mon to both diseases: thumbprinting, coarse 
serration and shallow ulcers, swollen mu­
cosal folds and decreased length and calibre 
of the bowel. Signs which are fairly sug­
gestive of ulcerative colitis include total 
large bowel involvement, rectal involve­
ment, fine serration and absence of 
haustration. Even more significant are a 
smooth contour of the wall, the presence of 
pseudopolyps and hazy longitudinal folds. 
On the other hand the signs that favour the 
diagnosis of granulomatous colitis are rectal 
sparing, proximal colitis, terminal ileitis, skip 
lesions (Fig. 7), abnormal haustrations, asym­
metry of the lumen, deep ulcers, nodularity 
or cobble-stone appearance of the mucosa 
and fistulas and abscesses.
The absence of some of the signs may be 
more helpful than the presence of others. 
For instance, the absence of involvement of 
the rectum or of the terminal ileum is in 
itself strongly suggestive of the diagnosis. 
The evolution of some cases has to be fol­
lowed before a definitive radiological dia­
gnosis can be made. In the distal colon the 
most prominent feature may be thumb­
printing and ischemic bowel disease must be 
considered in the differential diagnosis 
(Fig. 8). In such cases angiography is most 
helpful.
Finally, the necessity of performing 
barium studies in all suspected cases must 
be emphasized, especially in patients pre­
senting signs of partial obstruction with 
spontaneous and rapid recovery. Dilated 
pre-stenotic small bowel loops may simulate 
colon on the plain films, or may be com­
pletely filled with fluid and thus not be 
visible. A complete radiological work-up, 
with small bowel series and barium enema, 
is necessary to detect these cases before fi- 
brotic stenosis makes a resection or a by­
pass the only therapeutic choice. The pre­
sence of enteroliths on the plain films should 
make the radiologist suspicious.
Patients with fever of unknown origin 
should undergo extensive gastrointestinal in­
vestigation, even in the absence of suggestive 
symptoms.
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MEDICAL TREATMENT OF CROHN’S DISEASE
JOHN E. LENNARD-JONES
A t present there is no medical cure for 
Crohn’s disease, but I do think that medical 
treatment has some contributions to make, 
in three ways. One tries to reduce the in­
flammation in the gut, to correct nutritional 
disturbances which, as Dr. McManus has 
shown, are rather common and, when we 
cannot do anything else, to relieve the pa­
tient’s symptoms.
Let us first of all try to reduce inflamma­
tion. We have various drugs available for 
this purpose. There are antibacterial agents, 
by which I mean sulfonamides other than 
salicylazosulfapyridine and, of course, anti­
biotics. These do not have, as far as I know, 
any specific role but they are sometimes 
useful. I suspect that they exert their bene­
ficial effect by decreasing secondary infec­
tion. A drug that I have found useful but 
for which there has been no controlled trial 
as yet is ampicillin. I use it under particular 
circumstances and I certainly do not use it 
on every patient. More interest focuses on 
the drug that we in the United Kingdom 
call sulphasalazine, which is marketed in 
Europe as Salazopyrin and in the United 
States as Azulfidine. This is a compound 
of sulfapyridine and 5-amino-salicylic acid. 
There has been as yet no controlled clinical 
trial of this drug in Crohn’s disease. There 
are, however, trials in progress in Scan­
dinavia and we are conducting a controlled 
trial in Britain. The results are not yet avail­
able. I cannot tell you, on the basis of these 
trials, whether this drug is useful in Crohn’s 
disease, nor can I tell you how it works. All 
I can say is that in some patients with 
Crohn’s disease it does appear to have some 
beneficial effects and often it is worth try­
ing in a given patient. More than this we 
cannot say at the moment.
We come, then, to the corticosteroids and 
Dr. McManus has shown us that the mor­
tality from Crohn’s disease changed after 
1953. Whether this was due to corticosteroids 
or not is still an open question because 
there has been a greatly different attitude in 
the treatment of Crohn’s disease in recent 
years. Corticosteroids are very widely used. 
Extraordinary as it may seem, there has 
been no direct controlled trial of these 
drugs in Crohn’s disease. The difficulties of 
conducting controlled trials in this disease 
are extreme. Our attempts to undertake such 
trials have usually failed. This is explained 
by the diversity of the disease in regard to 
its anatomical distribution, its acuteness or 
chronicity, as well as other differences, all 
making it extremely difficult to obtain 
matched groups. Most data on cortico­
steroids, therefore, are retrospective, but 
there is some indirect evidence from con­
trolled trials— particularly of azathioprine—  
that corticosteroids do play a part in man­
agement.
Table I presents the data of Drs. Cooke 
and Fielding from Birmingham, England. 
They analyzed the effects of corticosteroids 
in their patients using a number of different 
parameters, clinical, hematological and bio­
chemical. They found that, of the 89 pa­
tients in their series, 14 had an apparently 
good response, 54 had a fair response and 
21 had no response. An interesting point 
is the number of months that elapsed be­
tween the diagnosis and the treatment of 
this disease. For those who had a good 
response, the mean number of months from
TABLE I —Clinical Response to T reatment Related to the Interval Between D iagnosis of 
Crohn’s D isease and the Start of Treatment*
Good response Fair response Poor response
No. of patients......................................
Months from diagnosis (mean). . . .  
Significance of difference. . . . . . .
..........  14
..........  19.14
.......... P <  0.01
54
56.17 
P <  0.01
21
91.33
♦Reproduced by permission from Cooke WT, F ielding JF: Corticosteroid or corticotrophin therapy in 
Crohn s disease (regional ileitis). Gut 11:921,1970.
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diagnosis was 19; for those who had a fair 
response, it was 56 months; and those who 
had no response, 91 months. These differ­
ences are statistically significant. We may 
judge from this that steroids perhaps have 
their greatest role in the patients with the 
shortest history. This, of course, is not sur­
prising. My impression is that these drugs 
have two main uses. First of all, in a pa­
tient with a short history and acute symp­
toms, they may induce clinical remission, 
and in these circumstances they may be 
given for a short period of time. There are 
other groups of patients, particularly those 
with very extensive disease of the small in­
testine, where surgical treatment is not ap­
plicable, or those who have had multiple 
resections of small intestinal lesions, in 
whom the long-term use of corticosteroids is 
permissible and useful. I do not believe 
that corticosteroids remove the underlying 
disease process, they merely suppress it; 
in such patients suppression is worth while 
and the risks of corticosteroid therapy are 
justifiable.
In another series of patients it has been 
shown that those on long-term cortico­
steroids have a higher mortality than pa­
tients not so treated (Prior et al, 1970). The 
difficulty with such an analysis is that usual­
ly it is the most severely affected patients 
who tend to be treated with corticosteroids. 
The other problem with this particular 
series is that the causes of death in the 
steroid-treated group of patients are uncom­
mon. In my own experience and that of 
others the complications reported have not
Fig. 1.—Progression of mean disease activity 
score in patients receiving prednisolone with or 
without azathioprine for Crohn’s disease. (Repro­
duced from W illoughby JM, Kumar PJ, Beck­
ett  J, et al: Controlled trial of azathioprine in 
Crohn’s disease. Lancet 2: 944, 1971.)
been met. So while I do not doubt the data 
the authors record, I am not sure that it is 
generally applicable.
We must now consider immunosuppres­
sive drugs, and in particular, azathioprine, 
the one most commonly used. At present 
the situation is rather confused. Azathio­
prine was introduced some years ago by 
Brooke and his colleagues with some en­
thusiasm. Since the initial optimistic reports, 
some controlled trials have proved possible. 
I know of five such trials, through publica­
tions and personal communications. Fig. 1 
presents the data from a controlled trial by 
Willoughby and his colleagues (1971) at 
St. Bartholomew’s Hospital in London. They 
scored the activity of the disease according 
to a point system using symptoms, hema­
tologic and biochemical findings, and vari­
ous clinical manifestations of the disease. In 
Group I the patients had acute symptoms, 
and in Group II the disease was in remis­
sion at the start of the trial. The patients 
with acute symptoms were treated with cor­
ticosteroids with or without azathioprine. As 
shown in the figure, the symptoms scores 
decreased and the patients improved. At 
this point the steroids were withdrawn. In 
those receiving the placebo the symptoms 
became worse again, but those treated with 
azathioprine tended to remain well. In 
Group II the patients in remission started 
out with a low activity score. The steroids 
were then withdrawn. In those given a place­
bo the symptoms became worse, but in 
those taking azathioprine tablets, while the 
symptoms became a little worse they were 
not as severe as in the controls.
While this is the most convincing trial to 
date suggesting that azathioprine may have 
a place in the treatment of Crohn’s disease, 
one other published trial showed no bene­
ficial effects from the use of azathioprine. 
This was conducted by Rhodes and his col­
leagues (1971) from Cardiff, Wales, whose 
patients had very chronic Crohn’s disease. 
The patients received azathioprine or a con­
trol tablet for two months according to a 
cross-over scheme, and no benefit from the 
azathioprine was demonstrable. I do not find 
this very surprising because of the type of 
patient treated. Two other trials have been 
reported to me in which no benefit from 
azathioprine was evident.
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The conclusion from all this is that aza- 
thioprine is not a wonder drug, nevertheless 
I think it has a role in the treatment of 
some patients with Crohn’s disease. My 
practice is to use it when there is a real 
therapeutic problem, and it has been my 
impression that sometimes it is useful but 
not always. We use it in a dose of 2 m g/kg  
body weight/day, and with this dose hema­
tological complications are almost unknown.
I am not going to dwell on the subject 
of nutrition because it is so familiar to you. 
The greatest nutritional defect is of calo­
ries. The patient is thin and the weight loss 
is often the result of an inadequate intake 
of calories, combined with loss of protein. 
We all know that resection of the terminal 
ileum can lead to vitamin Bn deficiency and 
such patients need replacement of the vi­
tamin indefinitely if there has been a large 
or total ileal resection. Dr. McManus has 
mentioned the apparent iron deficiency 
which may be due to marrow depression. I 
would urge you to measure not only the 
serum iron but also the total iron-binding 
capacity because, if both parameters are low, 
you can give the patient as much iron as 
you like but it will not raise his hemoglobin.
Lastly, a few words about symptomatic 
treatment. When there are strictures in the 
intestine and surgical treatment is not ad­
visable for some reason, a low-residue diet 
may help. I am not a great believer in low- 
residue diet, but this is a positive indication. 
Treatment of diarrhea due to passage of bile 
acids into the colon is important, but I do 
not have the time to discuss it further. The 
physician may have a role in the manage­
ment of some of the anorectal complications 
with the topical application of corticosteroids, 
but more often their treatment is surgical.
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SURGICAL TREATMENT OF CROHN’S DISEASE
FRANK L. WEAKLEY
W e , as surgeons, must always remember 
that we are dealing with a disease where 
the results of surgical treatment are most 
unsatisfactory in many cases. Therefore, we 
must think of Crohn’s disease as primarily a 
medical disease where surgical management 
enters only when there are complications. 
Also, we must not think that the neces­
sity for an operation is caused by the failure 
of medical management but, rather, that the 
surgeon and internist are working together 
to treat the various manifestations and com­
plications of a disease for which we do not 
have a specific cure.
When to operate is of course the first 
question to answer. And, generally speaking, 
an operation should be considered at the 
time when all parties concerned—intern­
ist, surgeon and patient— feel that the pa­
tient’s future is threatened, or his perform­
ance falls short of his desires or inherent 
capabilities. Of course, when unrelenting 
toxicity is present in spite of all non-opera- 
tiye management, or when there is obstruc­
tion which may be the predecessor of a 
massive nutritional deficit, or when a per­
foration with abscess formation or other 
septic complications exists, then there is an 
absolute or near-absolute indication for 
surgical treatment. Now, having placed sur­
gery in its proper perspective with regard 
to the treatment of the patient with Crohn’s 
disease, perhaps it would be appropriate for 
us to discuss management in terms of 
specific do’s and don’t’s for the surgeon. 
There are, definitely, some surgical problems 
that can be avoided and there are certain 
things the surgeon can do to assist the pa­
tient’s recovery.
The first thing for the surgeon to remem­
ber is not to disturb the diseased bowel 
unless he intends to resect it. Do not divide 
adhesions and do not mobilize bowel "just 
to be able to examine it better. The reason 
for this is that many of the adhesions have 
a lumen and we have encountered adhesions 
that, when divided, showed fistulization visi­
ble to the naked eye. Now this is not limited 
to massive adhesions, for often the “banjo­
string” type adhesions when divided, al­
though they do not show gross fistulization 
at the time of laparotomy, will prove to have 
at least potential openings present on micro­
scopic examination. The fissures so well 
shown in an earlier presentation, are an ex­
cellent example of this because microscopi­
cally there is total destruction of the normal 
bowel architecture with a severe inflamma­
tory reaction in the surrounding area. Divi­
sion of these adhesions allows the inflam­
matory mass to find a way to drain, resulting 
in fistulous tracts and abscesses.
Sometimes Crohn’s disease is severely 
interfering with the patient’s well-being and 
health and yet it is all anterior; by that I 
mean it is confined to the bowel and its 
mesentery and therefore removal of the in­
volved portion of the bowel with reanasto­
mosis removes the disease. The difficult 
decision for the surgeon is, of course, where 
to transect the bowel. Sometimes it is very 
difficult to find the correct site but there 
are signs—often very subtle—which can 
be helpful in selecting the proper place of 
resection. For example, the obliteration of 
the mesentery-bowel angle is an indication 
of the presence of the disease. Also, the 
serosal changes which are often quite subtle 
will mark the abnormal bowel, even though 
obstruction is present and the non-involved 
portion of the small bowel is dilated and 
hypertrophied. Because these signs may be 
quite subtle, the presence of lymphadeno- 
pathy adjacent to the bowel— not in the 
central nodes but in the small nodes along­
side the straight vessels that run to the bowel 
from the vascular arcades— is a more 
helpful indication of the presence of dis­
ease. When lymphadenopathy in this area 
diminishes, the place for resection is more 
readily demarcated. It has already been 
alluded to, and most of us are aware, that 
one of the sources of many iatrogenic com­
plications in the past has been the indis­
criminate use of a bypass type of operation, 
rather than an exclusion, in the surgical 
treatment of Crohn’s disease. Of course this 
does not do anything to cure the disease,
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for the intestinal contents still have a choice 
of two ways to go and they tend to follow 
the normal route and the disease is allowed 
to smoulder and progress. So this is the 
wrong type of definitive operation when there 
is active disease and the only time when it 
would be of help is in the very few cases 
where the disease activity has ceased but 
residual bowel obstruction is present. Of 
course we all know the world-famous case 
of President Eisenhower; his disease was 
not active and this fact was recognized by 
the surgeon at the operating table and the 
bypass type of operation was done, because 
his problem was not toxicity but mechanical 
obstruction.
Exclusion of the disease, if it is truly a 
complete exclusion, will render the patient 
temporarily well, but one should always plan 
a resection of the diseased segment later. 
And so, in the case of the disease that is 
non-obstructive, the surgical closure of the 
more normal adjacent bowel, with an ex­
cluding type of anastomosis, will allow the 
patient to return to better nutritional health 
at which time the disease can be more safely 
removed. One must remember, however, 
that the disease may flare up in the excluded 
segment, making the patient acutely ill again. 
When the ileal disease involves the sigmoid 
secondarily, it is not excluded by an ileo- 
transverse colonic anastomosis. By exclud­
ing the total area of the disease with an 
ileostomy, the process can subside and the 
secondarily involved adjacent structures can 
easily and safely be resected with the pri­
mary disease 10 weeks later. The ileostomy 
can be taken down at the same time or sub­
sequently.
If there is posterior perforation and ab­
scess formation, or if there is a high degree 
of obstruction because of the disease itself, 
then total exclusion of the disease with no 
attempt to remove it would be the operation 
of choice. At a later late the disease can be 
removed by an operation of lesser magni­
tude than would have been necessary when 
the disease was more active. So, do not 
resect diseased bowel for retroperitoneal in­
flammation or for posterior perforation. Do 
not disturb the diseased bowel; just bypass 
and exclude it and the associated abscess 
completely. With exclusion bypass the dis­
ease will subside, the abscess will resolve
and the resection—in 10 weeks’ time— 
will be a simpler procedure.
Do not resect short-term acute disease 
simulating appendicitis. Leave the appendix 
alone. Close the abdomen, consult the gas­
troenterologist for non-operative manage­
ment and prompt remission of the disease 
usually follows. And here we are talking 
about the patient who is acutely ill for a 
few days and the surgeon operates because 
signs of peritoneal irritation are present. 
Instead of acute appendicitis he finds acute, 
short-term Crohn’s disease. This is usually 
resolved with medical management and does 
not require resection. The reason for not 
taking out the appendix is that iatrogenic 
problems can occur. To a surgeon unini­
tiated in Crohn’s disease, an appendix could 
look quite innocent at the operating table 
and he would remove it to prevent the de­
velopment of an ordinary appendicitis at a 
later date. He could easily fail to recognize 
that the appendix is involved by Crohn’s 
disease. It would be tempting to ascribe the 
fat wrapping, the obliteration of the me­
sentery-bowel angle, the segmental changes 
in the serosa of the appendix, the presence 
of lymphadenopathy in the mesoappendix, 
and the prominent vessels of the cecum, to 
the inflammatory reaction of acute appen­
dicitis. To do an appendectomy under these 
circumstances just because one has already 
surgically exposed the area is to invite fis- 
tulization and other related problems.
An additional principle of management 
is worth mentioning for duodenal involve­
ment. We would ordinarily think that re­
moval of the adjacent diseased segment and 
closure of the hole in the duodenum would 
be the appropriate form of management be­
cause the duodenum is only secondarily 
involved. But closure is hazardous and 
faulty healing of the duodenum involved by 
Crohn’s disease is the rule. Fistulization 
often results and, of course, a duodenoileal 
fistula or a duodenocutaneous fistula is 
catastrophic in the presence of a fresh ileo­
colic anastomosis. A much safer method of 
managing such a problem is to resect the 
disease and make an ileocolonic anasto­
mosis, but instead of attempting to close 
the duodenum, open the jejunum and make 
a three-layer anastomosis with the duodenal 
opening. This provides a large lumen for
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the duodenum, with well-vascularized tissue 
at the defect. It decompresses the duodenum 
as long as necessary and it does not divert 
the intestinal contents permanently. Healing 
is assured in an area previously involved by 
inflammatory disease.
Finally, I would like to leave you with a 
very useful clinical observation for which we 
have as yet no explanation. We have found, 
through the management of many patients 
with Crohn’s disease with problems such as 
we have reviewed, that ACTH, but not 
prednisone or cortisone, seems to protect 
and assure a more proper healing of an 
anastomosis after a resection for Crohn’s
disease, even when there are subtle changes 
indicative of the presence of Crohn’s dis­
ease at the site of anastomosis. On the basis 
of our experience to date, I recommend that 
you give 40 units of ACTH, intramuscularly 
or intravenously, daily in the postoperative 
period. This seems to ensure proper healing 
of the anastomosis.
Through the application of principles such 
as these, surgical care becomes—as is med­
ical care— a phase in the on-going manage­
ment of the patient afflicted with Crohn’s 
disease. And the surgeon and the internist 
become participants in a continuing team 
acting for the overall welfare of the patient.
RECURRENT CROHN’S DISEASE
F. T. de DOMBAL
C rohn’s disease, as you know, presents a 
major problem, that of recurrence, which 
hangs over every patient who has had sur­
gery for this disease. For while one can give 
the patient with ulcerative colitis a reason­
able guarantee that the disease will not 
recur, no such assurance can be given the 
patient with Crohn’s disease.
Fig. 1 gives a representative statement of 
the problem from a number of series. The 
reported overall recurrence rates after sur­
gery for Crohn’s disease vary from 3% to 
62%. However, if there is one major point
that I would like to make, it is that overall 
recurrence rates are completely meaningless 
in the context of Crohn’s disease, and I will 
present some evidence that will, I hope, 
demonstrate this point.
First of all, if we consider the primary 
operation performed for Crohn’s disease we 
find that in our hands (in Leeds, England) 
the recurrence rate varies with the type of 
operation, from 60% for small bowel re­
section alone through 40% for small bowel 
resection and right hemicolectomy, coming 
right down to 10% to 15% after proctoco-
NUGENT SCHOFIELD GUMP CROHN WENCKERT LEEDS COLCOCK STAHLGREN VANPATTER
1 9 7 3  1 9 6 5  1 9 6 6  1 9 5 8  1 9 7 1  1 9 7 1  1 9 6 0  1 9 6 1  1 9 5 4
Fig. 1.—Recurrence rates of Crohn’s disease as reported from various series. (Reproduced by per­
mission from de D ombal FT: Results of surgical treatment for Crohn’s disease. Br J Surg 59: 826, 
1972.)
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lectomy. Therefore, it first appears that the 
recurrence rate depends on the type of op­
eration which, in turn, often reflects the 
site of disease. Second, the recurrence rate 
after the initial operation depends upon the 
age of the patient at the time of the first 
operation. In our own patients, in the second 
decade of life the recurrence rate is 52% 
and it progressively drops to reach the low 
level of 7% for patients operated on be­
tween the ages of 60 and 70. Another find­
ing is that the recurrence rate depends on 
the duration of the disease. Cumulative 
statistics for 170 patients with small and 
large bowel disease illustrate this relation­
ship (Fig. 2). One notes two peaks of high 
recurrence, one relating to very short- and 
the other to long-lasting disease.
This biphasic feature of the recurrence 
rate in relation to time is also seen in Fig. 3 
which shows the cumulative recurrence rate 
following initial surgery. The risk of recur-
of Crohn’s disease.
Fig. 3.—Cumulative recurrence rates in small 
and large bowel disease. (Reproduced by permis­
sion from de Dombal FT, Burton T, Goligher 
JC: Recurrence of Crohn’s disease after primary 
excisional surgery. Gut 12: 519, 1971.)
rence is highest in the immediate post­
operative period and again 10 to 15 years 
later. We have also observed (compare 
Figs. 2 and 3) that the patients who under­
went surgery early in the course of their 
disease tended to have an early recurrence, 
while the patients who had their operation 
later on (let us say after 20 years of medical 
management) tended to have their recur­
rence late. I do not want to complicate the 
issue after having agreed that we really do 
not know what Crohn’s disease is! But there 
is evidence to suggest that there may be (a) 
one type of Crohn’s disease which presents 
early, comes to surgery early and recurs 
early after operation and (b) another more 
benign type which presents late, comes to 
surgery late and recurs late.
It is also worth noting that in our series 
a reoperation for recurrence was not neces­
sarily a disaster. After one operation the 
risk of further surgery is 34%, after two 
operations the risk of a third is only 20% 
and, in our few patients with three opera­
tions, the risk of a fourth is about 30%.
Finally, I would like to attempt to answer 
the question — does it really matter 
whether postoperative recurrence occurs 
early or late? I think it does. As you can see 
from Fig. 4, in the group of patients in 
whom the disease recurred early, 17%
EARLY LATE
RECURRENCE RECURRENCE
(18 pati*nf t )  (33pati*n**)
Fig. 4.—Comparison of results from early and 
late recurrence of the disease.
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eventually died, and at the time of the 
review 45% of the survivors were, in one 
way or another, dissatisfied with the out­
come of their management. On the other 
hand the late recurrence, which occurs from 
five to 10 years after the initial operation, 
is by no means a disaster. The overall 
mortality in this “late” group was 5% and 
when reviewed 95% of the survivors were 
in good health and were satisfied with the 
outcome of their treatment.
In summary I would like to underline two 
points about recurring Crohn’s disease. First 
of all, recurrence rates have been quoted in 
a vastly different fashion around the world, 
primarily I think, because of a lack of 
definition of what recurrence is and also 
because of failure to apply the actuarial 
methods that we have been using in our own 
statistics. Secondly, I think there are two 
types of postoperative recurrence. While a 
recurrence taking place one or two years 
after surgery carries an excessively high 
morbidity and an appreciable mortality, re­
currence which appears five to 10 years 
after an operation has a much more favour­
able prognosis, albeit after further resection.
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ULCERATIVE COLITIS
ETIOLOGY AND EPIDEMIOLOGY OF ULCERATIVE COLITIS
R. J. SPENCER
So that all the contributions can be ade­
quately presented, I am limiting my own to 
only the most essential points.
It was once believed that ulcerative co­
litis was primarily a disease of Jewish 
people, that is, the incidence in Jewish 
people was higher than in the non-Jewish 
population. Current articles have indicated 
that this is not true. However, Mendelhoff 
found a slightly increased incidence of 
ulcerative colitis in the Jewish population of 
Baltimore. It is interesting that this was not 
the case in the Jewish people who lived 
beyond the strict confines of the metropoli­
tan area and it is therefore suggested that 
the condition may be a disease of urbaniza­
tion. Our findings in Rochester, Minnesota, 
have been somewhat similar but our do­
cumentation is not complete.
Table I shows the annual incidence of 
ulcerative colitis in the Rochester popula­
tion. Note that, unlike any of the other po­
pulations that have been reported, in Ro­
chester we find a slightly increased incidence 
in males. The annual incidence of the dis­
ease is within the generally reported range. 
In Table II the death rate of the disease in 
Rochester is seen to be comparable to that 
reported elsewhere. This seems to indicate 
that the disease is unrelenting and, regard­
less of the type of treatment, the same rate 
of survival can be predicted. I would like, 
humbly, to offer you my own theory of the 
etiology of this disease.
I feel that it is an immunologic disease, if 
not in etiology at least in its pathogenesis. 
The uncommitted lymphocytes, when ex­
posed to an antigen, become large lympho­
cytes. The large lymphocytes then can 
pass on the information to a plasma 
cell to produce an antibody, or to a 
small immunologic lymphocyte which is the 
mediator of the delayed hypersensitivity 
reaction. We feel that this is the etiology or 
perpetuator of ulcerative colitis. I think that 
we have demonstrated quite well in lab­
oratory tests, as shown in Fig. 1, that the 
survival rate of colonic epithelium in a tis­
sue culture exposed to lymphocytes from a 
patient with ulcerative colitis is markedly 
reduced. The control normal lymphocytes 
do not demonstrate this capacity. Now, if
TABLE II.—Average Annual Death Rate from 
Ulcerative Colitis in Rochester per 100,000 
Compared with that Reported E lsewhere
Death rale 
per 100,000
Rochester, Minnesota, 1935-1964 0.40
Acheson, 1960
U.S.A., 1952-1956 .....................  0.47
Canada, 1952-1957 .................... 0.49
England and Wales, 1953-1955 0.85
Evans and Acheson, 1965 
Oxford, England, 1951-1960... 0.70
Mosbech, 1960
Denmark, 1951-1959 ................  0.60
Wigley and MacLaurin, 1962 
Wellington, New Zealand,
1954-1958 ................................ 0.90
T able I.—Annual Incidence of Ulcerative Colitis per 100,000 in Rochester
Age No. o] No. of Total incidence per
(years) men women Total 100,000*
0 - 9 .......................................................... 4 1 5 3
10 - 19.........................................................  4 3 7 5
20 - 29 .......................................................... 17 18 35 21
30 - 39 .........................................................  10 13 23 17
40 - 4 9 .........................................................  6 4 10 9
50 - 59 .........................................................  9 6 15 17
60 - 6 9 .........................................................  3 6 9 14
Over 70........................................................ 1 3 4 8
Total............................................................ 54 54 108 11.7
*Male, 13.2, female 10.5, age-adjusted rate 11.6 (adjusted to United States 1950 total white population).
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Fig. 1.—Effect of lymphocytes from a patient with ulcerative colitis on autologous colon cell viability.
we use the sera from patients with ulcerative 
colitis we find that there is no change in 
the cell survival in tissue culture. There­
fore, the factor concerned seems to be 
a cellular factor. When colonic epithelial 
cells are incubated with a hash made from 
lymphocytes obtained from patients with 
ulcerative colitis, they also demonstrate a 
decreased survival rate. This phenomenon 
occurs not only in ulcerative colitis, but 
also in granulomatous colitis. After co­
lectomy in patients with either chronic 
ulcerative colitis or Crohn’s disease, we find 
that the lymphocytes become essentially 
normal again in that the cytotoxicity previ­
ously observed disappears rather rapidly. 
This reversion to normal could be claimed 
as the weakest point in our theory, for the 
lymphocytes should maintain their cytotoxic 
capacity. But we feel that because these 
lymphocytes are no longer challenged their 
cytotoxic capacity disappears.
To summarize the etiology of ulcerative 
colitis, I simply maintain that it is an im­
munologic disease of delayed hypersensit­
ivity as we have demonstrated by in vitro 
methods of investigation.
CLINICAL FEATURES, PATHOPHYSIOLOGY, COMPLICATIONS AND  ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS
G. J. DEVROEDE
The initial symptom of ulcerative colitis is 
bloody diarrhea, usually without abdominal 
pain, but constipation may be a feature of 
distal colitis in which the patients pass 
bloody mucus between formed stools. Emo­
tional trauma, anxiety and depression are 
not prominent features reported in re­
trospective studies. Compared with patients 
suffering from irritable colon and with 
normal controls, patients with ulcerative 
colitis have significantly fewer antecedents 
and a lower stress index. Finally, as tested 
by the Minnesota Multiphasic Personality 
Inventory (MMPI test), patients with ulcer­
ative colitis are less neurotic as a group than 
patients with psychosomatic disease and, in 
particular, those with irritable colon. There­
fore, there is no evidence for a psycho­
somatic basis for ulcerative colitis. In most
patients the disease has remissions. In a 
1963 survey the Leeds group found that 
80% of their patients were leading a normal 
life at that time. Many patients with mild 
or moderate colitis have no demonstrable 
physical signs. Even in the acutely ill, 
clinical signs may be difficult to interpret. 
The Leeds group demonstrated that clini­
cians had no difficulty in assessing the 
presence and severity of abdominal tender­
ness and distension, but they were less con­
sistent in evaluating pallor, anemia, dehydra­
tion, guarding and rigidity.
At endoscopy (Fig. 1) normal subjects 
have a normal vascular pattern without con­
tact bleeding. In ulcerative colitis, the vas­
cular pattern disappears. Contact bleeding 
is present in mild colitis, free bleeding 
in moderate colitis and muco-pus is
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Fig. 1.—(a) Normal mucosa. The vascular pattern is clearly visible; there is no erythema and there 
are no petechiae. (b) Mild ulcerative colitis. The vascular pattern is not evident; there is 
practically no free bleeding. At biopsy there was severe atypia with numerous mitoses, (c) Mild 
ulcerative colitis with carcinoma in situ at biopsy. A healed granular lesion of the mucosa is present 
which is characteristic o f the disease, (d) A more active form of the disease. Free bleeding is present; 
the healed granular lesion of the mucosa is still recognizable, (e) Moderate ulcerative colitis. There is 
free bleeding and the vascular pattern is absent. The healed granular mucosal lesion is no longer 
evident, (f) This mucosa is very fragile so that a slight touch with a cotton-tipped applicator induces 
profuse bleeding (same area as e). (g) Severe ulcerative colitis showing diffuse involvement with massive 
free bleeding and muco-pus. (h) Another case of severe ulcerative colitis. There are loss of vascular 
pattern, diffuse involvement, free bleeding and pseudopolyps, (i) The reversibility of these lesions may be 
striking by gross examination although microscopic abnormalities persist. The pseudopolyps seen in (h) 
have been epithelialized and some vessels are visible, since this patient’s clinical condition markedly 
improved. (Published by courtesy of the Olympus Corporation of Canada, G. D. Searle & Co. of 
Canada Ltd. and the ACMI Company.)
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passed in severe colitis, sometimes as­
sociated with edema, pseudopolyps and 
strictures. There is good observer agree­
ment in distinguishing normal and abnormal 
proctoscopic findings, the presence or ab­
sence of a vascular pattern, contact bleeding 
and edema. The difficulties lie with the very 
mild and the very severe forms of the dis­
ease. Thus, in patients with very mild colitis, 
the pathologist may report mild inflamma­
tion while the gross appearance is normal. 
Unfortunately, a similar degree of inflam­
mation may be reported in patients without 
colitis. There is also difficulty in assessing 
the severity of colitis.
The reported percentage of patients with 
distal proctitis who later develop total 
colitis ranges from 6% to 30%. Increasing 
use of colonoscopy is beginning to show that 
patients who have limited distal colitis as 
indicated by barium enema may, in fact, 
have more extensive disease. Another pro­
blem is the difficulty in correlating histo­
logical and endoscopic findings in mild co­
litis. Thus, the question of proximal pro­
gression is not settled.
Colonic function is impaired in ulcerative 
colitis. Net absorption of sodium is lower 
than in controls. This is the result of a de­
creased insorption (the movement from the 
lumen to the blood) and an increased ex- 
orption (the leakage from the blood to the 
lumen). This is accompanied by a decrease 
in the potential difference that exists be­
tween the mucosa and the serosa, the de­
crease being more marked in patients with 
severe colitis than in patients in quiescent 
stages. In addition to loss of fluid and elec-
TABLE I.—Local Complications of Ulcerative 
Colitis (Leeds 1963)
C om plication
Percentage o f  
465 cases
Anorectal complications: 25.9
abscess 6
fistula-in-ano 5.4
rectovaginal fistula 2.2
fissure-in-ano 12.3
Pseudopolyposis 12.5
Stricture 11.2
Perforation 2.8
Carcinoma 1.7
Dilatation: of diseased colon 3.0
above diseased colon 0.4
Massive hemorrhage 1.5
trolytes, nitrogen and blood are also lost. If 
the fecal output is measured in normal sub­
jects and before and after proctocolectomy 
in ulcerative colitis, it will be found that 
after proctocolectomy patients still lose 
more water and sodium than normal sub­
jects. However, they no longer lose nitro­
gen and this is the major metabolic benefit 
provided by proctocolectomy.
There are local and systemic complica­
tions of ulcerative colitis. In our experience 
the incidence of anorectal complications is 
much lower than what has been reported 
from Leeds (Table I). Pseudopolyps occur 
in severe colitis owing to edema and 
inflammation and when the colitis subsides 
they may coexist with a normal vascular 
pattern. Strictures may occur early in the 
course of the disease and must be distin­
guished from carcinoma and Crohn’s 
disease. Perforation occurs in 6% of the first 
attacks and in 3% of subsequent attacks; 
the incidence is greater in severe colitis and 
total colitis. Cancer risk is a major prob­
lem in chronic ulcerative colitis. About 20% 
of the patients develop cancer for each 
decade after the first 10 years of disease. 
The age of the patient at the time of onset 
does not affect cancer risk and the risk is 
much greater than in patients with granu­
lomatous colitis. It is at its highest in 
patients who have total colitis. There is no 
published report of a cancer complicating 
colitis which has remained limited to the 
rectum. The exact incidence of acute dila­
tation of the colon in ulcerative colitis is un-
Fig. 2.—Transverse colon diameter on a plain 
film of the abdomen.
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known because the definition of toxic mega- 
colon is based on radiological examination 
and the normal values for colonic dia­
meter have been determined only recently. 
The normal diameter of the transverse co­
lon never exceeds 5.5 cm and in colitis with 
toxic dilatation it can reach as high as 15 
cm (Fig. 2). Another feature of the mega­
colon in ulcerative colitis is that in contrast 
to normal subjects and patients with un­
complicated colitis, the transverse colon is 
wider than the ascending colon. The clinical 
course of acute dilatation is unpredictable 
but it carries a very high mortality. Factors 
known to precipitate the development of a 
megacolon are barium enemas, hypokalemia, 
opiates and anticholinergics.
Systemic complications of colitis are 
numerous. Ninety percent of liver biopsies 
in ulcerative colitis are abnormal and
changes range from mild inflammation to 
cirrhosis, with the majority showing fatty 
infiltration and focal necrosis. In the biliary 
tract, pericholangitis, sclerosing cholangitis 
and carcinoma of the bile ducts may occur. 
Finally, arthritis and ankylosing spondylitis 
are frequent. Arthritis occurs in 11% of 
patients with a long-standing history of co­
litis. It is usually monoarticular, sym­
metrical, involves the knees or ankles and 
is usually cured by colectomy. In contrast, 
ankylosing spondylitis does not heal after 
surgery. Its incidence is high, especially in 
males, and the condition has a familial ten­
dency. Eighteen percent of patients with 
ulcerative colitis have sacroiliac arthritis 
compared with 4% in the general popula­
tion, and their relatives also have an in­
creased incidence if the probands have 
severe colitis and total colitis.
HISTOPATHOLOGY OF CHRONIC ULCERATIVE COLITIS
G. SANCHEZ-CASIS
T h e  course of ulcerative colitis is typically 
one of remissions and exacerbations, a fact 
that is reflected in the range of histological 
appearances observed in biopsy material. 
Therefore arbitrary divisions are necessary 
based on specific variations in the histo- 
pathology. For this reason I shall consider 
three separate phases of the disease: (1) 
acute; (2) quiescent; (3) chronic persistent.
In the acute phase the more important 
changes are edema, congestion, infiltration 
with polymorphonuclear leukocytes with 
reduction of mucus production and forma­
tion of characteristically superficial crypt 
abscesses, and a total participation of the 
colonic glands in the disease process (Fig. 
1). Usually, in this phase, the disease is well 
localized to the mucosa; however, in very 
acute cases the submucosa may show edema 
and dilatation of the capillaries.
The quiescent or inactive phase is cha­
racterized by an attempt at restitution, but 
residual changes such as glandular dis­
organization, abnormally small or short 
glands, fibrosis of the lamina propria and
hypertrophy of the tunica muscularis mu­
cosae are usually found (Fig. 2).
Fig. 1.—Rectal biopsy showing the acute phase 
of ulcerative colitis. Note the marked inflamma­
tory infiltrate, crypt abscesses and reduction of 
mucus production with degeneration of some of 
the glands.
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Features of the chronic persistent phase 
are persistent ulceration, infiltration with 
polymorphonuclear leukocytes, crypt ab­
scesses and, more significantly, the presence 
of psudopolyps and precancerous changes.
The pseudopolyps consist of edematous 
granulation tissue and persistent inflam­
matory crypt abscesses. Another sign o f  
long-standing disease is Paneth’s cell meta­
plasia with excessive mucus production by 
the mucosal glands.
Finally, in the stenotic segment of a long­
standing case of chronic ulcerative colitis, a 
precancerous stage with a wide range of 
dysplasia may be present (Fig. 3) before the 
stage of frank carcinoma in situ is reached. 
Severe atypia with adenocarcinoma may 
also develop (Fig. 4).
In summary, the degeneration of the 
crypts with participation of the total mucosa 
in the acute phase and the precancerous or 
dysplastic changes in the chronic persistent 
phase are the most characteristic diagnostic 
features of chronic ulcerative colitis. Other 
important features include a “healed gra­
nular” mucosa, a persisting inflammatory 
reaction and an irregular glandular pattern; 
the absence of fissures is a particularly 
valuable sign in differentiating the early 
phase of chronic ulcerative colitis from 
Crohn’s disease.
Fig. 2.—Rectal biopsy showing the quiescent 
phase. Note the irregular mucosal pattern with a 
decrease in the number and size of the glands. 
Note also the absence of inflammation.
Fig. 3.—Rectal biopsy demonstrating chronic 
persistent disease. Note the colonic glands with 
disorganization, atypia and dysplastic changes. A  
marked degree of inflammation persists.
Fig. 4.—Rectal biopsy shows chronic persistent 
disease. Note the complete disorganization of the 
glands and the presence of an undifferentiated 
adenocarcinoma in a case of long-standing ulcera­
tive colitis.
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RADIOLOGY IN ULCERATIVE COLITIS
H. SUPELANO-GUEVARA
T he classical radiological signs of ulcerative 
colitis were well reviewed by Marshak and 
Lindner in 1966. More recently Margulis 
et al and Stanley et al gave detailed descrip­
tions of the typical radiological features per­
mitting identification of ulcerative and 
granulomatous colitis (Table I). In spite of 
these typical signs, however, it may be ex­
tremely difficult to distinguish these two 
types of colitis. Other conditions must also 
often be considered in the differential diag­
nosis, for example amebiasis, tuberculosis, 
ischemic colitis and diverticulitis.
Radiographic examination of the colon 
by barium enema generally demonstrates 
the gross pathologic findings (Fig. 1).
One of the earliest and most acute condi­
tions in inflammatory disease is edema. It 
is manifested by a coarse mucosal pattern 
(Figs. 2 and 3) and separated folds which 
are particularly well seen on the post-eva­
cuation film. On these films the haustral 
folds are seen to be wide and shallow. This 
finding is encountered in all types of in­
flammatory disease.
Superficial ulcerations are typically seen 
in the rectosigmoid colon but may appear 
throughout the entire colon. As the disease 
progresses haustrations tend to disappear
and spasm and irritability of the colon are 
seen (Fig. 4). Eventually shortening and 
rigidity of the bowel develop, producing a 
stove-pipe appearance. Pseudopolyps are 
likely to occur at this stage.
Fig. 1 .—The transverse colon shows a moderate 
degree of ulceration along the upper border.
TABLE I.—Comparison of the Radiographic F indings “T ypical” of Ulcerative Colitis and
Granulomatous Colitis
Ulcerative colitis
1. Total involvement of colon
2. Rectum involved in continuity with descend­
ing colon if colonic involvement is complete
3. Concentric, circumferential involvement
4. Shallow or “collar-button” ulcers
5. Pseudopolyps in active disease
6. No fistulas or abscesses
7. Shortening of colon without localized 
strictures
8. Gaping ileocecal valve
9. Toxic megacolon prevalent
10. Significant increase in incidence of cancer 
with long-standing ulcerative colitis
Granulomatous colitis
1. Segmental or focal involvement (skip lesions) 
of colon
2. Ascending colon most often involved
3. Non-circumferential involvement
4. Deep ulcers (greater than 2 mm) and 
fissures perpendicular to bowel lumen
5. Longitudinal ulcers ofter creating “cobble­
stone” effect
6. Frequent fistulas or abscesses
7. Frequent strictures
8. Thickened ileocecal valve criss-crossed by 
ileocecal fistulas
9. Toxic megacolon less frequent
10. Cancer incidence less markedly increased
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Collar-button ulcers have been described 
as occurring more commonly with ulcerative 
colitis but according to Margulis et al the 
incidence of this type of ulcer is almost 
identical in both ulcerative and granulo­
matous colitis.
Deep ulcers which penetrate beyond the 
mucosal membrane (2 mm or more as meas­
ured on the radiograph) constitute evidence 
of a more severe reaction of the colonic 
wall.
Fistulas and abscesses result from deep
Fig. 2.—Spot film of the descending colon show­
ing a fuzziness of the mucosal outline with nu­
merous tiny ulcerations.
Fig. 3.—Post-evacuation film. The mucosal folds 
are hazy and thickened in a symmetrical fashion.
ulcers that penetrate beyond the limits of 
the colon. Their presence indicates, particu­
larly in granulomatous colitis, severe and 
invasive disease. Perforations following 
ischemic colitis have been reported. Ame­
biasis, salmonellosis, actinomycosis and tu­
berculosis all can cause sinuses and fistulas.
Toxic megacolon is typically associated 
with a fulminating course in ulcerative colitis 
but it is now known to occur in Crohn’s 
disease as well as in amebiasis and ischemic 
colitis. Occasionally the development of 
megacolon is precipitated by the use of a 
barium enema.
The appearance of the bowel wall is of 
greater significance than increased calibre 
of a portion of the colon. In the segments 
maximally involved the normal haustral pat­
tern is completely absent. In less affected 
portions the interhaustral septa may persist 
but appear unusually thick and may be in­
complete or wavy in contour.
Despite the marked distension the bowel 
wall does not appear to be under great pres­
sure. The dilated segments tend to maintain 
a cylindrical or tubular configuration with 
rounded, sometimes tapering, ends. The 
cause of so-called toxic segmental dilatation 
is unknown but is related to acute inflam­
matory changes affecting all coats of the 
bowel wall, often with necrosis and perfora­
tion.
Fig. 4.—Minimal narrowing and rigidity of the 
colon. The haustral markings are absent or irre­
gular in the distal transverse and descending colon.
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MEDICAL MANAGEMENT OF ULCERATIVE COLITIS
JOHN E. LENNARD-JONES
I am glad that the* subject that has been 
assigned to me is the “management” of 
colitis and not just its treatment because 
this is a condition that has to be managed, 
and we do not have a medical cure, al­
though there is a surgical cure.
The clinician may first see the patient 
during an acute attack of colitis and then 
his first job is to assess the severity of the 
disease. There are some useful guides in 
assessing severity, but suffice it to say at 
the moment that it depends largely on the 
extent of the colon involved and also the 
depth to which the mucosa is ulcerated. 
It also depends on the physique of the pa­
tient and, in particular, his age. Having 
assessed the severity of the disease, one has 
to decide on the treatment. There are situ­
ations in which surgical treatment is the 
immediate and initial form of therapy, and 
the use of medical therapy such as cortico­
steroids is contraindicated. I will devote most 
of my time to medical management. One 
may see a patient during remission of the 
colitis. Here, one has to consider the prog­
nosis for that patient, depending on the 
nature of his disease up to that time. One 
has to try, if one decides to continue with 
medical treatment, to prevent relapse, but 
if a relapse occurs, to treat it energetically 
and quickly, the emphasis being on “quick­
ly”. It is also the clinician’s job to prevent 
cancer, and this will be dealt with elsewhere 
in this symposium.
Sometimes one sees a patient with chro­
nic, persistent symptoms, where the obvious 
question is: Is the treatment for that patient 
optimal? I propose to spend most of my 
time on the acute attack and medical treat­
ment, but I will mention the matter of pre­
venting relapse.
The treatment of colitis cannot be stand­
ardized, but one can make some generali­
zations. Quite a high proportion of patients 
with colitis have inflammation restricted to 
the distal colon, namely the rectosigmoid 
and perhaps the lower descending colon. 
These patients generally do not have any
systemic upset such as fever, loss of appe­
tite, loss of weight, or metabolic distur­
bances. One can think of treatment under 
several headings. There are general meas­
ures, replacement therapy, drug therapy and 
surgical treatment. Patients with distal dis­
ease and no systemic upset can usually lead 
a normal life and do not require admission 
to hospital. There is some evidence that a 
few benefit from a milk-free diet but I only 
prescribe it for those for whom it is defi­
nitely helpful. These patients bleed and the 
only replacement therapy likely to be needed 
is iron.
Drug therapy consists mainly of salicyl- 
azosulfapyridine (Salazopyrin) and topical 
corticosteroids. The evidence for the use of 
Salazopyrin in colitis is reasonably well 
established. Fig. 1 shows the symptomatic 
response after three weeks in a controlled 
trial done some years ago. The first group 
of patients was treated with Salazopyrin in 
an initial dose of 4 g daily, subsequently 
reduced to 2 g daily. Patients receiving an 
inert tablet in a double-blind manner form 
the group on the right side of Fig. 1. 
Notice that more of the patients receiving 
Salazopyrin were symptom-free or improved 
than patients who were given the control 
tablet, most of whom were unchanged. The 
patients shown in black had to stop the
Fig. 1.—Response of colitis to salicylazosulfapy- 
ridine.
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treatment because of side effects. Often 
gastrointestinal side effects such as nausea 
can be helped by the use of enteric-coated 
tablets but these are ineffective in prevent­
ing other side effects such as headache, 
malaise, and hematological disorders. The 
frequency of these side effects depends very 
much on the dose used.
Corticosteroids can be given in supposi­
tory form if the upper limit of the disease 
can be seen, that is if only the lower 10 cm 
of the rectum is involved. Otherwise the 
steroid has to be given as a retention enema.
Retention enemas can be given as a drip, 
by means of a disposable pack or using a 
plastic bladder syringe and rubber catheter. 
The patient can make up his own enemas 
from tablets and solution. It is an advan­
tage if one can alter the volume of the 
enema and the concentration of the steroid. 
Fig. 2 shows data from four patients who 
were given retention enemas of different 
volume, 50 ml, 100 ml, 150 ml and 200 
ml. The area of colon in contact with the 
solution was estimated by adding a little 
barium to the therapeutic enema. A small 
enema of 50 ml usually stayed in the rec­
tum and sigmoid colon; 100 ml ascended 
a variable distance, in one patient nearly 
to the hepatic flexure but in another re­
maining in the rectosigmoid. As you might 
expect, 150 ml tended to go a little further
SO wo 150 200
Fig- 2.—Area of colon in contact with therapeutic 
enemas of differing volumes.
but in one patient did not go any higher 
than did 50 ml. The lesson is that if one 
is going to use topical steroids, one must 
cover the diseased area of colon with the 
solution, and the only way of finding out 
if you are doing so in a particular patient 
is to add a little barium to the solution 
(Swarbrick et al, 1974).
Ulcerative colitis associated with some 
systemic upset, such as fever, weight loss 
and metabolic disturbances is, of course, 
usually a more extensive disease. These pa­
tients often need admission to hospital for 
replacement therapy, which is important 
and is sometimes neglected. Since large ni­
trogen losses can occur in ulcerative colitis, 
the emphasis is now on a high protein, 
nutritious diet containing a large number 
of calories, rather than a low-residue diet. 
A potassium supplement is often required 
because potassium is lost in diarrhea and 
corticosteroids cause a loss of potassium 
from the kidney. To rely on topical cortico­
steroids for the treatment of extensive co­
litis is, in my opinion, a mistake. These 
patients almost always require systemic 
steroids in the form of oral prednisolone 
or an equivalent drug, perhaps supple­
mented by topical steroids. They may also 
be helped by corticotrophin or ACTH, and 
I was interested by Dr. Weakley’s comments 
on ACTH.
What dose of steroids should one use? 
Fig. 3 shows results from a trial with three 
groups of 20 patients, one group given 60 
mg of prednisone, another group 40 mg
Fig. 3.—Number of patients in remission at 
different times after treatment with prednisone. 
(Reproduced from Baron JH , C o n n e l l  A M , 
K anaghinis TG, et al: Out-patient treatment of 
ulcerative colitis. Comparison between three doses 
of oral prednisone. Br Med J 2: 441, 1962.)
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and a third group 20 mg daily. The figure 
shows the number of patients going into 
remission over a specified period of time. 
Note that with the bigger dose more pa­
tients went into remission, but there was 
an increase in side effects when the dose 
was increased from 40 mg to 60 mg daily. 
For this reason my own practice is to use 
prednisolone, 40 mg daily, as the optimal 
dose to start with, and I think that it is 
a mistake to start with smaller doses as 
these are often ineffective.
Fig. 4 shows comparison of the effects of 
a trial of cortisone 200 mg daily and cor- 
ticotrophin 80 units daily (Truelove and 
Witts, 1959). You will observe that the 
proportion that went into remission was 
greater with corticotrophin than with cor­
tisone. We have had a number of patients 
who failed to respond to the administration 
of prednisolone but responded to ACTH. 
We have tried to find out why this is -so. 
Is it a quantitative effect or is it a quali­
tative effect of corticotrophin which causes 
secretion of other steroids? We do not 
know, but ACTH is a useful drug and is 
worth bearing in mind for the patient with 
a more severe form of ulcerative colitis.
I will now discuss the treatment of very 
severe colitis. The problem here is that the 
colitis may be severe in different ways. It
may be severe because there is a brisk sys­
temic inflammatory reaction with high fever 
and perhaps associated complications such 
as arthritis. It is this group of patients who 
may do well with either intravenous cortico­
steroids or ACTH. It may be severe because 
there is a grave metabolic disturbance with 
fluid and electrolyte imbalance or, more 
commonly, protein loss with loss of muscle 
bulk and emaciation. The treatment of pa­
tients in this group is, of course, along 
metabolic lines. Or it may be severe be­
cause the mucosa is deeply ulcerated and 
the inflammation has penetrated into the 
muscle, causing loss of tone and dilatation, 
or even to the peritoneum, causing perfo­
ration. I regard the condition in this group 
of patients as a surgical emergency and not 
to be treated with corticosteroids.
If remission of the colitis is achieved, 
and this occurs in at least two-thirds of the 
patients with distal colitis although less 
commonly in patients with more severe 
forms of colitis, the major question is how 
to keep such a patient well. There is cer­
tain advice one can give to the patient. 
Infection may bring about relapse and 
therefore he must be careful, for instance, 
when travelling abroad. I think that broad-
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spectram antibiotics can precipitate a re­
lapse, and he needs to be warned of this 
danger. There are also long-term drug treat­
ments, and Fig. 5 shows a comparison of 
the ratios of relapse over a period of one 
year in patients initially in remission and 
receiving either Salazopyrin or placebo tab­
lets (Misiewicz et al, 1965). These results 
have since been confirmed and extended 
in Oxford (Dissanayake and Truelove, 
1973) and I believe there are good grounds 
for giving Salazopyrin indefinitely to the 
patient with ulcerative colitis in remission 
who can take this drug without trouble. 
In a similar trial over a period of six months 
the proportion of patients given either pred­
nisone 15 mg a day or a control tablet, 
whose disease recurred, was the same. This 
dose of prednisone therefore did not reduce
the relapse rate (Lennard-Jones et al, 1965). 
In my opinion, unlike Crohn’s disease, 
there is little or no indication for long-term 
low-dose steroid therapy in ulcerative co­
litis. This type of therapy leads to problems 
and it is probably of no benefit.
Lastly, I have said that the job of the 
clinician is to prevent cancer. We will hear 
more about this, but I consider the follow­
ing as the high risk factors: extensive co­
litis, a history of over 10 years’ duration, 
onset in childhood, and continuous symp­
toms rather than intermittent disease with 
periods of remission. One must be aware 
that patients in remission with these clinical 
features are at a risk from cancer (Lennard- 
Jones et al, 1974). One must bear these 
factors in mind as one continues managing 
the patient in remission.
PROGNOSIS OF ULCERATIVE COLITIS AFTER MEDICAL TREATMENT
JAMES P. McMANUS
We have endeavoured to learn more about 
the course and outcome of patients with 
ulcerative colitis from a retrospective study 
of 399 patients treated in our unit from 
1950 to 1967. Of these patients, half pre­
sented during their initial attack and half 
were first seen in a relapse. The assessment 
of the severity of the colitis was based on 
objective criteria using a scoring procedure 
devised by a team of experienced clinicians 
and utilizing such variables as original tem­
perature readings, the number of bowel 
movements, and the sedimentation rate. The 
patients, on the basis of their score, were 
then classified as severely, moderately, or 
mildly affected by colitis.
The characteristics of the population 
studied can be summarized as follows: 80% 
of our patients were between 20 and 50 
years of age; perhaps not surprisingly older 
patients tended to appear in their first at­
tack, whereas younger patients were more 
likely to be seen in relapse. No significant 
relation could be found between the sev­
erity of the disease and the patient’s state 
during the attack. Furthermore, first attacks 
tended to have a sudden onset, whereas the
patient seen with a relapse tended to give 
a history of a more gradual onset of his 
bout of colitis.
Since 1957, the number of referrals to 
the unit has tended to remain fairly con­
stant, averaging about 25 patients annually, 
so from our experience there seems to be 
no increase in the incidence of colitis in 
the southeast of Scotland.
We considered the short- and long-term 
outcomes without any specific reference to 
mode of treatment, but it can be assumed 
that all patients had what was the best ac­
cepted means of treatment available at that 
particular time. Consideration of the rela­
tion of the short-term outcome to the sever­
ity of the initial attack shows that the clas­
sification of severity seems to be fairly 
accurate since only one patient whom we 
judged to be only mildly or moderately ill 
died from his disease (Fig. 1). As Dr. 
Lennard-Jones has mentioned, age is of 
some importance and we found an increas­
ing mortality rate with age particularly in 
patients over the age of 50, who had a very 
appreciable mortality rate of 35% . The 
deaths, with the one exception mentioned,
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occurred in patients who were classified as 
severely ill.
The duration of the disease before refer­
ral is also relevant. When the duration of 
symptoms was less than three months, that 
is, in patients with acute onset of ulcerative 
colitis, the mortality rate was 34.1%. How­
ever, at the other end of the spectrum, pa­
tients with a long history of more than 10 
years had a mortality of 37.5%.
When we consider the extent of the dis­
ease we run into the difficulty of how this 
may be determined. Colonoscopy was not 
available in the years covered by our sur­
vey, and we are the first to admit that 
barium enema studies tend to underestimate 
the extent of the disease. Generally we can 
say that the patients with a normal barium 
enema, that is, with their disease confined 
to the rectum, tended to do very well. There 
was no appreciable difference in the mor­
tality rates of patients with colitis and pan­
colitis as determined radiologically.
With respect to laboratory investigation, 
suffice it to say that in patients with severe 
ulcerative colitis there is an increased in­
cidence of abnormalities in liver function, 
of hypokalemia, of hypoalbuminemia, leu­
kocytosis and anemia. As regards the local 
and systemic complications, we have found 
— and cannot satisfactorily explain—that 
inflammatory polyps (which is probably a 
better term than pseudopolyps) and fecal 
stasis were associated with a more favour­
able outcome than when either of these 
features was absent provided the activity 
of the colitis was of the same degree.
YEAHS OF FO L L O W  UP
Fig. 1.—Survival rate in patients with mild, 
moderate and severe colitis in the first referred 
attack.
In patients who developed a toxic mega­
colon we observed a mortality rate of 45%, 
and if perforation supervenes in these pa­
tients the mortality rises to a staggering 
75%.
With reference to the relapse rate and 
mortality, we have failed to observe any 
difference between left-sided colitis and 
pancolitis, but we tended to operate much 
more frequently on patients with pancolitis. 
This may have altered our mortality fig­
ures. The severity of the attack appeared 
to be much more important than the extent 
of the disease. A severe left-sided colitis 
is more serious than moderately active dis­
ease affecting the whole colon. Patients over 
the age of 50 with severe colitis appeared 
to be at great risk.
When we examine the long-term out­
come, again over the age of 50 there is a 
high total mortality. In those patients with 
chronic continuous disease there is a higher 
rate of surgical intervention. Of these pa­
tients 82% were operated on, in contrast 
to 30% of patients with only episodic 
exacerbation of their disease. Patients with 
chronic continuous disease also have a high­
er mortality —  25% in our experience, 
compared with 14% for patients with epi­
sodic disease. The severity of the disease 
in the first attack continues to influence 
the long-term prognosis. In our series pa­
tients with severe colitis had the highest 
mortality rate, 32%; in moderate colitis it 
was 15% and the patients who initially 
presented with mild colitis had a long-term 
mortality rate of 4.5%. Thus the first at­
tack is a very critical time and the subse­
quent trend in mortality perhaps reflects
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Fig. 2.—Results of long-term follow-up of 369 
patients with ulcerative colitis.
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the inadequacy of present management.
The long-term follow-up of 369 patients 
is shown in Fig. 2: 33 died and 79 had 
radical surgery, leaving 257 patients at risk. 
Of these, 158 had a further attack.
When we look at the pattern of the dis­
ease in the subsequent attacks, we can sim­
ply state that there was a positive correlation 
between the severity of the first referred 
attack and the subsequent attack. However, 
there appears to be a trend towards im­
provement. There was less tendency to 
severe exacerbation in the long-term fol­
low-up. When the progression of the dis­
ease in further attacks is examined and 
provided radiological methods are used— 
and I should qualify this further by speci­
fying a conventional barium enema—there 
is a suggestion that the disease tends to 
involve shorter lengths of the colon during 
subsequent attacks. Patients with partial 
involvement initially seem to show lesser 
degrees of involvement, and patients seen
initially with total involvement of the colon 
show an apparent diminution of their dis­
ease during the subsequent years.
To assess the morbidity from the disease 
we have used the relapse rate and the hos­
pital admission rate. Both rates, and the 
mortality rate, correspond very closely for 
patients seen in their first attack and those 
first seen in a relapse. The highest degree 
of morbidity and mortality occurred in pa­
tients who were moderately ill. This again, 
I think, is probably a reflection of our sur­
gical aggressiveness, as patients severely ill 
tended to be operated on earlier. The long­
term survival rate for the entire group is 
80% but this is markedly improved if the 
patients did not require surgery. A very 
interesting observation is that patients who 
were submitted to operation continued to 
suffer from an increased mortality in their 
long-term follow-up. Therefore even sur­
gery does not seem to be the complete 
answer in the treatment of this condition.
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SURGICAL TREATMENT OF ULCERATIVE COLITIS
DONALD C. McILRATH
Dr. L ennard-Jones has told us that the 
physician manages the patient with chronic 
ulcerative colitis, but the surgeon has the 
opportunity to cure him. As a surgeon, I am 
delighted to hear these comments because 
any physician who holds these beliefs will 
tend to refer the patient for appropriate sur­
gical therapy at the optimal time during the 
course of the disease. It is unfortunate, how­
ever, that the surgeon often does not see the 
patient at the optimal time. All too often the 
patient is debilitated nutritionally or shows 
signs of excessive administration of steroids 
over an unbelievably long period of time.
The basic indications for surgery can be 
considered as absolute— perforation, fistula, 
malignant change and toxic megacolon— 
or less definite— when there has been an 
inadequate response to medical treatment. 
Most delays in performing colectomy seem 
to occur in patients to whom the last in­
dication applies. It has been mentioned by 
several participants that a dreaded com­
plication of ulcerative colitis is the devel­
opment of malignant change in the colon. 
Fig. 1 shows a photograph of a resected 
colon with three separate areas of adeno­
carcinoma superimposed on chronic ulcer­
ative colitis. It can be appreciated that there 
is very little gross change associated with 
these malignant growths and, consequently, 
detection of the tumours was difficult. This 
example is only one of the reasons why 
early recognition of the development of ma­
lignant change in the colon usually is de­
layed. The need for proctocolectomy prior 
to its onset is apparent.
The surgical treatment of patients with 
chronic ulcerative colitis entails one of two 
basic procedures. Total proctocolectomy 
with permanent ileostomy is the common 
procedure of choice. The alternative is ab­
dominal colectomy and ileorectostomy. This 
is possible when the rectum is free of dis­
ease and a satisfactory long-term result can 
be expected. Factors to be considered in the 
selection of patients for abdominal colec­
tomy and ileorectostomy can be listed as:
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(1) the long-term functional result expected;
(2) the risk of neoplasm; (3) the develop­
ment of progressive proctitis; and (4) the risk 
of the operation. The risk of malignant 
change and ulceration developing in the re­
tained rectum are the primary concerns asso­
ciated with this procedure. Several other sur­
gical procedures have been advocated for the 
management of patients who develop the 
complication of toxic megacolon. Some sur­
geons have used ileostomy alone but, in my 
opinion, this operation is inadequate because 
it does not alter the basic disease process in 
the colon which is the source of the patient’s 
serious illness. For the same reason multiple 
colostomies and ileostomy are not appeal­
ing. I prefer to do abdominal colectomy or 
proctocolectomy with ileostomy.
The modern ileostomy described initially
by Warren and McKittrick and popularized 
subsequently by Brooke and by Crile and 
Turnbull has been used extensively during 
the past 20 years. With this basic type of 
ileostomy the incidence of stomal complica­
tions and the frequency of revision have 
been reduced markedly. Of current interest 
is the ileal pouch procedure described by 
Kock which offers the advantage of elimi­
nating the need for a permanent appliance. 
My colleagues and I have used this pouch in 
a limited number of patients who underwent 
proctocolectomy for chronic ulcerative coli­
tis and we are in the process of evaluating 
the early results. In my opinion a longer 
period of follow-up will be necessary to 
compare the advantages and disadvantages 
of the Kock pouch with the well-known re­
sults of the common type of ileostomy.
PROGNOSIS AFTER PROTOCOLECTOMY
F. T. de DOMBAL
T he complications and prognosis after 
proctocolectomy can conveniently be di­
vided into those of the short term and the 
long term. Fig. 1 relates to the short-term 
consequences and illustrates two points. 
First, total proctocolectomy for ulcerative 
colitis by no means always ensures a 
straightforward recovery. We have listed 
some of the complications such as delayed 
healing of the abdominal wound or of the 
perineum, other major complications such 
as cardiovascular and pulmonary c o n d i­
tions, and also postoperative hospital stay 
of over four weeks. Therefore, proctocolec­
tomy is not an operation to be undertaken 
lightly.
Second, the complication rate, post­
operative morbidity and mortality depend, 
to a large extent, on whether the operation 
was performed electively, as a matter of 
urgency, or as an emergency procedure. 
Actually these data relate to a survey pub­
lished in 1966 by Watts et al, and in the last 
10 years, in Leeds, the overall postoperative 
mortality has fallen dramatically. The 
mortality rate for each category has not
changed very much but, with the use of
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Fig. 1.—Postoperative morbidity and mortality 
after proctocolectomy for ulcerative colitis. (Re­
produced by permission from W atts JM, de 
D ombal FT, G oligher JC: Early results of sur­
gery for ulcerative colitis. Br J Surg 53: 1005, 
1966.)
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more timely surgery and also by cutting 
down the time spent reaching a decision 
about whether to operate on a patient with 
severe colitis, we have transferred many of 
our patients from a more urgent to a less 
urgent category. All these facts are, in 
my view, eloquent argument for using a 
timely and safe elective operative procedure 
rather than waiting for the patient to be­
come desperately ill and then performing a 
high-risk emergency operation.
Now, going on to long-term implications 
and long-term prognosis, I would like, if I 
may, to express surprise at the results shown 
by Dr McManus. It is true that in Leeds we 
may be guilty of observer variation in many 
fields of medicine, but it is difficult to have 
very much observer variation when you are 
dealing with the patient’s death. Either the 
patient is alive, or he is dead. And I have 
to say that most of the patients in our series 
are alive (Fig. 2). This excludes, I must 
admit, all incidental and unrelated deaths 
(which in our series were comparable to the 
death rate of a matched sample of the 
general population). In the years since we 
gathered these data, the curve has drifted 
up a little bit but it is still very much level. 
Indeed, one of the most sober and rational 
assessments that I can give you is that our
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Fig. 2.—Cumulative mortality following surgery 
for ulcerative colitis. (Reproduced by permission 
from G o l ig h e r  JC, editor: Ulcerative Colitis, 
London, Bailliere Tindall, 1968, p 528.)
patients with ileostomy now can get life in­
surance at competitive rates.
I would also like you to consider the 
patient with total colonic involvement and 
to compare his expected mortality with and 
without surgery. The cumulative mortality 
on present day conservative management, 
combined with major surgery when it be­
comes necessary, is much higher than the 
cumulative mortality after elective procto­
colectomy (Fig. 3). To put this in somewhat 
bold and simplified terms, if you have total 
involvement of the colon by ulcerative colitis, 
and if you accept medical management for 
25 years, you have a fifty-fifty chance of 
living or dying. But if you have an elective 
proctocolectomy, there is a greater than 
90% chance that you will be alive after 25 
years.
This comparison applies to all patients, 
including the elderly. It is true that for 
elderly patients, elective major surgery is a 
much more serious hurdle and, in fact, 20% 
will succumb to causes related to the opera­
tion in the following two to three years. But 
the medical management of these patients 
with present-day methods is even more 
hazardous and therefore I don’t think that 
we may put off surgery just because the pa­
tients may suffer from handicaps (such as 
blindness or muscular skeletal disability) 
that may make an ileostomy a totally un­
realistic alternative; but having considered 
such exceptions, I repeat that one should 
not put off elective surgery simply because 
the patient is over 60 years of age.
If we now look at patients with distal 
colitis or ulcerative proctitis (and these form 
%
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Fig. 3.—Cumulative mortality with conservative 
management compared with that from proctoco­
lectomy. (Reproduced by permission from W a tt s  
JM, d e  D o m b a l  FT, G o l ig h e r  JC: Long-term 
prognosis of ulcerative colitis. Br Med J 1: 1447, 
1966.)
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a large percentage of the total group), the 
cumulative mortality over 25 years is just 
about the same with or without elective 
surgery. I do not think therefore that nowa­
days we should systematically advocate sur­
gery for all patients with distal colitis or 
proctitis, although occasionally such a pa­
tient will come to operation for a specific 
indication.
So far I have assumed that the only point 
that matters is the survival of the patient. 
However, I am extremely aware that the 
quality of life the patient leads after total 
proctocolectomy is crucial. In fact, 10% 
to 20% of our patients will admit, if you
CONSERVATIVE OPERATIVE
R ectal
( 20%)
D ista l
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T o ta l
(45%)
4.—Comparison of the risks of conservative 
and surgical management in ulcerative colitis.
press them hard enough, that they have 
some degree of inconvenience from their 
ileostomy. It is an important factor which 
must be taken into account.
So, in trying to formulate a broad man­
agement policy for patients with ulcerative 
colitis (Fig. 4), perhaps we should bear the 
following points in mind. For patients with 
rectal disease alone, the mortality of con­
servative therapy over the years is less than 
2% while the mortality after proctocol­
ectomy is of the order of 7 %. Furthermore, 
the patient has the inconvenience of an 
ileostomy. Thus, generally speaking, we 
would not recommend proctocolectomy for 
ulcerative proctitis and we are inclined 
towards conservative management. We are 
more equivocal about the patient with 
distal or left-sided colitis, or procto­
sigmoiditis because, in rough terms, the risk 
to life of conservative management over a 
period of over 20 to 25 years is about 10%, 
and this is just about the same as the risk of 
proctocolectomy. In addition, the surgical 
patient has an ileostomy and I think this 
perhaps would influence us slightly in 
favour of conservative management. But I 
think that in patients with total involvement 
of the colon and rectum, there is such a risk 
to life on continued present-day medical 
management, we would be inclined to 
favour the much lower risk to life after 
proctocolectomy and accept any problems 
that the ileostomy brings.
Finally, we are looking at ulcerative 
colitis in Leeds yet again and although the 
results from our most recent survey, cover­
ing up to 1974, are not complete, I can tell 
you that our current data do not change 
very much the overall conclusions I have 
just presented to you. This is disappointing 
in view of the many recent developments in 
conservative management, but it does vali­
date perhaps the conclusions I have just 
described.
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ISCHEMIC BOWEL DISEASE
MUCOSAL INJURY IN LOW FLOW STATES
GUSTAVO BOUNOUS
N e c r o sis  of the intestinal mucosa as a com­
plication of prolonged circulatory insuf­
ficiency has been studied extensively since 
it was first described by Dupuytren in 1823 
in patients who died in shock following ex­
tensive burns. The lesion has been reported 
under the names: non-occlusive mesen­
teric ischemia or infarction, ischemic en­
teropathy, mesenteric ischemia without 
vascular occlusion, tryptic enteritis, terminal 
hemorrhagic necrotizing enteropathy.
The rarity with which antemortem diagnosis 
is made at the present time and the post­
mortem autolysis of the intestinal mucosa 
preclude a reliable estimate of its actual 
frequency. It is also possible that often this 
condition goes unreported because of the 
negative nature of the important feature — 
absence of vascular occlusion. Most cases of 
ischemic enteropathy have been described 
as following congestive heart failure. Oc­
casionally, it can develop after severe burns 
or as a postoperative complication in critic­
ally ill patients. The lesion appears as 
patchy, segmental or diffuse areas of dark 
red mucosa; its distribution is without rela­
tion to the vascular pattern and usually 
there is no involvement of the muscular and 
serosal layers; the submucosal vessels are 
dilated. Histologically, the mucosa is necro­
tic, often hemorrhagic. The necrotic process 
appears to have its origin in the absorbing 
cells near the tip of the villus, then spreads 
to the lamina propria and to the other 
epithelial cells covering the villus. Crypt 
cells are usually preserved. The lesion can 
be found almost anywhere in the small and 
large bowel although it is most frequently 
found in the terminal ileum.
Why is the mucosa of the intestine the 
first apparent anatomical site of degenera­
tive necrosis during severe circulatory insuf­
ficiency? Ischemic enteropathy has been 
attributed in the past to a selective reduction 
of intestinal mucosal blood flow aimed at pro­
tecting more vital organs. Modern techniques
of investigation have demonstrated, however, 
that this is not the case and that actually a 
certain degree of autoregulation protects in­
testinal capillary flow during shock. A more 
appealing theory is based on the intestinal 
countercurrent exchanges of oxygen; the 
proximity of inflow and outflow vessels in 
the lamina propria allows diffusion of oxy­
gen at this level during low flow states 
thereby short-circuiting the capillary bed 
at the tip of the villus. A second element of 
greater intestinal vulnerability to ischemia 
is the particular intestinal milieu. During 
profound circulatory insufficiency the bio­
synthesis of mucin, a rapid-energy-requiring 
process, is very soon affected by decreased 
cellular respiration. The loss of the mucus 
barrier exposes the mucosa to the activity of 
pancreatic proteases (Fig. 1) and other po­
tentially injurious elements that may be 
present in the chyme. In fact, hemor­
rhagic enteritis in experimental shock is 
minimized either by previous ligation of 
pancreatic ducts or pretreatment with an 
elemental semihydrolyzed diet. Therefore, 
it would appear profitable to pursue the 
concept that the qualitative aspects of the 
intestinal content play an important role 
in the maintenance of mucosal integrity fol­
lowing severe circulatory insufficiency.
Fig. 1. —Effect of local pre-treatment with a 
trypsin and chymotrypsin inhibitor (area between 
arrows) on the development of hemorrhagic ne­
crosis in the ileum of a dog during severe shock.
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CLINICAL FEATURES OF ISCHEMIC BOWEL DISEASE
HENRY HADDAD
The clinical features of intestinal ischemia, 
regardless of the cause, are similar in most 
cases. The diverse clinical settings are more 
a reflection of the amount of ischemic 
damage than of the cause or location of the 
ischemia. Acute mesenteric ischemia can be 
suspected on the basis of the history and 
physical examination but a firm diagnosis 
and determination of its cause usually re­
quire detailed radiological investigation in­
cluding barium studies, arteriography and 
even surgical exploration.
Vascular Disorders of the
Small Bowel
Acute Occlusion of the Superior
Mesenteric Artery
This condition continues to carry a 
mortality rate of over 90%. The only 
hope of decreasing the morbidity and mor­
tality lies in elective surgery of chronic in­
testinal ischemia and in the early diagnosis 
and management of the acute episode.
Diagnosis of acute occlusion of the su­
perior mesenteric artery (SMA) is still com­
monly made at a stage when extensive 
resection of gangrenous bowel is necessary. 
Tradition dictates that these patients should 
present with sudden onset of severe abdo­
minal colic, followed by the passage of 
mucus and blood per rectum and, in a few 
hours, signs of peritonitis and shock. We 
should, however, recall that when the blood 
supply to the small bowel is interrupted, 
bowel wall ischemia proceeds outwards 
from mucosa and only with serosal involve­
ment is there a peritoneal reaction. It is 
during the early period before infarction is 
complete that the opportunity for corrective 
arterial surgery exists.
Acute mesenteric thrombosis may present 
quite insidiously, beginning with mild ab­
dominal cramps, and the condition of a pa­
tient with severe intestinal damage may re­
main normal for hours and even days. The 
clinician’s usual inclination to wait until
there is a “surgical abdomen” may destroy 
the patient’s only chance of survival.
Pain is present in almost all cases of 
ischemia. The early colicky and perium­
bilical pain soon becomes severe, steady and 
poorly localized. Many associated symptoms 
have been recorded—anorexia, nausea, 
vomiting, diarrhea, const ipat ion,  melena 
and hematemesis. But these are seldom 
helpful in pinpointing the diagnosis. One of 
the most characteristic features is the lack 
of significant abdominal signs even when 
the pain is unbearable. Severe abdominal 
distension is frequently found even when 
peristalsis is present. Evidence of gastroin­
testinal bleeding can also be found in most 
patients but it is seldom gross except when 
the colon is involved. With the progression 
of ischemia, peritonitis develops. A peculiar 
mottled cyanosis of the abdominal wall has 
been reported. When the amount of 
ischemic bowel is large, dehydration is 
frequent and severe shock eventually 
develops. Laparotomy at this stage usually 
represents a futile gesture.
The SMA may be occluded by an em­
bolus or by thrombosis. Early diagnosis is 
more likely with embolism because of an 
associated cardiac arrythmia. SMA oc­
clusion resulting from thrombosis is more 
difficult to diagnose as less than half of 
these patients have a history of heart dis­
ease. An epigastric bruit may be present. 
Prodromal symptoms of chronic ischemia 
are often difficult to evaluate but on occa­
sion they may be obvious; they antedate the 
acute attack in as many as 50% of the 
patients. One of the major problems in the 
evaluation of these patients is the lack of 
correlation between the anatomical defects 
shown by arteriography and the clinical 
symptoms.
Non-occlusive Mesenteric Ischemia
A most dramatic development over the 
past 15 to 20 years has been the emergence 
of non-occlusive mesenteric ischemia as a
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frequent and potentially treatable condition.
A recent computer analysis showed that 
it was impossible to differentiate patients 
with occlusion of a major vessel from those 
with perfusion defects. Non-occlusive mes­
enteric infarction usually occurs in elderly 
patients with diffuse atherosclerosis. How­
ever, other conditions may be responsible, 
such as generalized peritonitis, pancreatitis, 
septicemia, cerebral disorders and advanced 
malignant neoplasms.
Small Vessel Disease
Changes in the smaller and more distal 
arteries tend to affect shorter segments of 
bowel. Clinically there is abdominal pain 
with evidence of intraperitoneal inflamma­
tion. Causes of this type of lesion include: 
systemic lupus erythematosus, rheumatoid 
arthritis, radiotherapy, allergic vasculitis, 
sepsis and potassium-induced intestinal 
ischemia. Stenosis may develop with result­
ing malabsorption or partial small bowel 
obstruction. Such malabsorption is non­
specific and its ischemic etiology cannot be 
established by any of the currently used 
absorption studies.
Celiac Axis Syndrome
This syndrome is due to stenosis or throm­
bosis of the celiac artery, caused by ex­
ternal compression or atherosclerosis. Ob­
struction due to external compression re­
presents an unusual and controversial cause 
of bowel ischemia. Most patients are young 
women complaining of vague post-prandial 
pain. An epigastric bruit can usually be 
heard. Not all patients are relieved by re­
moval or division of the compressing 
structures.
Vascular D isorders of the Colon
Ischemic disease of the colon, regardless 
of cause, produces the same spectrum of 
pathological, clinical and radiological mani­
festations. The outcome depends on the 
severity of the ischemia. The majority of 
episodes of colonic ischemia produce 
transient and reversible changes. Any part 
of the colon may be involved but the splenic 
flexure, descending and sigmoid colon are
the most common sites. The rectum is not 
always spared and recent reports have 
documented the entity of ischemic proctitis.
Gangrene of the Colon
Gangrene of the colon usually occurs in 
the sixth or seventh decade of life. There is 
frequently associated cardiovascular dis­
ease. The onset is usually sudden with very 
severe generalized abdominal pain, worse 
on the left side, nausea and vomiting. These 
symptoms are followed shortly by profuse 
diarrhea and the stool may contain blood. 
On examination there is evidence of intra­
peritoneal inflammation and occasionally 
intestinal perforation. If the rectum is in­
volved, proctosigmoidoscopy reveals hem­
orrhagic ulceration or extensive mucosal 
edema and friability. An adherent whitish 
or greyish membrane may cover the mu­
cosa. A precise diagnosis as this stage may 
not be possible but it is usually clear that 
immediate laparotomy is indicated.
Reversible Ischemic Lesions
In most episodes of colonic ischemia the 
clinical, radiological and pathological 
changes are completely reversible. The pa­
tient presents with a short history of left­
sided or lower abdominal pain which is 
soon followed by bloody diarrhea. Blood 
loss is usually minimal. A history of previ­
ous bowel disorders is frequently lacking. 
Physical examination usually reveals ten­
derness over the involved segment of colon. 
Signs of peritoneal irritation persisting for 
more than a few hours should be considered 
as evidence of irreparable tissue damage. 
Fever and leukocytosis are helpful in asses­
sing the progress of these lesions.
Sigmoidoscopy is of value when the 
rectosigmoid colon is involved.
The early development of pseudotumours, 
resulting from submucosal hemorrhages, is 
pathognomonic of ischemia. Within several 
days large ulcerations replace these masses 
and the appearance is no longer specific.
Early and repeated barium enemas are 
essential to the diagnosis of colonic isch­
emia. The pathognomonic thumbprints (Fig. 
1) disappearing on subsequent studies are 
the major sign. These changes are thought
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to be due to submucosal hemorrhages which 
are subsequently reabsorbed or evacuated. 
A barium enema one week after the onset 
of the process may show either a return to 
normal or a pattern of segmental colitis. 
Once the latter pattern has developed, the
Fig. 1.—Barium enema showing thumbprinting 
of the descending colon.
Fig. 2 .—Ischemic stricture of the descending 
colon.
ischemic nature of the disease may be 
missed. It is important to realize that this 
condition is marked by a constantly changing 
picture.
Fibrotic Ischemic Stricture
With a more severe degree of infarction 
a stricture (Fig. 2) will develop after 
several weeks. Continued bleeding suggests 
stricture formation. The symptoms may be 
those of incomplete large bowel obstruction. 
The typical site of the stricture is the splenic 
flexure but it may occur in any part of the 
large bowel, including the rectum.
Chronic Ischemic Proctitis
The entity of chronic progressive ischemic 
proctitis has now been documented. The 
symptoms are non-specific. Proctoscopy 
shows discrete ulcerations. Deep rectal bio­
psy may suggest an ischemic process.
It may be difficult to differentiate this 
entity from other forms of inflammatory 
bowel disease. This is especially true in the 
older age group, in whom there is a second­
ary rise in the prevalence of the other forms 
of inflammatory bowel disease. The fin ding 
of vascular pathology at arteriography can­
not be taken as definitive proof of the isch­
emic nature of the bowel lesion. What is 
important in the final analysis is the blood 
that actually reaches the mucosa and there 
is, as yet, no clinical test to measure this.
Mesenteric Venous Occlusion
The incidence of venous occlusion in re­
ported series of bowel ischemia is less than 
10%. Acute occlusion may occur with hy- 
percoagulable states, carcinoma, portal hy­
pertension, sepsis, extrinsic compression, di­
rect injury and the use of contraceptive 
pills. It may develop spontaneously without 
demonstrable cause. Clinically the disease 
may present as a fulminating abdominal 
catastrophe. In other cases, especially those 
without demonstrable cause, symptoms of 
abdominal discomfort, anorexia and change 
in bowel habit develop over a period of one 
or two weeks. Physical findings are non­
specific. Superior mesenteric arteriography 
shows a prolonged arterial phase and failure 
to opacify the venous system.
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ANGIOGRAPHY IN ISCHEMIC BOWEL DISEASE
D. DILENGE
A ngiography plays a useful role in the 
diagnosis of intestinal ischemia. It is of value 
both in the occlusive form, where it permits 
an objective evaluation of the nature and 
degree of arterial obstruction, and in the 
non-occlusive form. In the latter, by exclud­
ing occlusive disease arteriography may al­
low us to postulate other conditions which 
are associated with a reduction in arterial
flow or with an increase in the distal vas­
cular resistance (capillary or venous).
Stenosis or obliteration of one or more 
of the mesenteric arteries is usually arterio­
sclerotic in origin and usually involves the 
origin of any of the three main mesenteric 
arteries. Signs of coexisting aortic and 
generalized arteriosclerosis are frequently 
present. Less frequently, the calibre of the
Fig. la
Fig. 1.—Completely asymptomatic thrombosis of the celiac and superior mesenteric arteries, 
(a) Contrast material injected into the aorta shows a grossly dilated inferior mesenteric artery 
(large arrow). This provides adequate arterial supply to the territories of the thrombosed vessels by 
shunting blood via the marginal artery of Drummond (small arrows) and anastomotic vessels. Note 
on (b) the retrograde filling of the celiac artery (arrow) and its branches.
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arteries may be reduced by other causes. 
Among these are compression by neighbour­
ing aneurysms of the aorta, fibrous dysplasia, 
emboli and traumatic lesions.
However, it is well known that stenosis 
or even complete obliteration of one or 
more of the three mesenteric arteries may 
be asymptomatic. The development of symp­
toms, among other things, depends on the 
efficiency of the collateral circulation. Such 
an event is well illustrated in Fig. 1.
The development of transpancreatic anas­
tomotic pathways produces a typical mor­
phology (Fig. 2).
There are numerous examples in the lit­
erature of severe arterial lesions associated
with a complete absence of ischemic mani­
festations. Chienne, in 1969, during the 
course of an autopsy, noted a complete 
thrombosis of the celiac axis and of the supe­
rior and inferior mesenteric arteries in a pa­
tient who probably died from unrelated 
causes.
To illustrate some of the angiographic 
ieatures of the occlusive form of intestinal 
ischemia, I will present five cases studied 
during the past five years.
Case R eports
Case 1 .—A 58-year-old man presented a 
clinical picture suggestive of abdominal an­
gina. Angiography of the abdominal aorta
440 THE CANADIAN JOURNAL OF SURGERY Vol. 17
Fig. 2.—Stenosis of the celiac artery. Note the 
anastomotic network between the superior mesen­
teric artery (right-hand arrow) and the right he­
patic artery (left-hand arrow) in the region of the 
pancreas. Anastomoses are typically tortuous.
Fig. 3.—Arteriography in a patient with abdominal 
angina. There is a severe narrowing of the origins 
of the celiac (top arrow) and superior mesenteric 
(middle arrow) arteries well seen on the lateral 
view (a). The mesenteric artery (bottom arrow) 
is poorly filled (a).
Fig. 3b
Fig. 3.—(b) On the anteroposterior view there is an obvious reduction in the number of pa­
tent branches coming from the celiac and superior mesenteric arteries.
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Fig. 4b
Fig. 4.—Selective arteriography in a patient with 
abdominal angina, (a) The injection of the superior 
mesenteric artery shows changes in the calibre of 
several branches (arrows) which are known as 
“stationary arterial waves” and are typical of 
fibrous dysplasia, (b) The injection of the inferior 
mesenteric artery in the same patient reveals a 
different variety of vascular anomaly in the left 
colic (simple arrow) and sigmoid arteries (weight­
ed arrows). These aneurysmal dilatations (white 
arrows) in a “string of beads” pattern are most 
marked distally.
Fig. 5.—Ischemic colitis. Selective angiography 
of the inferior mesenteric artery demonstrates a 
narrowing at the origin of the sigmoid and superior 
hemorrhoidal arteries (arrow). This severe stenosis 
causes a prolongation of the circulation time in 
these two vessels as contrast material remains in 
the late phase of the serial films.
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Fig. 6.—Ischemic proctitis. The stenosis seen at 
the origin of the inferior mesenteric artery (arrow) 
appears to be in this case the only obstructive le­
sion responsible for the rectal lesions.
(Fig. 3) prior to surgery revealed not only 
numerous irregularities at the level of the aorta 
but also an important reduction in the mesen­
teric vascular supply. Pathological examination 
confirmed the presence of an ischemic bowel 
lesion.
Case 2 .—A 32-year-old woman appeared to 
have mesenteric angina. Angiography revealed 
typical signs of fibrous dysplasia (Fig. 4). The 
associated “string of beads” aneurysmal dilata­
tions have not, to our knowledge, been reported 
previously.
Case 3 .—The clinical picture in a 67-year- 
old man was dominated by abdominal pain, 
weight loss and rectal bleeding. Ischemic colitis 
was suspected. Selective angiography (Fig. 5) 
revealed a severe stenosis of two branches of 
the inferior mesenteric artery. A striking hemo­
dynamic phenomenon was observed—the 
vascular territory of these two arterial branches 
remained opacified long after the injection. 
This has been interpreted as a sign of reduced 
blood flow.
Case 4.—A 56-year-old woman with proc­
titis was found to have a stenosis of the inferior
Fig. 7.—Ischemic proctitis. Ischemia was precipitated by carbon monoxide poisoining in this patient 
with stenosis of the origins of the celiac, superior mesenteric (left-hand arrow) and inferior mesenteric 
(right hand-arrow) arteries. Treatment of the poisoning was followed by rapid recovery.
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mesenteric artery (Fig. 6). The reversibility of 
symptoms and the healing of the rectal lesions 
after vascular surgery supported our diagnosis.
Case 5 .—This case is of particular in­
terest. A previously asymptomatic 43-year-old 
man developed ischemic proctitis following 
carbon monoxide poisoning. Angiography de­
monstrated a significant stenosis at the origin 
of the superior mesenteric artery (Fig. 7) and 
an additional stenosis at the origin of the in­
ferior mesenteric artery. As in the preceding 
case, the signs of reduced blood flow could
be demonstrated in the territory of the inferior 
mesenteric artery. The proctitis resolved com­
pletely. This case illustrates how, in the pre­
sence of a precarious but usually adequate 
blood flow, a concurrent insult may precipitate 
ischemia of the bowel.
Finally, I would like to show the case of 
a patient presenting with discrete rectal 
ulcers (Fig. 8). Certain authors consider that 
such lesions may be ischemic in nature; 
angiography in this patient showed opaci­
fication of the ulcer sites.
Fig. 8.—Ulcers of the rectum. Selective injection of the inferior mesenteric artery supplemented 
by the subtraction technique reveals two areas of increased density (arrows) corresponding to two ul 
cerations confirmed at operation.
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SURGICAL TREATMENT OF ISCHEMIC BOWEL DISEASE
D. C. McILRATH
I would like to summarize some of the 
things the previous speakers have said in 
dealing with the subject of ischemic bowel 
disease and touch upon some practical as­
pects I have found important in manage­
ment.
Table I gives a very simple classification 
of the causes of intestinal ischemia. They 
are divided into arterial and venous groups 
and the arterial group is further subdivided 
into occlusive and non-occlusive lesions. 
Certainly the non-occlusive form has been 
well reviewed by the other speakers. With 
regard to the lesions that do cause vas­
cular obstruction sufficient to produce a 
clinical problem, we are talking, essentially, 
about four things. The first is embolization 
which, in our experience, usually results 
from some cardiac problem, either atrial 
fibrillation or a mural thrombus develop­
ing after myocardial infarction. One should 
be alert to the diagnosis of embolism and 
look for a possible source. In fact, it occurs 
not only in patients with known heart dis­
ease but also when there is no clinically 
recognizable heart problem.
Thrombosis usually complicates chronic 
atherosclerosis. Polyarteritis and other in­
flammatory arterial lesions of the bowel 
must be kept in mind and, fortunately, often 
affect a small segment of the intestinal tract 
which is easily resected. The hazard in this 
particular situation is that these patients 
are often very ill as a result of their sys­
temic disease.
Compression of the arterial tree has al­
ready been mentioned and is a condition 
recognized by some. It is known as the 
arcuate ligament syndrome, celiac compres­
sion syndrome, Nicholson’s syndrome, all 
terms referring to compression of the celiac 
trunk or superior mesenteric artery. We 
have, unfortunately, also seen several pa­
tients in full body casts in whom a compres­
sion of the arterial tree has developed 
sufficient to produce gangrene of the entire 
small bowel and, in some instances, of the 
stomach and the proximal colon. As a re­
sult, when any patient who is in a full body
cast develops distension of the abdomen or 
some other type of gastrointestinal distress, 
one should keep in mind the possibility of 
compression of. the visceral arterial supply.
In Table I the condition is broken down 
in perhaps a simpler way, according to the 
extent of the ischemic lesion. Unfortunately, 
extensive acute lesions usually involve most 
of the small intestine and resection does not 
solve the problem because the remaining 
bowel is too short to support life. In the 
chronic form, diffuse atherosclerotic disease 
affects at least two of the major vessels sup­
plying the gut. In our experience this has 
been a tragic situation that is seldom helped 
by surgical intervention. These patients are 
thin and emaciated and develop abdominal 
pain with any challenge such as a meal 
which increases the need for perfusion of 
the intestinal tract. If one does arteriograph- 
ic studies the disease is often found to be 
so diffuse that a bypass or revascularizing 
procedure is not satisfactory.
Such studies should not be omitted, how­
ever, because there will be the occasional 
patient for whom it is possible to provide 
significant help. In segmental disease, in­
farction of one or two feet of bowel may 
occur so that resection is possible without 
disturbing the greater part of the intestine. 
Clinically, infarction of the small intestine 
will typically manifest itself by the abrupt 
onset of pain, vomiting and diarrhea. The 
blood pressure tends to fall, the pulse accel-
TABLE I.—I ntestinal I schemia
Causes:
1. Arterial
Occlusive
Embolization
Thrombosis
Polyarteritis
Compression
Non-occlusive (malperfusion)
2. Venous
Occlusive
Types:
1. Extensive
Acute (infarction)
Chronic (abdominal angina)
2. Segmental
Ischemic colitis
Segmental infarction of small bowel
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erates, and the abdomen progressively be­
comes distended and tender.
There are three different approaches to 
the surgical treatment of acute small bowel 
ischemia. The first is resection of the intes­
tine, and usually it is the only thing that 
can be done. Klass, in 1951, described 
embolectomy. We have not encountered too 
many patients in whom this was possible 
and where the bowel remained viable. 
Marston has reported going through the 
ileocolic artery, using a catheter to extract 
the thrombus from the superior mesenteric 
artery, and then anastomosing the ileocolic 
artery to the iliac artery.
As far as abdominal angina is concerned, 
it is a more chronic form of disease, with 
pain after meals, loss of weight, diarrhea, 
and perhaps an audible abdominal bruit. 
In these cases, a very careful interpretation 
of an arteriogram may suggest what might 
be accomplished by surgery. The celiac ar­
tery compression syndrome tends to occur 
in young women who often have had sev­
eral operations in an attempt to cure ab­
dominal pain. This pain is often vague and 
does not fit any of the usual pain patterns. 
There may or may not be a bruit. The cor­
rection of this problem is, of course, to
release the arcuate ligament. We have not 
treated surgically enough patients with this 
condition to determine for ourselves wheth­
er the concept is valid, but there are cer­
tainly enthusiasts with large series.
Boley, in his description of ischemic co­
litis in 1963, pointed out its various clinical 
manifestations. Pain of acute onset may 
develop, with or without nausea and vomit­
ing, and, often, rectal bleeding as well as 
tenderness and abdominal distension. Proc­
toscopic examination may be helpful. The 
radiological findings have been mentioned 
earlier. Arteriography, unfortunately, is not 
often helpful because in a large percentage 
of healthy individuals the inferior mesen­
teric artery is not visualized. In regard to 
surgical treatment, the acute case may de­
velop peritonitis and one must operate to 
resect the affected bowel. In some patients 
the acute lesion is less severe but leads to 
a stricture which may produce obstruction 
or pose a problem of differential diagnosis 
from a malignant lesion. When surgery is 
necessary for such a lesion, satisfactory re­
sults can usually be obtained by segmental 
resection of the affected bowel and, if the 
bowel has been prepared beforehand, it can 
be accomplished as a one-stage procedure.
GENERAL DISCUSSION
D r. McManus: To start our discussion 
period, I would like to ask Mr. de Dombal 
to clarify for me his statistics on long-term 
survival after proctocolectomy for ulcerative 
colitis. It seems to me that on the graph 
he presented, the mortality curve was almost 
parallel to the abscissa, which would repre­
sent practically no mortality on long-term 
follow-up. This certainly has not been our 
own experience in Edinburgh.
Mr. de Dombal: I think we are talking 
at cross purposes; what I have been dis­
cussing is long-term disease-related mortal­
ity. I am sorry if I have not made this 
absolutely clear. We are talking about two 
things: one is a long-term disease-related 
mortality after proctocolectomy, and al­
though this is not parallel to the abscissa,
it is not far from it. As I have mentioned 
before, some hard-headed insurance men in 
Leeds will give our patients life insurance 
at competitive rates. But, in addition to 
what the figure presents, there is an appre­
ciable unrelated mortality after proctoco­
lectomy and this is almost within 1% of 
the mortality observed in a sample of the 
population matched for age and sex. So, 
there are two components to mortality ob­
served after total proctocolectomy. If you 
want a further semi-anecdotal piece of evi­
dence to support the correctness of our 
statistics, some of our patients with ileo­
stomies have been claiming they deserve 
better life insurance rates than the rest of 
the population because, as they say, they 
cannot develop cancer of the colon.
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D r . D evroede: I would like to support 
Mr. de Dombal because three years ago we 
published the Mayo Clinic’s experience with 
ulcerative colitis in children. We compared 
the survival of the children undergoing 
proctocolectomy with that of the other chil- 
den who did not have this operation. We 
did not exclude unrelated death from our 
statistical analysis. There was a significantly 
higher survival in the group that had proc­
tocolectomy. Also, there was no statistical 
difference between the long-term survival 
of the group with proctocolectomy and a 
matched normal control population. Like 
others, we noted an 18% drop in survival 
during the first two years after operation 
but this was a retrospective study and in­
cluded children who had surgery for a vari­
ety of reasons and those undergoing emer­
gency operations for major life-threatening 
complications. In spite of this initial, rather 
high, mortality they had a better chance 
of long-term survival than the others who 
did not have definitive surgery.
M em ber  of the Au d ience: Earlier, one 
of the speakers made reference to the fact 
that ulcerative colitis starts in the rectosig­
moid colon and then spreads proximally. 
This has been described in a number of 
books on the subject. Personally, I have 
never seen this progression of ulcerative 
colitis and, in my experience, the disease 
is either localized and remains localized in 
the rectosigmoid area or it is already gen­
eralized at the time the patient is first seen. 
I would like to hear about your experience 
on this matter.
D r . L ennard-Jones: We have followed up 
a group of patients, just as you have de­
scribed, with ulcerative proctitis. This was 
in the 1960s, and we made the diagnosis 
when we could see the upper limit of the 
disease on sigmoidoscopy. Over 10% of 
them went on to develop more extensive 
or total colitis. The Leeds experience, if I 
may speak for Mr. de Dombal, also shows 
that a proportion of the patients develop 
more extensive colitis, but perhaps he would 
like to elaborate on this subject himself. 
M r . de D om bal: While I agree with Dr. 
Lennard-Jones that ulcerative colitis does 
tend to progress, the question raises a num­
ber of interesting problems. I wonder wheth­
er, in fact, there is a more extensive disease
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to begin with but the radiologists are just 
not able to document this. If this were the 
case, then with improvements in diagnostic 
methods we would expect in our more re­
cent results to have a smaller proportion 
of patients with initial proctitis developing 
total colitis and I think we have some evi­
dence that this is true.
It may well be, therefore, that this is one 
of the reasons for the conflicting views in 
the literature but, even so, looking at our 
latest data, I am reasonably certain that 
10% to 15% is a fair figure for those with 
originally distal disease who are going to 
develop more extensive or total involve­
ment of the colon over the next 20 years. 
Our problem is that to test this hypothesis 
would require a 20-year follow-up period. 
D r . D e v r o e d e : Like the member of the 
audience, I too have never seen a case of 
ulcerative proctitis progress to total colitis. 
I feel that the limitations of our diagnostic 
methods have given misleading information. 
In the past year I have seen five patients 
with a disease that was diagnosed as distal 
colitis on x-ray which actually turned out 
to be total colitis on colonoscopy. The first 
of these had a barium enema in 1968, and 
a radiological diagnosis of distal colitis was 
made. Later, the barium enema was re­
peated in our institution and the radiologists 
again reported distal colitis. At colonoscopy 
the patient had total colitis going all the 
way around to the cecum as proved by 
biopsy, and in one of the rectal biopsy spe­
cimens we found a carcinoma in situ. So 
I feel that the question of progression is 
far from settled. It is possible that there 
is a progression from proctitis to procto­
colitis but it is also equally true that very 
often we do not appreciate the true extent 
of the disease initially.
D r . L e n n a r d -Jo n e s: There is one useful 
diagnostic point I would like to mention. 
Patients with proctitis usually pass solid 
stools, and if you have a patient who has 
so-called proctitis but who passes frequent 
liquid stools, it is almost certain that he has 
extensive colitis. We have had patients with 
total colitis and completely normal x-rays 
so perhaps this point is one of the useful 
distinguishing clinical features. Reverting to 
some of the presentations on ulcerative co­
litis from Mr. de Dombal and Dr. Devroede,
both of whom I respect greatly, it must be 
remembered that they do represent a par­
ticular attitude to the management of total 
colitis. Now, I am going to be thoroughly 
provocative here but I do have the neces­
sary data to back my words. The problem 
in reaching conclusions about the manage­
ment of total colitis is that many of the 
series published have dealt with the early 
days before our current concepts of man­
agement were developed. Just to give you 
an example, Dr. Devroede’s study of chil­
dren began in 1919, and Mr. de Dombal 
presented data from the early 1960s. Now, 
I am in complete agreement with Dr. Mc- 
Ilrath that surgery plays a vital role in the 
treatment of colitis and about 20% of our 
own patients eventually require surgery. The 
difficulty for the person treating colitis is 
to get a balanced view on the subject. At 
our own institution we have been prospec­
tively following up patients with extensive 
colitis since 1966. Our policy is that they 
are treated surgically if they do not respond 
rapidly to medical treatment during their 
first admission, if they have recurrent severe 
attacks of colitis, if there is a long history 
of disease, or if, in our opinion, there is 
an increased risk of malignancy. All chil­
dren who fail to grow are also treated sur­
gically. With the indications mentioned, the 
likelihood of surgical treatment for extensive 
ulcerative colitis at our hospital, computed 
actuarily, is about 20% in five years. We 
must not regard all patients with total colitis 
as the same, because there are individual 
differences. In the patients in our series 
who had no surgical treatment the excess 
mortality due to colitis over a five-year 
period was 0.003/patient/year.* This is 
much less than the mortality that Mr. de 
Dombal has shown us. I think it is fair to 
say that quite a high proportion of patients 
with total colitis do need surgical treatment 
— and I would admit to this without any 
qualification whatsoever—but there is also 
a proportion of patients who can continue 
with medical treatment, remain well and 
have a low mortality. The other recent series 
on the management of colitis comes from 
Copenhagen and was published in the Scan-
*Lennard-Jones JE, Misiewicz JJ, Parrish JA, 
et al: Prospective study of outpatients with ex­
tensive colitis. Lancet 1: 1065, 1974.
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dinavian Journal of Gastroenterology this 
year. This is a study by Dr. Riis and his 
colleagues who have very similar indications 
for total colectomy.* Their mortality from 
colitis is extremely low. They also have 
about a 20% operation rate at five years 
and, interestingly but not unexpectedly, 
their mortality rate tends to follow surgical 
treatment because surgery is reserved for 
their more seriously ill patients. I regard 
this survey from Copenhagen as superb. It 
is a group taken from one geographical 
area, it is not selected and it is beautifully 
analyzed by actuarial methods. I do think 
it is an absolute classic on this subject and 
I commend it to you.
D r. D evroede: I am afraid I do not have 
the experience of Dr. Lennard-Jones and 
what I am going to say represents mainly 
the Mayo Clinic experience with ulcerative 
colitis in children. Needless to say, several 
questions may be raised about the validity 
of our data. First, the treatment in 1919 
was not the same as in 1974; second, the 
availability of steroids may have drastically 
changed the prognosis; and, third, the Mayo 
Clinic population is a highly selected one 
and represents a small segment of the total 
population with ulcerative colitis. To an­
swer some of the questions raised, we did 
look at survival before and after 1953, the 
year when steroids became available for the 
treatment of ulcerative colitis, and we found 
the survival rates before and after that date 
to be identical. So it seems that we have 
made no progress in this respect. As 
Weedon and Taylor have shown, we have 
made progress in Crohn’s disease but cer­
tainly not in ulcerative colitis. To test the 
validity of the argument that referred pa­
tients do not form a representative group, 
we analyzed the life history of the children 
who developed cancer and classified their 
ulcerative colitis as mild, moderate or severe 
from onset to cancer detection. Of these 
patients 75% had mild or moderate ulcer­
ative colitis and yet they developed cancer. 
So it was not because the Mayo Clinic chil­
dren were more acutely ill with ulcerative 
colitis that they showed a high incidence
*Bonnf.vie O, Binder V, Anthonisen P, et at: 
Prognosis of ulcerative colitis. Scand J Gastroen­
terol 9: 81, 1974.
of cancer on medical management. There­
fore we feel that having mild colitis is no 
insurance against malignant change. Finally, 
Dr. Taylor, consultant in statistics at the 
Mayo Clinic, modified the actuarial method 
used to eliminate the problem of losing pa­
tients during the follow-up period. His 
method also took into account the year 
after the onset of the disease when the pa­
tient was first seen at the Clinic and entered 
in the study. Mr. de Dombal, you have 
stated earlier that the burden was upon the 
physician to prevent cancer in patients with 
total colitis and I think this is a very im­
portant point. We have had some hopes 
with the carcinoembryonic antigen but 
Janowitz of New York has just published 
his results, indicating that CEA determina­
tion is not a useful screening procedure. 
D r. Lennard-Jones: Please, I do not want 
anybody to misunderstand me and think 
that I do not believe in surgery for ulcer­
ative colitis, because I do! And I do be­
lieve that the risk of cancer in patients with 
extensive or total ulcerative colitis, with a 
history of over 10 years, is very great. I 
think that these patients must be followed 
up very carefully and, if this is not possible, 
surgical treatment is the right thing for 
them. We feel that in our particular hos­
pital, with the facilities at our disposal, we 
can keep track of our patients and so far 
our results, in my opinion, have been rea­
sonably acceptable. Like Dr. Janowitz, we 
have also studied the CEA antigen and 
have found it to be of no use in detecting 
early cancer. I know there is a consider­
able controversy on the question of dys­
plasia in rectal biopsies. We do find it, in 
our own experience, to be useful in detect­
ing patients at risk from cancer. My prob­
lem as a physician is to try to define the 
risk for the individual patient rather than 
the group as a whole and this is the area 
on which we are concentrating our research 
at the moment.
M r. de D o m ba l: First of all, one must 
agree that our study was not entirely repre­
sentative and presented a predominantly 
surgical point of view. I think this is an 
important comment and I am glad for the 
opportunity to discuss it. However, as far 
as medical management is concerned, the 
results that I have presented were largely,
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or almost exclusively, obtained during a 
period when we had an extremely compe­
tent gastroenterologist working in our unit 
and I really think that the patients received 
the highest form of medical management 
that was available at the time. And yet, 
even he, using conventional methods of 
medical management, could not achieve bet­
ter results than the results I have presented 
to you. Second, the only other thing that 
has changed during the past 10 years, as 
far as our medical management of ulcer­
ative colitis is concerned, is that we have 
tried treating our patients with immuno­
suppressive agents and our results have not 
been very impressive. Since 1953, when the 
results of our survey became available, we 
have adopted a much more agressive policy 
towards patients with total colonic involve­
ment and the overall mortality in our series 
for these patients has fallen from around 
2.7% to around 1%. Finally, in our orig­
inal group of patients with total colitis in 
whom we have been adopting a very ag­
gressive surgical approach, we have now 
almost ceased to see severe attacks and 
carcinoma over the period of the last 10 
years. The severe attacks that we see now 
in our own unit are in patients with total 
involvement of the colon referred from else­
where who have been managed conserva­
tively.
D r . K o n o k : Up until now we have been 
discussing the treatment of patients in whom 
a definitive diagnosis of ulcerative colitis 
has been made. Recently we have had cases 
where clinically, radiologically and pathol­
ogically the disease resembled ulcerative 
colitis, yet the evolution of the disease and 
the histological findings in rectal biopsies 
were not compatible with the diagnosis. 
With your permission I would like to pre­
sent an actual case history to serve as a 
basis for discussion. A 56-year-old woman 
was transferred to our care from another 
hospital where she had been investigated 
and treated for rheumatic pains in her 
shoulder. She gave a history of several 
years of frequent, loose, non-bloody, green­
ish bowel movements. During her initial 
hospitalization, she developed crampy ab­
dominal pains and a barium enema done 
at the time revealed fairly extensive ulcera­
tion of the left and transverse colon. Initi-
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ally she was treated conservatively but when 
she developed a distended, diffusely tender 
abdomen and her general condition deter­
iorated, she was transferred to our hospital 
for treatment. On admission she had clinical 
signs of impending shock, septicemia, an 
acute surgical abdomen, free air under both 
diaphragms and a distended transverse 
colon. Preoperative sigmoidoscopy showed 
an essentially normal rectum with a few 
punched-out ulcerations and normal inter­
vening mucosa. Our diagnosis was fulmi­
nating ulcerative colitis and a total colec­
tomy with ileostomy was performed. Now, 
after a rather stormy postoperative period, 
she is doing well and repeated sigmoid­
oscopies have shown a normal rectum. I 
will ask Dr. Sanchez-Casis to report on the 
pathology.
D r. Sanchez-Casis: Inside the specimen 
we found longitudinal as well as transverse 
ulcerations; in the ascending colon the mu­
cosa was almost completely absent; the 
transverse and descending colon were less 
severely affected. There were several per­
forations and the wall of the colon was not 
thickened as one usually sees in Crohn’s 
disease. On microscopic examination, in the 
non-ulcerated colon there were degenerated 
crypts with necrotic cells and polymorpho­
nuclear leukocytes. Sections from the areas 
of ulceration showed that the surrounding 
mucosa also participated in the inflamma­
tory process which, again, is more charac­
teristic of ulcerative colitis than of Crohn’s 
disease. There was also quite marked edema 
of the submucosa but no evidence of granu­
lomas. Many sections were taken and scru­
tinized for other entities such as vasculitis 
or ischemic colitis, but from the pathological 
appearances we favoured the diagnosis of 
ulcerative colitis. The postoperative rectal 
biopsies showed an almost completely nor­
mal mucosa with very minimal inflammatory 
changes.
D r. Konok: I would like to ask the panel 
to discuss the diagnosis and the advisability 
of doing an ileorectal anastomosis.
Dr. Weakley: I am very glad that there 
is no secret answer that is being withheld 
from us. From the data presented I am 
convinced that this is a case of Crohn’s dis­
ease. You have just heard the many features 
with which a nearly typical case of colonic
Crohn’s disease can present. I would like 
to state the evidence that this is Crohn’s 
disease. There is segmentation, as shown by 
the fact that some areas of the mucosa are 
normal and others abnormal; there are dif­
ferent degrees of inflammation; there are 
areas of relatively normal mucosa adjacent 
to mucosal ulcerations, both microscopically 
and in the gross specimen; there is a dif­
ference in appearance of the ascending, 
transverse, and descending colon in the 
gross specimen; and the rectum is spared 
from advanced disease but has relatively 
minimal patchy ulceration and inflamma­
tion. All of these findings support the diag­
nosis of Crohn’s disease. What makes it 
unusual to many observers is that there is 
toxic dilatation. Yet we have shown for 
many years that toxic dilatation of the colon 
can occur in Crohn’s disease. More recently 
other groups have agreed that the relatively 
short-term, devastating type of Crohn’s dis­
ease may manifest itself by toxic dilatation 
of the colon. The colon in this type of case 
does not have time to acquire the degree of 
transmural involvement that we are used to 
seeing in the more chronic type of disease. 
Therefore my diagnosis is fulminating 
granulomatous colitis with toxic dilatation.
With regard to the question of an eventu­
al ileorectal anastomosis, it would be my 
recommendation that when the patient’s 
health is restored and provided the rectum 
is spared by the disease, an ileoproctostomy 
could be done. It has been our experience 
that in the patient who has enjoyed a 
year of good health after colectomy and 
ileostomy for inflammatory colonic disease 
and who has a rectum normal enough to be 
expected to perform its function adequately, 
takedown of the ileostomy and re-establish­
ment of intestinal continuity to the rectum 
will result in long-term success in about 
two-thirds of such patients.
Before leaving the subject of management 
of the patient with toxic dilatation of the 
colon, I would like to mention our “less 
than colectomy” operation, or simultaneous 
decompression and exclusion of the colon. 
It consists of construction of a loop ileo­
stomy combined with a decompressive colo­
stomy. We have observed that the high 
mortality of colectomy in toxic dilatation 
of the colon occurs when there is transmural
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involvement which has caused perforation 
and air under the diaphragm, or when at the 
time of operation the surgeon can observe 
sealed-off perforations. In these cases the 
operation of colectomy and ileostomy has 
been associated with mortality figures of 
30% to 50% , so we felt there was a need 
for something less than total colectomy. 
Simultaneous decompression and diversion 
allow the patient to get over the crisis and, 
at a later time, an abdominal colectomy and 
ileostomy (or a proctocolectomy and ileo­
stomy if there is involvement of the rectum) 
can be carried out electively after elimination 
of the toxic products in the lumen of the 
colon. When we reviewed about 1,000 con­
secutive patients treated in our institution 
for ulcerative colitis, there were about 60 
patients with toxic dilatation of the colon. 
These were severely ill patients with dilata­
tion of the transverse colon to 10 to 14 cm. 
In approximately one-third of the 60 pa­
tients we employed a “less than colectomy” 
type of procedure, because we could observe 
sealed-off perforations at the time of laparo­
tomy, and we felt that manipulation of the 
bowel would lead to gross peritoneal soil- 
age and sepsis with a prohibitively high 
mortality. Since then, we have extended the 
indication for exclusion and decompression 
to the toxic patient who is debilitated but 
does not have colonic dilatation. It is this 
metabolically depleted, ill patient who can 
withstand the colectomy better when his 
metabolism has been returned to a more 
anabolic state. We still believe that the treat­
ment for the unresponsive patient with 
either type of ulcerative colitis is total colec­
tomy and ileostomy. But diversion by ileo­
stomy and decompression by “blow-hole” 
colostomy can eliminate the devastating 
mortality encountered when definitive sur­
gery is performed in a period of grave crisis 
or severe depletion.
Member of the Audience: Is there an 
absolute indication for proctocolectomy in 
a patient with total colitis of 10 to 15 years’ 
duration?
D r. Lennard-Jones: I agree with most 
speakers that patients who have had total 
ulcerative colitis for a period of 10 to 15 
years should usually have a colectomy. It 
so happens that in our centre we do not al­
ways do this because we feel that, with the
facilities available to us, we are able to fol­
low up such patients very closely with biop­
sies, x-rays and, now, colonoscopy. In due 
course we will let you know about our re­
sults.
Mr. de Dombal: I would also like to speak 
briefly about long-term disease. It seems to 
me that this is something that caused some 
confusion in our earlier discussion. I do not 
think that Dr. Lennard-Jones and I disagree 
about this at all. We both agree that pro­
phylactic proctocolectomy is not necessary 
in patients with proctitis alone; also that 
there is a tenuous argument in favour of this 
operation in distal colitis, in view of our 
present knowledge of the incidence of can­
cer and of long-term survival under medical 
management. Meanwhile, there is a definite 
indication for surgery in patients with total 
colonic involvement. I say this because, in 
addition to cancer risk, half to three-quarters 
of the patients with total colitis will require 
surgery anyway, usually during a severe at­
tack when they are quite ill. Of course if 
Dr. Lennard-Jones can show (in a long­
term objective study of the type he is cur­
rently doing) that our aggressive approach 
is unnecessary, or could be avoided in cer­
tain patients with long-term total colitis, 
then we would be delighted to adopt what 
would be a happier, more selective approach. 
Until that time, with a little reluctance, we 
would recommend a proctocolectomy and 
ileostomy for a patient with total colitis of 
10 to 15 years’ duration.
Dr. L ennard-Jones: I think that Mr. de 
Dombal is absolutely right. At the moment, 
colitis is being divided, basically, into low- 
risk, medium-risk and high-risk groups. It 
can be divided this way both for the acute 
attack and for the long-term risk of cancer. 
Now, people with total colitis are the high- 
risk group for the acute attack and they are 
also in the high-risk group for cancer. As a 
generalization the world over, it is better to 
treat the high-risk group with proctocolec­
tomy. What we are trying to do is to take 
the whole problem one step further; what 
we would like to do is to pinpoint the in­
dividual patients who are at high risk from 
the acute attack and the individual patients 
who are at high risk from cancer. If we can 
do this, then one has taken the matter to its 
logical conclusion. This is the key question
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and this is what we are trying to do with 
our clinical investigation. We may be right, 
or we may be wrong, and I hope that in due 
course we will be able to give you some 
information on this matter, but at the present 
time I am not recommending this approach 
for everybody.
Member of the Audience: What rela­
tionship has pregnancy to ulcerative colitis 
and Crohn’s disease?
Mr. de Dombal: This is really a tough 
question. Let us take four aspects in se­
quence. First of all, does pregnancy in ul­
cerative colitis harm the child? We have 
looked very carefully at the rate of con­
genital abnormalities and stillbirths in ul­
cerative colitis and we have no evidence 
from our series that a child of a mother with 
ulcerative colitis is more likely to be born 
deformed or stillborn than one in the gen­
eral population. The second question is 
whether the mother is more likely to be 
harmed by having ulcerative colitis. The 
answer is “No” while she is pregnant, but 
there is an increased risk in the immediate 
postpartum period, when she is about three 
times as likely to have an acute attack as 
she would if she had not been pregnant. I, 
myself, wonder if this is related to the di­
minished plasma cortisol levels which are 
present at this time, and I also wonder if 
there is not an indication for prophylactic 
steroids. Perhaps Dr. Lennard-Jones would 
like to comment on this later. Turning now 
to Crohn’s disease, women with this condi­
tion tend to be subfertile. But there is also 
another worrying feature, namely that all 
reported series include a rather small group 
of women whose babies have been stillborn 
around the thirty-sixth week of pregnancy.
I feel that it is prudent to hospitalize women 
with Crohn’s disease for about the last 
month of pregnancy and watch them very 
closely. There may also be an indication 
for inducing labour early in these women. 
Finally, pregnancy has a variable effect on 
Crohn’s disease. Some women get worse 
during their pregnancy, and others get bet­
ter. In summary, I would think there is no 
overall indication for prophylactic steriliza­
tion of women affected by either disease.
D r. Lennard-Jones: We have not studied 
this question directly but we, too, see quite 
a number of women with colitis associated
with pregnancy. On medical grounds I see 
no contraindication to pregnancy in these 
patients unless they are ill at the time with 
their disease. The relapse rate of ulcerative 
colitis in pregnancy is the same as the gen­
eral relapse rate and when pregnant patients 
do relapse we treat them in the same way 
as if they were not pregnant. They should 
be watched very carefully in the postpartum 
period although I, personally, do not give 
them steroids prophylactically at this stage. 
Member of the A udience: What is the 
medical management of toxic megacolon? 
D r. McIlrath: One should avoid giving a 
barium enema, or any medication which 
might enhance the problem. Either measure 
not only can precipitate an acute attack but 
can also increase its magnitude once it has 
begun. Intestinal suction by means of a 
nasogastric tube, or a longer tube, is help­
ful but the major effort should be directed 
toward the prompt and accurate replacement 
of fluid and electrolyte losses and restoration 
of circulating blood volume as soon as pos­
sible so that when surgery becomes neces­
sary the operative risk will be reduced.
D r. Lennard-Jones: I think it is important 
that we define toxic megacolon. The upper 
limit of the normal diameter of the trans­
verse colon on a plain radiograph of the 
abdomen has been defined as 5.5 cm. But 
when one makes the diagnosis of toxic 
megacolon it is important that, in addition 
to the dilatation, mucosal irregularities 
should be evident. Occasionally one may see 
severe distal colitis with dilatation of the 
proximal normal colon but the haustrations 
are normal and the mucosa is smooth. The 
diagnosis of toxic megacolon requires a 
dilated colon and an irregular mucosal sur­
face, particularly one with the filling defects 
that Professor Brooke has called “mucosal 
islands”. Any part of the colon may become 
dilated, although the transverse colon is the 
most common site. When I see these signs 
I do not regard the situation as a medical 
problem but, rather, as a surgical emergency. 
We confine our treatment purely to resus­
citation, and our surgical colleagues will 
undertake an operation as soon as the pa­
tient is fit to withstand it. I have seen Mr. 
O. V. Lloyd-Davies of St. Mark’s Hospital, 
London, operating on patients with toxic 
megacolon and he has a trick which I have
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always thought to be useful for decompress­
ing the dilated colon. After he has opened 
the abdomen, an assistant passes a rubber 
tube up through the anus and the surgeon 
decompresses the colon by manipulating 
the tube around the colon from within the 
abdomen. This leaves the surgeon with an 
empty and flaccid colon to deal with. Toxic 
megacolon has a high mortality and our 
aim must be to prevent it from developing. 
We have not had a toxic megacolon at St. 
Mark’s Hospital for quite some time now 
and I think Mr. de Dombal has hinted that 
they also are seeing it much less often.
Dr. D evroede: I think Mr. de Dombal 
stated earlier that 80% of the patients who 
have had proctocolectomy do not have ma­
jor inconvenience. Could you comment 
about impotence in the male patient after 
proctocolectomy?
Mr. de Dombal: I am glad that you have 
raised this point as this is another reason 
why we tend to operate on people with total 
involvement of the colon relatively early. 
There is a small but definite incidence of 
impotence in the male after proctocolectomy 
and, in our experience, it is related to the 
age of the patient. We have found in Leeds 
that the rate of long-term postoperative 
sexual complications, that is to say infer­
tility, failure of ejaculation and impotence, 
in men under the age of 40 is less than 3 %. 
After 40 the risk becomes much higher. It 
is not possible to say without control studies 
whether this is an anatomical defect, or is 
something related to a lack of sexual interest 
on the part of the patient after his operation. 
We have tried to answer this question and 
we cannot.
Dr. D evroede: I suspect that in many pa­
tients the impotence that develops has 
nothing to do with their operation but is 
psychogenic.
Mr. de Dombal: We have found that the 
majority of the early problems do clear up 
in the immediate few months after surgery, 
especially in men under the age of 40. Our 
patients find this piece of news extremely 
reassuring.
Dr. Lennard-Jones: Among the members 
of the British Ileostomy Association there 
is great concern about this problem. They 
have asked Professor Brooke and me to 
help them investigate it and within a year
or two we hope to have some data on the 
subject. I think that we are dealing with a 
largely hidden difficulty which, with the 
increasing freedom in discussion of sexual 
matters, is coming into the open.
Member of the Audience: Could some­
one comment on the use of immunosuppres­
sive agents in Crohn’s disease and ulcerative 
colitis?
Dr. Lennard-Jones: The information in 
ulcerative colitis is meagre at the moment. 
There has been, to my knowledge, only one 
controlled trial and this trial, by Dr. True- 
love and his collaborators in Oxford, gave 
equivocal results, with a slight bias towards 
azathioprine. We are awaiting the publica­
tion of the second half of their report which 
should be available quite soon. In Crohn’s 
disease, as I have already mentioned, there 
has been one trial with a positive result and 
one with a negative result.
Dr. Spencer: In the United States there is 
currently a multi-institutional, double-blind, 
prospective study going on of the use of 
cortisone and azathioprine in the treatment 
of both ulcerative colitis and Crohn’s dis­
ease. I expect the preliminary results to be 
available in approximately 18 months. 
Member of the Audience: Could the 
British members of the panel comment on 
the use of ileorectal anastomosis advocated 
by Mr. Aylett of Britain?
Mr. de Dombal: I have seen Mr. Aylett’s 
patients and I am the first to admit, coming 
from a centre that does a different operation, 
that about 30% of his patients have very 
good results. There are another 30% to 
40% who have about four or five bowel 
motions a day and these seem to be getting 
along reasonably well. But the remainder of 
the patients have more bowel movements 
a day— up to eight or 10 in some cases— 
and in these I would consider the results of 
the operation unsatisfactory. I think what 
needs to be done in terms of the short-term 
prognosis is to find out why an ileorectal 
anastomosis works for some patients and not 
for others. Perhaps we could find a reliable 
prognostic index that would enable us to 
select the 30% of our patients for ileorectal 
anastomosis so that proctocolectomy can be 
performed for the remaining 70%. There 
may be a very real cancer risk following ab­
dominal colectomy but this is a long-term
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problem and we do not have accurate data 
available.
D r . L ennard-Jo n es : We have been very 
interested in this problem at St. Mark’s Hos­
pital. Some of my colleagues interviewed a 
group of Mr. ^ ylett’s patients and a group 
of our own patients who have been treated 
by colectomy and ileorectal anastomosis. I 
cannot remember the figures exactly but I 
think that about 25% of the patients had 
fewer than three bowel movements a day. 
Most patients have between three and six 
bowel actions a day and there was a group 
with more than six. There were some other 
interesting observations. Quite a high pro­
portion of the patients had one bowel action 
during the night and about 5 % had urgency 
of defecation. I would agree with Mr. de 
Dombal that about 50% of the patients 
with ileorectal anastomosis have a good re­
sult. You may be interested to know that 
approximately 20% of patients treated 
surgically for ulcerative colitis at our hos­
pital undergo colectomy and ileorectal 
anastomosis. At the present time we do not 
have a prognostic index. It has been shown 
that a patient with an ileorectal anastomosis 
loses less water and salt than a patient with
an ileostomy. The difference is not great 
but quite significant. It looks as though 
most patients do well if the effluent from 
their ileum is small, in the same way that 
some patients have a liquid ileostomy ef­
fluent and other have a semisolid ileostomy 
output. I know some surgeons who will not 
convert an ileostomy to an ileorectal anas­
tomosis if the effluent from the ileostomy is 
liquid. On the other hand, if it is semisolid 
and, let us say, 300 g a day, they feel that 
the patient may do well with an ileorectal 
anastomosis. The outcome of this operation 
correlates rather poorly with the degree of 
inflammation found in the rectum. There 
is an increased cancer risk in the rectum that 
is difficult to assess at the present time. 
These patients must be followed up indefi­
nitely with sigmoidoscopic examinations and 
multiple biopsies. I think ileorectal anasto­
mosis is a useful operation in young patients 
as it may tide them over a critical period 
in their lives. But one must explain to the 
patient beforehand that this operation may 
or may not be successful, that they will 
have to be followed up indefinitely, and that 
they may have to have an ileostomy at a 
later date.
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NOTICES
ONTARIO HEART FOUNDATION
The Ontario Heart Foundation is sponsor­
ing an International Symposium entitled 
“The Child With Congenital Disease After 
Surgery” to be held at the Inn on the Park 
Hotel, Toronto, Ontario, June 5-7,  1975. 
Thirty-six speakers from around the world 
are presenting papers on all aspects of cur­
rent scientific research relevant to the clini­
cian and practitioner concerned with con­
genital heart disease. For further information 
write to: Ontario Heart Foundation, Profes­
sional Education, 310 Davenport Road, 
Toronto, Ontario M5R 3K2, or telephone 
416 - 962-3600.
CANADIAN ASSOCIATION 
OF PAEDIATRIC SURGEONS
The Canadian Association of Paediatric 
Surgeons will hold its seventh Annual 
Meeting on January 22, 1975 in Winnipeg, 
Manitoba. The guest speaker will be Dr. 
David J. Waterston of London, England. 
For further information write to the Secre­
tary: Dr. Gordon Cameron, 4E 11 - 
McMaster University Medical Centre, 1200 
Main Street West, Hamilton, Ontario 
L8S 4J9.
CANADIAN UROLOGICAL 
ASSOCIATION
The Canadian Urological Association will 
hold its next Annual Meeting June 29 to 
July 2, 1975 at Jasper Park Lodge, Jasper, 
Alberta. For details please write to Dr. W. 
H. Lakey, Secretary, Canadian Urological 
Association, C.M.A. House, Box 8244, 
Ottawa, Ontario, K1G 3H7.
ERRATUM: In the September issue of the 
Journal the name of Dr. Claude L. Fortin 
was omitted from the list of authors of the 
article “La preparation au traitement chirur- 
gical de l’hyperthyroi'die a l’aide du propra­
nolol: etude de 15 observations”. We offer 
our apologies to Dr. Fortin and to our 
readers for this oversight.
